<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 1.1?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Antibiotics (Basel)</journal-id><journal-id journal-id-type="iso-abbrev">Antibiotics (Basel)</journal-id><journal-id journal-id-type="publisher-id">antibiotics</journal-id><journal-title-group><journal-title>Antibiotics</journal-title></journal-title-group><issn pub-type="epub">2079-6382</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7830376</article-id><article-id pub-id-type="pmid">33477401</article-id><article-id pub-id-type="doi">10.3390/antibiotics10010084</article-id><article-id pub-id-type="publisher-id">antibiotics-10-00084</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Clavulanic Acid Production by <italic>Streptomyces clavuligerus</italic>: Insights from Systems Biology, Strain Engineering, and Downstream Processing</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-1339-972X</contrib-id><name><surname>L&#x000f3;pez-Agudelo</surname><given-names>V&#x000ed;ctor A.</given-names></name><xref ref-type="aff" rid="af1-antibiotics-10-00084">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-9858-9559</contrib-id><name><surname>G&#x000f3;mez-R&#x000ed;os</surname><given-names>David</given-names></name><xref ref-type="aff" rid="af2-antibiotics-10-00084">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-1013-5809</contrib-id><name><surname>Ramirez-Malule</surname><given-names>Howard</given-names></name><xref ref-type="aff" rid="af1-antibiotics-10-00084">1</xref><xref rid="c1-antibiotics-10-00084" ref-type="corresp">*</xref></contrib></contrib-group><aff id="af1-antibiotics-10-00084"><label>1</label>Escuela de Ingenier&#x000ed;a Qu&#x000ed;mica, Universidad del Valle, A.A., Cali 25360, Colombia; <email>viclopezag@gmail.com</email></aff><aff id="af2-antibiotics-10-00084"><label>2</label>Grupo de Investigaci&#x000f3;n en Simulaci&#x000f3;n, Dise&#x000f1;o, Control y Optimizaci&#x000f3;n de Procesos (SIDCOP), Departamento de Ingenier&#x000ed;a Qu&#x000ed;mica, Universidad de Antioquia UdeA, Calle 70 No. 52-21, Medell&#x000ed;n 050010, Colombia; <email>dandres.gomez@udea.edu.co</email></aff><author-notes><corresp id="c1-antibiotics-10-00084"><label>*</label>Correspondence: <email>howard.ramirez@correounivalle.edu.co</email>; Tel.: +57-2-3212100 (ext. 7367)</corresp></author-notes><pub-date pub-type="epub"><day>18</day><month>1</month><year>2021</year></pub-date><pub-date pub-type="collection"><month>1</month><year>2021</year></pub-date><volume>10</volume><issue>1</issue><elocation-id>84</elocation-id><history><date date-type="received"><day>23</day><month>12</month><year>2020</year></date><date date-type="accepted"><day>12</day><month>1</month><year>2021</year></date></history><permissions><copyright-statement>&#x000a9; 2021 by the authors.</copyright-statement><copyright-year>2021</copyright-year><license license-type="open-access"><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>Clavulanic acid (CA) is an irreversible &#x003b2;-lactamase enzyme inhibitor with a weak antibacterial activity produced by <italic>Streptomyces clavuligerus</italic> (<italic>S. clavuligerus</italic>). CA is typically co-formulated with broad-spectrum &#x003b2;&#x02011;lactam antibiotics such as amoxicillin, conferring them high potential to treat diseases caused by bacteria that possess &#x003b2;&#x02011;lactam resistance. The clinical importance of CA and the complexity of the production process motivate improvements from an interdisciplinary standpoint by integrating metabolic engineering strategies and knowledge on metabolic and regulatory events through systems biology and multi-omics approaches. In the large-scale bioprocessing, optimization of culture conditions, bioreactor design, agitation regime, as well as advances in CA separation and purification are required to improve the cost structure associated to CA production. This review presents the recent insights in CA production by <italic>S. clavuligerus</italic>, emphasizing on systems biology approaches, strain engineering, and downstream processing.</p></abstract><kwd-group><kwd>clavulanic acid</kwd><kwd><italic>Streptomyces clavuligerus</italic></kwd><kwd>systems biology</kwd><kwd>strain engineering</kwd><kwd>downstream processing</kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="sec1-antibiotics-10-00084"><title>1. Introduction</title><p>The accessibility to effective treatment alternatives of infectious diseases depends on the availability of appropriate antibiotic compounds in the market. Efficient antibiotic production is crucial for health systems worldwide, especially in outbreaks, epidemics, and health emergencies, in which the antibiotic supply chain can be put under pressure.</p><p>Additionally, the acquired antibiotic resistance phenomenon became a global concern as it may increase the vulnerability of health systems [<xref rid="B1-antibiotics-10-00084" ref-type="bibr">1</xref>]. The antibiotic resistance phenomenon emerged along with the antibiotic era [<xref rid="B2-antibiotics-10-00084" ref-type="bibr">2</xref>,<xref rid="B3-antibiotics-10-00084" ref-type="bibr">3</xref>]. Years before penicillin was used at global scale, a penicillinase enzyme able to inactivate penicillin was discovered in bacteria extracts [<xref rid="B4-antibiotics-10-00084" ref-type="bibr">4</xref>]. Antibiotic resistance has forced humanity to maintain an endless search for new and more powerful antibiotics. In this regard, the pharmaceutical industry plays a key role in the development of effective treatments against such multidrug-resistant bacteria [<xref rid="B1-antibiotics-10-00084" ref-type="bibr">1</xref>]. Since the discovery of benzylpenicillin in the 1920s, the class of compounds referred to as &#x003b2;-lactam antibiotics has been the most extensively used antibiotics. Nevertheless, a significant number of different antibiotic compounds (such as carbapenems, cephamycins, cephalosporins, and monobactams) has been developed and implemented in the clinical practice as a strategy to evade the acquired resistance [<xref rid="B5-antibiotics-10-00084" ref-type="bibr">5</xref>]. The new combinations of antibiotics are aimed to increase their spectrum of activity and overcome the resistance barriers developed by the bacteria. In order to mitigate the bacterial resistance to &#x003b2;-lactam antibiotics, several compounds have been identified as &#x003b2;-lactamase inhibitors. Those compounds can irreversibly inactivate the &#x003b2;-lactamases allowing the &#x003b2;-lactam antibiotics to act against the infection. The main &#x003b2;-lactamase inhibitors are Sulbactam, Tazobactam, and clavulanic acid (CA) as clavulanate salt. </p><p>CA is a &#x003b2;-lactam compound with modest antibiotic activity but high inhibition capacity of &#x003b2;-lactamase enzymes. The CA molecule is an analog of the penicillin nucleus, in which the characteristic sulfur atom has been substituted by an oxygen atom. CA is one of the so-called &#x0201c;clavam metabolites&#x0201d; produced by the filamentous bacterium <italic>Streptomyces clavuligerus</italic> (<italic>S. clavuligerus</italic>); most of those metabolites have the characteristic fused bicyclic &#x003b2;-lactam/oxazolidine ring. Nevertheless, the CA molecule (<xref ref-type="fig" rid="antibiotics-10-00084-f001">Figure 1</xref>) has 3R, 5R stereochemistry, opposite to the 3S, 5S configuration present in other clavam metabolites, which do not exhibit &#x003b2;-lactamase inhibition activity, although some of them have antibacterial or antifungal properties [<xref rid="B6-antibiotics-10-00084" ref-type="bibr">6</xref>]. In addition to the stereochemistry, the inhibitory effect of CA has been explained by the presence of the &#x003b2;-lactam/oxazolidine ring that bonds irreversibly with a serine residue in the catalytic center of the &#x003b2;-lactamase enzyme, thus rendering it inactive [<xref rid="B7-antibiotics-10-00084" ref-type="bibr">7</xref>]. Currently, CA is used in combination with other &#x003b2;-lactam antibiotics as an effective treatment against several clinical syndromes including pneumonia and exacerbations of chronic obstructive pulmonary disease, complicated intra-abdominal infections, acute infectious diarrhea, urinary tract infections, pharyngitis, surgical, wound, and skin infections [<xref rid="B8-antibiotics-10-00084" ref-type="bibr">8</xref>]. Some of them are caused by resistant pathogenic bacteria already included in the World Health Organization priority list: <italic>Escherichia coli</italic>, <italic>Staphylococcus aureus</italic>, <italic>Neisseria gonorrhoeae</italic>, <italic>Streptococcus pneumonia</italic>, and all <italic>Enterobacteriaceae</italic> and <italic>Klebsiella</italic> species [<xref rid="B1-antibiotics-10-00084" ref-type="bibr">1</xref>].</p><p>CA is produced worldwide at large scale by several pharmaceutical companies, and it is also prescribed in more than 150 countries [<xref rid="B9-antibiotics-10-00084" ref-type="bibr">9</xref>]. CA has a relatively limited market availability and a middle&#x02013;high cost for the health system, especially in the developing countries when compared with the income level, being quite inaccessible for people without health insurance. The cost of CA is mainly related to the complexity of the production process, the current uncertainties about the regulatory elements controlling the CA biosynthetic gene cluster and the intellectual property associated with its production [<xref rid="B6-antibiotics-10-00084" ref-type="bibr">6</xref>]. Despite the significant number of studies related to CA production in <italic>S. clavuligerus</italic> submerged cultivations, low titers (~1 g&#x02219;L<sup>&#x02212;1</sup>) are still obtained when using a wild type strain. The productivity of CA production bioprocess is also compromised by the downstream processing: CA separation from fermentation broths and precipitation as clavulanate salt. This review presents a holistic overview of CA production process: CA biosynthesis; CA production in <italic>S. clavuligerus</italic> submerged cultivation; recent advances in strain engineering; and elucidation of regulatory elements controlling CA production, systems biology approaches, and downstream processing (<xref ref-type="fig" rid="antibiotics-10-00084-f002">Figure 2</xref>). </p></sec><sec id="sec2-antibiotics-10-00084"><title>2. Overview of CA Biosynthesis in <italic>S. clavuligerus</italic></title><p>The <italic>Streptomyces</italic> genus produces a wide variety of secondary metabolites with antimicrobial activity (approximately two-thirds of which occur naturally) [<xref rid="B10-antibiotics-10-00084" ref-type="bibr">10</xref>]. In 1971, Nagarajan et al. [<xref rid="B11-antibiotics-10-00084" ref-type="bibr">11</xref>] reported a new Streptomycete species as producer of two cephalosporin compounds. This new species was then named and described as <italic>S. clavuligerus</italic> by Higgens and Kastner, also in 1971 [<xref rid="B12-antibiotics-10-00084" ref-type="bibr">12</xref>]. Later, in 1976, Howarth and Brown [<xref rid="B13-antibiotics-10-00084" ref-type="bibr">13</xref>] described the CA chemical structure, which was elucidated via spectroscopic and X-ray analyses and reported as a novel fused &#x003b2;-lactam compound with a significant inhibitory activity of &#x003b2;-lactamases. In 1977, Reading and Cole described the cultivation conditions of <italic>S. clavuligerus</italic> to produce CA and the spectrometric method for CA detection [<xref rid="B7-antibiotics-10-00084" ref-type="bibr">7</xref>].</p><p>In 1941, the biochemist Selman Waskman described the most accepted definition of &#x0201c;antibiotic&#x0201d; as a small molecule made by microorganisms that inhibits the growth of another microorganism. During the &#x0201c;golden age&#x0201d; of antibiotics, approximately 70&#x02013;80% of the antibiotics discovered came from Streptomycetes, but the evolutionary reason for the development of antibiotic biosynthetic capacity of soil bacteria and its ecological role are still unknown. Soil bacteria are not very efficient at up-taking nutrients, and their growth rate is considerably low in comparison with other bacteria and fungi. A plausible hypothesis that iswidely accepted implies that antibiotics secretion allows the producer to control the organisms competing for the same nutritional resources in a hostile multispecies environment [<xref rid="B2-antibiotics-10-00084" ref-type="bibr">2</xref>,<xref rid="B14-antibiotics-10-00084" ref-type="bibr">14</xref>]. This is consistent with the secondary nature of antibiotics secretion under nutritional restriction. However, the antibiotic compounds at very low concentrations can modulate the transcriptional profiles of target bacteria and the products of resistance genes would silence those messages, opposing the theory of the development of attack and defense mechanisms [<xref rid="B14-antibiotics-10-00084" ref-type="bibr">14</xref>]. Mathematical estimations point out that Streptomycetes are able to produce around 100,000 antibiotics and only 3% of them have been discovered [<xref rid="B15-antibiotics-10-00084" ref-type="bibr">15</xref>]. Similarly, the existence of cryptic biosynthetic gene clusters (BGCs) suggests a higher capacity of antibiotic production in those organisms [<xref rid="B16-antibiotics-10-00084" ref-type="bibr">16</xref>,<xref rid="B17-antibiotics-10-00084" ref-type="bibr">17</xref>,<xref rid="B18-antibiotics-10-00084" ref-type="bibr">18</xref>]. </p><p>CA is secreted as a secondary metabolite, also referred as a specialized metabolite, by <italic>S. clavuligerus</italic> under nutritional restriction. The role of CA in the physiology and adaptation of <italic>S. clavuligerus</italic> is also unknown. As a &#x003b2;-lactamase inhibitor, CA may be part of a self-resistance mechanism involving the synthesis of &#x003b2;-lactam antibiotics, &#x003b2;-lactamase enzymes, and &#x003b2;-lactamase inhibitors; possibly developed by <italic>Streptomyces</italic> species to defend themselves from the effect of the antimicrobials [<xref rid="B10-antibiotics-10-00084" ref-type="bibr">10</xref>]. CA biosynthesis is induced during phosphate limited conditions; recently it has been proposed that CA production may be a consequence of a homeostatic response aimed to compensate for the ATP deficit under phosphate depletion [<xref rid="B19-antibiotics-10-00084" ref-type="bibr">19</xref>]. This mechanism would trigger a strong activation of oxidative and amino acid metabolism, producing reduced cofactors and ATP and favoring the antibiotic biosynthesis as a feasible mechanism to adjust the ATP generation [<xref rid="B20-antibiotics-10-00084" ref-type="bibr">20</xref>,<xref rid="B21-antibiotics-10-00084" ref-type="bibr">21</xref>]. Moreover, the simultaneous secretion of penicillin and cephalosporins antibiotics along with &#x003b2;-lactamase enzymes and &#x003b2;-lactamase inhibitors would tightly control the energetic impact of an ATP-consuming futile cycle of polymerization/degradation of the cell wall caused by the &#x003b2;-lactam antibiotics accumulation [<xref rid="B19-antibiotics-10-00084" ref-type="bibr">19</xref>,<xref rid="B22-antibiotics-10-00084" ref-type="bibr">22</xref>,<xref rid="B23-antibiotics-10-00084" ref-type="bibr">23</xref>].</p><p>CA is a product of the clavam pathway, which proceeds towards two branches: the CA and the clavams 5S biosynthesis [<xref rid="B6-antibiotics-10-00084" ref-type="bibr">6</xref>]. The clavam pathway contains two sets of reactions: the so-called &#x0201c;early&#x0201d; and &#x0201c;late&#x0201d; steps. The early steps start with the condensation of the glycolysis intermediate glyceraldehyde-3-phosphate and the amino acid L-arginine, producing the <italic>N</italic><sup>2</sup>-(2-carboxyethyl)-arginine. This condensation is catalyzed by the <italic>N</italic><sup>2</sup>-(2-carboxyethyl)-arginine synthase (CEAS). The early steps comprise five well-known reactions leading to the (3S, 5S)-clavaminic acid. The formation of the clavaminic acid is considered a bifurcation point of the carbon flowing through the pathway. The CA biosynthesis late steps consider the reactions leading to CA, as well as the reactions forming the clavam 5S compounds after the clavaminic acid bifurcation [<xref rid="B24-antibiotics-10-00084" ref-type="bibr">24</xref>,<xref rid="B25-antibiotics-10-00084" ref-type="bibr">25</xref>,<xref rid="B26-antibiotics-10-00084" ref-type="bibr">26</xref>]. The known reactions of the clavam pathway are summarized in <xref ref-type="fig" rid="antibiotics-10-00084-f003">Figure 3</xref>. The &#x003b2;-lactam compound deoxyguanidinoproclavaminic acid is synthesized from the <italic>N</italic><sup>2</sup>-(2-carboxyethyl)-arginine in the second reaction of the clavam pathway, catalyzed by the &#x003b2;-lactam synthetase (BLS) [<xref rid="B27-antibiotics-10-00084" ref-type="bibr">27</xref>,<xref rid="B28-antibiotics-10-00084" ref-type="bibr">28</xref>,<xref rid="B29-antibiotics-10-00084" ref-type="bibr">29</xref>]. The hydroxylation of the deoxyguanidinoproclavaminic acid takes place to form the guanidinoproclavaminic acid; a reaction mediated by clavaminate synthase (CAS) [<xref rid="B29-antibiotics-10-00084" ref-type="bibr">29</xref>,<xref rid="B30-antibiotics-10-00084" ref-type="bibr">30</xref>,<xref rid="B31-antibiotics-10-00084" ref-type="bibr">31</xref>,<xref rid="B32-antibiotics-10-00084" ref-type="bibr">32</xref>]. Subsequently, the proclavaminic acid is produced by removing the amidino group from the arginine residue on the guanidinoproclavaminic acid, by action of proclavaminate amidino hydrolase (PAH) [<xref rid="B33-antibiotics-10-00084" ref-type="bibr">33</xref>,<xref rid="B34-antibiotics-10-00084" ref-type="bibr">34</xref>]. The dihydroclavaminic acid is obtained from the proclavaminic acid through oxidative cyclization and desaturation, both catalyzed by CAS, leading to the (3S, 5S)-clavaminic acid [<xref rid="B29-antibiotics-10-00084" ref-type="bibr">29</xref>,<xref rid="B35-antibiotics-10-00084" ref-type="bibr">35</xref>]. At this point, the late steps start with the carbon flux bifurcation in two branches: one branch leading to the clavulanate-9-aldehyde and further the CA, and the other branch forming clavam 5S compounds. It is important to highlight that the 3S, 5S stereochemistry of clavaminic acid is conserved in the synthesis of all clavam 5S compounds. In the case of the CA, a transition from 3S, 5S configuration to 3R, 5R is required. Some authors have suggested that this stereochemical inversion may occur via the N-glycyl-clavaminic acid intermediate to form the clavulanate-9-aldehyde with a 3R, 5R configuration, and therefore the CA [<xref rid="B36-antibiotics-10-00084" ref-type="bibr">36</xref>,<xref rid="B37-antibiotics-10-00084" ref-type="bibr">37</xref>]. However, more experimental evidence is required for the complete elucidation of intermediate reactions connecting the clavaminic acid with the clavulanate-9-aldehyde [<xref rid="B36-antibiotics-10-00084" ref-type="bibr">36</xref>,<xref rid="B37-antibiotics-10-00084" ref-type="bibr">37</xref>], which is lastly reduced to CA by the action of clavulanate dehydrogenase (CAD) [<xref rid="B38-antibiotics-10-00084" ref-type="bibr">38</xref>]. Recently, G&#x000f3;mez et al. [<xref rid="B39-antibiotics-10-00084" ref-type="bibr">39</xref>] proposed six reaction steps for the 3S, 5S to the 3R, 5R transition, by using a computational approach. </p><p>In addition to the CA, other metabolites have been identified as side compounds of this biosynthetic pathway, namely, N-glycyl-clavaminic acid, N-acetylglycyl-clavaminic acid, and N-acetyl-clavaminic acid. It has been suggested that those compounds result from the intermediate steps involved in the transition of the 3S, 5S stereochemistry into the 3R, 5R of CA [<xref rid="B36-antibiotics-10-00084" ref-type="bibr">36</xref>]. Additionally, several metabolites (2-hydroxymethylclavam, 2-formyloxymethylclavam, clavam-2-carboxylic acid, and alanylclavam) have been identified and grouped as clavam 5S compounds due to their 3S, 5S stereochemistry [<xref rid="B37-antibiotics-10-00084" ref-type="bibr">37</xref>,<xref rid="B40-antibiotics-10-00084" ref-type="bibr">40</xref>,<xref rid="B41-antibiotics-10-00084" ref-type="bibr">41</xref>]. Despite their structural similarity and common precursors, only the clavam compounds with a bicyclic nucleus formed by the &#x003b2;-lactam ring and an oxazolidine ring with 3R, 5R stereochemistry can effectively inhibit the &#x003b2;-lactamases [<xref rid="B10-antibiotics-10-00084" ref-type="bibr">10</xref>,<xref rid="B40-antibiotics-10-00084" ref-type="bibr">40</xref>]. </p><p>Glycerol is the main substrate in the CA production by <italic>S. clavuligerus</italic> as it has direct incorporation into the glycolytic pathway by forming glyceraldehyde 3-phosphate, the first C-3 precursor of CA [<xref rid="B42-antibiotics-10-00084" ref-type="bibr">42</xref>,<xref rid="B43-antibiotics-10-00084" ref-type="bibr">43</xref>]. Then, the carbon flux splits into three pathways, two of them belonging to the primary metabolism: glycolysis and gluconeogenesis, and one belonging to the secondary metabolism: the clavam pathway [<xref rid="B43-antibiotics-10-00084" ref-type="bibr">43</xref>,<xref rid="B44-antibiotics-10-00084" ref-type="bibr">44</xref>,<xref rid="B45-antibiotics-10-00084" ref-type="bibr">45</xref>]. In addition to glyceraldehyde 3-phosphate, the need for a C-5 precursor implies the constant demand for L-arginine. This amino acid is synthesized in the urea cycle while L-glutamate and L-aspartate promote its biosynthesis by fueling the urea cycle in the oxidative direction [<xref rid="B42-antibiotics-10-00084" ref-type="bibr">42</xref>,<xref rid="B43-antibiotics-10-00084" ref-type="bibr">43</xref>,<xref rid="B44-antibiotics-10-00084" ref-type="bibr">44</xref>]. </p></sec><sec id="sec3-antibiotics-10-00084"><title>3. CA Production in <italic>S. clavuligerus</italic> Submerged Cultivation</title><p>Besides CA, <italic>S. clavuligerus</italic> produces a plethora of secondary metabolites that can compete with CA biosynthesis and secretion. Those include some &#x003b2;-lactam (penicillin N, cephamicin C, cephalosporins, and other clavams) and non-&#x003b2;-lactam (holomycin, &#x003b2;-lactamase inhibitory protein and a tunicamycin-related antibiotic) antibiotics [<xref rid="B24-antibiotics-10-00084" ref-type="bibr">24</xref>,<xref rid="B46-antibiotics-10-00084" ref-type="bibr">46</xref>,<xref rid="B47-antibiotics-10-00084" ref-type="bibr">47</xref>,<xref rid="B48-antibiotics-10-00084" ref-type="bibr">48</xref>,<xref rid="B49-antibiotics-10-00084" ref-type="bibr">49</xref>,<xref rid="B50-antibiotics-10-00084" ref-type="bibr">50</xref>,<xref rid="B51-antibiotics-10-00084" ref-type="bibr">51</xref>,<xref rid="B52-antibiotics-10-00084" ref-type="bibr">52</xref>,<xref rid="B53-antibiotics-10-00084" ref-type="bibr">53</xref>,<xref rid="B54-antibiotics-10-00084" ref-type="bibr">54</xref>]. However, CA is currently the most important specialized metabolite produced by <italic>S. clavuligerus</italic> considering its clinical and industrial relevance. </p><p>CA is usually produced in submerged cultivation of <italic>S. clavuligerus</italic>, either wild type or engineered strains. Several operation modes and media compositions have been explored aimed to increase the characteristic low titters of the wild type strain, as Ser et al. [<xref rid="B55-antibiotics-10-00084" ref-type="bibr">55</xref>] reviewed recently. Such strategies might also enhance the CA titers of engineered strains in submerged cultivation. As previously mentioned, glycerol is the most common carbon source used in CA production. When comparing the CA production using glycerol and starch as carbon sources, glycerol promotes CA titers up to 5-fold the observed in cultivations with starch as carbon source [<xref rid="B56-antibiotics-10-00084" ref-type="bibr">56</xref>,<xref rid="B57-antibiotics-10-00084" ref-type="bibr">57</xref>]. Nevertheless, substrate inhibition can occur at glycerol concentrations higher than 50 g&#x02219;L<sup>&#x02212;1</sup> [<xref rid="B56-antibiotics-10-00084" ref-type="bibr">56</xref>]. As glycerol acts as the C-3 precursor, the biosynthesis of CA is enhanced by amino acid supplementation [<xref rid="B42-antibiotics-10-00084" ref-type="bibr">42</xref>,<xref rid="B58-antibiotics-10-00084" ref-type="bibr">58</xref>] and rich nitrogen sources like soy protein and soy flour [<xref rid="B56-antibiotics-10-00084" ref-type="bibr">56</xref>,<xref rid="B57-antibiotics-10-00084" ref-type="bibr">57</xref>] that provide abundant C-5 precursors through the urea cycle. Conversely, the use of dextrose or starch promote the secretion of Cephamycin C [<xref rid="B57-antibiotics-10-00084" ref-type="bibr">57</xref>,<xref rid="B59-antibiotics-10-00084" ref-type="bibr">59</xref>]. In a media screening study, Da Silva et al. [<xref rid="B60-antibiotics-10-00084" ref-type="bibr">60</xref>] observed the highest CA production (0.437 g&#x02219;L<sup>&#x02212;1</sup>) with the media having glycerol as the main carbon source and isolated soy protein, while the amino acid supplementation did not enhance the CA productivity. Neto et al. [<xref rid="B61-antibiotics-10-00084" ref-type="bibr">61</xref>] reported CA concentrations in batch, fed batch and continuous cultivations of 0.195, 0.404, and 0.293 g&#x02219;L<sup>&#x02212;1</sup>, respectively. The highest CA concentrations obtained in bioreactor cultivations using a wild type strain were reported by Teodoro et al. [<xref rid="B62-antibiotics-10-00084" ref-type="bibr">62</xref>]. In that study, batch and fed-batch operation modes were tested using a complex medium prepared with glycerol, malt, and yeast extracts, peptone and trace elements. Batch cultivations yielded 0.430&#x02013;0.530 g&#x02219;L<sup>&#x02212;1</sup> of CA while fed-batch cultivations with ornithine (3.7 g&#x02219;L<sup>&#x02212;1</sup>) led to a CA concentration of 1.560 g&#x02219;L<sup>&#x02212;1</sup> [<xref rid="B62-antibiotics-10-00084" ref-type="bibr">62</xref>,<xref rid="B63-antibiotics-10-00084" ref-type="bibr">63</xref>]. A complex culture medium provides important amounts of free or hydrolyzed amino acids, which act not only as nitrogen sources, but also as secondary carbon sources. Complex nitrogen sources, such as those containing soy protein, favor considerably the CA accumulation in contrast to the chemically defined media [<xref rid="B56-antibiotics-10-00084" ref-type="bibr">56</xref>]. The use of complex media with vegetable oils supplementation (olive, cotton, palm, and corn) as secondary carbon sources may enhance the CA production up to 2-fold when compared to glycerol as a supplement [<xref rid="B64-antibiotics-10-00084" ref-type="bibr">64</xref>,<xref rid="B65-antibiotics-10-00084" ref-type="bibr">65</xref>,<xref rid="B66-antibiotics-10-00084" ref-type="bibr">66</xref>]. However, the use of complex media leads to denser and more viscous fermentation broths due to the high concentration of suspended solids. Those factors may affect the mass transfer in the bioreactor and the downstream CA separation. Phosphate has a potential repressive effect on CA production; thus, culture media are commonly designed as phosphate-limited [<xref rid="B6-antibiotics-10-00084" ref-type="bibr">6</xref>,<xref rid="B42-antibiotics-10-00084" ref-type="bibr">42</xref>,<xref rid="B55-antibiotics-10-00084" ref-type="bibr">55</xref>]. In this regard, Saudagar and Singhal [<xref rid="B58-antibiotics-10-00084" ref-type="bibr">58</xref>] found a CA biosynthesis repression when increasing the phosphate concentration in the media over 100 mmol.L<sup>&#x02212;1</sup>. The studies indicated that CA accumulation is favored in the fed-batch operation under controlled conditions of pH, aeration, and stirring. Those conditions are more easily controllable in stirred tank bioreactors (STR) although the CA production studies are not restricted only to this configuration.</p><p>Other factors apart from culture media could affect the CA accumulation in submerged cultures of <italic>S. clavuligerus</italic>. The CA molecule shows high susceptibility to temperature and ionic strength in aqueous solutions, compromising the CA titers during the cultivation [<xref rid="B67-antibiotics-10-00084" ref-type="bibr">67</xref>,<xref rid="B68-antibiotics-10-00084" ref-type="bibr">68</xref>]. The pH conditions seem to affect CA yield, possibly more linked to molecule degradation than biosynthesis inhibition [<xref rid="B69-antibiotics-10-00084" ref-type="bibr">69</xref>]. The highest concentration of CA has been reported at neutral or slightly acidic pH conditions (6.8), regardless of the substrates used in the cultivations [<xref rid="B55-antibiotics-10-00084" ref-type="bibr">55</xref>]. A recent report showed that STR cultures of <italic>S. clavuligerus</italic> subjected to acid stresses (pH reduction from 6.8 to 6.3 at a rate of 0.1 pH every 6 h) may lead to higher global yields (<inline-formula><mml:math id="mm1"><mml:mrow><mml:mrow><mml:msub><mml:mi mathvariant="normal">Y</mml:mi><mml:mrow><mml:mi>CA</mml:mi><mml:mo>/</mml:mo><mml:mi mathvariant="normal">X</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>0.851</mml:mn><mml:msub><mml:mrow><mml:mrow><mml:mo>&#x000a0;</mml:mo><mml:mi mathvariant="normal">g</mml:mi></mml:mrow></mml:mrow><mml:mrow><mml:mi>CA</mml:mi></mml:mrow></mml:msub><mml:mo>.</mml:mo><mml:msub><mml:mi mathvariant="normal">g</mml:mi><mml:mi mathvariant="normal">x</mml:mi></mml:msub><mml:msup><mml:mrow/><mml:mrow><mml:mo>&#x02212;</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msup><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula> [<xref rid="B70-antibiotics-10-00084" ref-type="bibr">70</xref>]. Low temperatures favor the molecule stability; in this regard, higher titers have been reported during operating fermentations at 20 &#x000b0;C but the growth rate at such temperature is lower than that observed at 28 &#x000b0;C [<xref rid="B70-antibiotics-10-00084" ref-type="bibr">70</xref>,<xref rid="B71-antibiotics-10-00084" ref-type="bibr">71</xref>]. In addition, it has been found that both bacterial morphology in dispersed secondary mycelium and a high density spore suspension inoculum (with concentration &#x02265;5%) significantly improve CA biosynthesis [<xref rid="B72-antibiotics-10-00084" ref-type="bibr">72</xref>,<xref rid="B73-antibiotics-10-00084" ref-type="bibr">73</xref>,<xref rid="B74-antibiotics-10-00084" ref-type="bibr">74</xref>].</p><p>Regarding the operational variables associated to fermentative processes in <italic>Streptomyces</italic> species, the nutritional effects have been more studied than the effects of hydrodynamic conditions and reactor geometry [<xref rid="B75-antibiotics-10-00084" ref-type="bibr">75</xref>]. The conventional bioprocesses with <italic>Streptomyces</italic> strains are generally carried out in STRs, as this traditional geometry has been proven to be reliable as it assures good mixing, mass, and heat transfer rates [<xref rid="B76-antibiotics-10-00084" ref-type="bibr">76</xref>]. Novel impeller geometries for STR have been studied as feasible alternatives for improving the oxygen dissolution and nutrient dispersion during the fermentative process [<xref rid="B77-antibiotics-10-00084" ref-type="bibr">77</xref>]. Few studies involving the hydrodynamic patterns of reactors and its impact on growth, morphology, and mass transfer in <italic>Streptomyces</italic> cultures have been performed. Such studies are required for a more precise description of antibiotics biosynthesis in bioreactors [<xref rid="B75-antibiotics-10-00084" ref-type="bibr">75</xref>]. The reactor geometry, impeller configuration, and velocity of mixing may impact the oxygen availability on the system; it has been demonstrated that higher mixing velocities and turbulence gives better volumetric oxygen mass transfer coefficients (<italic>k<sub>La</sub></italic>), promoting higher specific growth rates [<xref rid="B76-antibiotics-10-00084" ref-type="bibr">76</xref>,<xref rid="B78-antibiotics-10-00084" ref-type="bibr">78</xref>]. The reactor design must be focused on balancing mass and heat transfer with shear rates, as the latter can cause hydrodynamic stress on cells, affecting their growth and productivity. In this direction, the novel single-use technologies can offer some advantages, in addition to the better sterility conditions attained in this kind of reactors [<xref rid="B75-antibiotics-10-00084" ref-type="bibr">75</xref>]. </p><p>In the operation of bioreactors, the agitation rate is related not only with the dissolved oxygen and mass transfer conditions, but also with the shear conditions. The shear forces may affect the broth rheology and transport of nutrients as well as the growth rate and morphology expression on <italic>Streptomyces</italic> species [<xref rid="B79-antibiotics-10-00084" ref-type="bibr">79</xref>,<xref rid="B80-antibiotics-10-00084" ref-type="bibr">80</xref>]. In the case of <italic>S. clavuligerus</italic>, agitation and aeration are also considered as factors potentially affecting the CA production. An increase of 50% in oxygen transfer in shake flask cultures increased the CA production 2-fold [<xref rid="B81-antibiotics-10-00084" ref-type="bibr">81</xref>]. Regarding the bioreactor operation, Rosa et al. [<xref rid="B82-antibiotics-10-00084" ref-type="bibr">82</xref>] found that intense agitation rates, i.e., 800&#x02013;1000 rpm, favored CA accumulation in STRs. The <italic>k<sub>La</sub></italic> observed in airlift reactors, operated in the range from 3 to 5 vvm, are rather comparable to those arising in STRs operating in the range of 600 to 1000 rpm; both conditions promote CA accumulation. An analysis of the <italic>S. clavuligerus</italic> response to shear stress conditions showed that high shear forces (up to 7.5 Pa.s) increase the growth rate, mycelial thinning, and CA production, in comparison with cultivations at low shear forces (&#x0003c;1 Pa.s) [<xref rid="B79-antibiotics-10-00084" ref-type="bibr">79</xref>]. Moreover, the mycelial diameter increased 57% under low shear forces when compared to the morphology at high shear stress (1.44 &#x000b5;m); suggesting that CA productivity might be affected by the surface&#x02013;volume ratio, and consequently by the transport rate of nutrients, oxygen, and product release [<xref rid="B79-antibiotics-10-00084" ref-type="bibr">79</xref>]. In summary, high CA concentrations are attained under adequate provision of C-3 and C-5 precursors that increase the carbon flux towards the biosynthetic pathway under phosphate limitation, while maintaining slightly acidic conditions, controlled temperature, high shear rates, and aeration. Such conditions promote both high biomass production and high CA secretion. Rich media are preferred due to their low cost, availability, and high amino acids content, but a proper C/N balance must be maintained along with the phosphate restriction; otherwise, low CA titers could be obtained.</p><p>CA chemical synthesis has been also explored as an alternative production method. In this regard, at least two different ways for the synthesis of CA have been reported by using diester and diene compounds [<xref rid="B83-antibiotics-10-00084" ref-type="bibr">83</xref>,<xref rid="B84-antibiotics-10-00084" ref-type="bibr">84</xref>]. Nevertheless, the mentioned approaches yield low concentrations of racemic mixtures of CA methyl esters. The products and yields of CA organic synthesis imply more complex and costly separation procedures than in case of the bioprocess. Thus, CA production via submerged cultivation with <italic>S. clavuligerus</italic> has been selected by the pharmaceutical industry as the more profitable alternative, given the stereochemical selectivity of the biochemical pathway. Likewise, research has focused on solving the key issues in the bioprocess instead of the chemical synthesis, namely, the low productivity of the strain, the susceptibility to hydrolysis, and the efficiency of the separation/concentration processes.</p></sec><sec id="sec4-antibiotics-10-00084"><title>4. Regulation of the CA Production in <italic>S. clavuligerus</italic></title><p>Successful secondary metabolite biosynthesis by the <italic>Streptomyces</italic> genus undergoes complex regulation at many levels, involving transcriptional regulators (pleiotropic regulators and pathway-specific regulators), sigma-factors, and small non-coding RNAs [<xref rid="B85-antibiotics-10-00084" ref-type="bibr">85</xref>]. Therefore, the system-level understanding of the complex regulatory interactions and signaling pathways may lead to novel improvement strategies in the CA production. </p><p>Usually, antibiotic biosynthetic clusters are regulated by two types of transcriptional regulators: pathway-specific regulators (PSRs) and pleiotropic regulators [<xref rid="B86-antibiotics-10-00084" ref-type="bibr">86</xref>]. At a lower level, PSRs are located inside the antibiotic biosynthetic cluster and these proteins can bind directly to the promoters of genes in the same biosynthetic pathway [<xref rid="B87-antibiotics-10-00084" ref-type="bibr">87</xref>,<xref rid="B88-antibiotics-10-00084" ref-type="bibr">88</xref>]. Similarly, at the top level, global regulators are known to control the production of antibiotics in the <italic>Streptomyces</italic> genus [<xref rid="B87-antibiotics-10-00084" ref-type="bibr">87</xref>,<xref rid="B88-antibiotics-10-00084" ref-type="bibr">88</xref>]. </p><p>The <italic>claR</italic> is a PSR that belongs to the LysR family and triggers the late genes (<italic>cyp, oppA1</italic>, and <italic>cad</italic>) of the CA biosynthetic pathway, specifically those participating in the reactions of CA and clavaminic acid biosynthesis [<xref rid="B85-antibiotics-10-00084" ref-type="bibr">85</xref>,<xref rid="B89-antibiotics-10-00084" ref-type="bibr">89</xref>]. Furthermore, the <italic>ccaR</italic> is a PSR located in the adjacency of the cephamycin C cluster, and triggers the synthesis of both CA and cephamycin C. The last compound is induced by the <italic>ccaR</italic> through the regulation of the early genes <italic>cas2</italic>, <italic>bls</italic>, <italic>pah</italic>, and <italic>orf2</italic> [<xref rid="B24-antibiotics-10-00084" ref-type="bibr">24</xref>,<xref rid="B85-antibiotics-10-00084" ref-type="bibr">85</xref>,<xref rid="B90-antibiotics-10-00084" ref-type="bibr">90</xref>]. The evidence suggests that both <italic>ccaR</italic> and <italic>claR</italic> form a regulatory system that controls the CA biosynthesis [<xref rid="B91-antibiotics-10-00084" ref-type="bibr">91</xref>]. Recently, by means of a comparative transcriptomic analysis, Pinilla and colleagues [<xref rid="B92-antibiotics-10-00084" ref-type="bibr">92</xref>] identified that CA cluster genes were up regulated, including both <italic>ccaR</italic> and <italic>claR</italic>, when <italic>S. clavuligerus</italic> was cultured in complex media.</p><p>As the CA titers in cultivations using the wild type strain are still low, engineered strains of <italic>S. clavuligerus</italic> perturbing these regulators have posed as attractive alternatives for improving the CA production. P&#x000e9;rez-Llarena and co-workers [<xref rid="B93-antibiotics-10-00084" ref-type="bibr">93</xref>] found that a deletion mutant of <italic>ccaR</italic> is unable to synthesize CA and cephamycin C; besides, an amplification of this gene led to 2&#x02013;3-fold rise in the CA and cephamycin C biosynthesis. Furthermore, Alexander and Jensen [<xref rid="B94-antibiotics-10-00084" ref-type="bibr">94</xref>] investigated the role of the CcaR protein in the cephamycin C gene cluster in <italic>S. clavuligerus</italic>. The <italic>ccaR</italic> gene was also considered as essential in the synthesis of CA, cephamycin C, and non-CA clavams [<xref rid="B94-antibiotics-10-00084" ref-type="bibr">94</xref>]. The authors also concluded that the lack of cephamycin C production in <italic>ccaR</italic> mutants was mainly due to the absence of some enzymes in the early and middle steps in the cephamycin C pathway. P&#x000e9;rez-Redondo et al. [<xref rid="B89-antibiotics-10-00084" ref-type="bibr">89</xref>] observed that high replication of the <italic>claR</italic> gene in multicopy plasmids led to 3-fold and 5&#x02013;6-fold increases in the CA and alanyclavam production, respectively, with a consequent reduction of cephamycin C production.</p><p>Furthermore, Kizildo&#x0011f;an and co-workers [<xref rid="B95-antibiotics-10-00084" ref-type="bibr">95</xref>] engineered a CA-overproducer (<italic>S. clavuligerus</italic> IDG3) strain yielding CA titers up to 6.690 g&#x02219;L<sup>&#x02212;1</sup>. In that study, the authors overexpressed clavaminic acid synthase (<italic>cas2</italic> gene) and the genes <italic>claR</italic> and <italic>ccaR</italic> independently using diverse promoters that were introduced into the industrial strain <italic>S. clavuligerus</italic> DEPA. The overexpression of <italic>ccaR</italic> under the control of a <italic>glpF</italic> promoter, introduced into <italic>S. clavuligerus</italic> DEPA, led to 25.9-fold CA production compared to its vector control. Qin et al. [<xref rid="B96-antibiotics-10-00084" ref-type="bibr">96</xref>] fused the <italic>neo</italic> gene (a kanamycin resistance gene without promoters) with <italic>claR</italic>, generating the <italic>S. clavuligerus</italic> (NEO) strain able to produce CA titers up to 3.260 g&#x02219;L<sup>&#x02212;1</sup>. Subsequently, and after a series of treatments and screening, the authors obtained a new engineered strain (M3-19), which produced up to 4.330 g&#x02219;L<sup>&#x02212;1</sup> of CA, an increase of 33.8% compared to the NEO strain. Recently, Cho et al. [<xref rid="B97-antibiotics-10-00084" ref-type="bibr">97</xref>] overexpressed the genes <italic>ccaR, cas1</italic>, and <italic>claR</italic> in the mutant strain <italic>S. clavuligerus</italic> OR. Upregulation of <italic>cas1</italic> improved the CA yield in <italic>S. clavuligerus</italic> OR, leading to CA concentration of 4.95 g&#x02219;L<sup>&#x02212;1</sup>, approximately 25% more compared to the control <italic>S. clavuligerus</italic> OR. Additionally, the overexpression of <italic>claR and ccaR</italic> in the same mutant strain increased the CA accumulation up to 5.66 g&#x02219;L<sup>&#x02212;1</sup> in shake flask cultivations. Nevertheless, a co-expression of <italic>claR, ccaR</italic>, and <italic>cas1</italic> did not improve the CA titers. Batch cultivation of <italic>S. clavuligerus</italic> OR with overexpressed ccaR and claR in a 7 L bioreactor accumulated 6.010 g&#x02219;L<sup>&#x02212;1</sup> of CA.</p><p>In addition to <italic>claR and ccaR</italic>, the regulatory pathway that controls CA production contains other important regulators. The CcaR formation is modulated by other regulatory proteins like AreB and ScaR, both &#x003b3;-butyrolactone receptor proteins. AreB is an autoregulation binding protein that belongs to the transcriptional regulators family termed IclR and is located upstream of the <italic>ccaR</italic> gene; it binds to the sequences (ARE, autoregulatory elements) located upstream of target genes [<xref rid="B24-antibiotics-10-00084" ref-type="bibr">24</xref>]. Santamarta and colleagues [<xref rid="B98-antibiotics-10-00084" ref-type="bibr">98</xref>] found that AreB modulates the assimilation and biosynthesis of lysine. The mutant <italic>&#x02206;areB</italic> of <italic>S. clavuligerus</italic> induces an increase in CA and Cephamycin C levels; highlighting an important role of <italic>areB</italic> in connecting secondary and primary metabolism. ScaR (Brp, &#x003b3;-butyrolactone receptor protein) is an autoregulator induced by &#x003b3;-butyrolactone that controls directly <italic>ccaR</italic> and indirectly <italic>claR</italic> via the AdpA signaling pathway. The AdpA transcriptional regulator is downregulated by ScaR (in <italic>scar</italic> mutants <italic>adpA</italic> is upregulated), and regulates positively the CA production, as it was demonstrated by the mutant <italic>&#x02206;adpA</italic> strain [<xref rid="B99-antibiotics-10-00084" ref-type="bibr">99</xref>].</p><p>In the <italic>Streptomyces</italic> genus, an important type of global regulators is the two-component system (TCS), which usually regulates both antibiotic production and morphological development. The TCS consists of a histidine kinase bound to the extracellular membrane, which senses external perturbations, and a response regulator, which triggers the transcription of target genes by undergoing a signal transduction pathway [<xref rid="B100-antibiotics-10-00084" ref-type="bibr">100</xref>,<xref rid="B101-antibiotics-10-00084" ref-type="bibr">101</xref>]. Fu and colleagues [<xref rid="B102-antibiotics-10-00084" ref-type="bibr">102</xref>,<xref rid="B103-antibiotics-10-00084" ref-type="bibr">103</xref>] found that CagRS is a pleiotropic regulatory TCS that has a positive effect on CA production. Transcriptome analysis of the mutant <italic>&#x02206;cagRS</italic> versus wild type shown that CagRS TCS induces the up regulation of the CA biosynthetic gene pathway and also that CagRS positively regulates glyceraldehyde 3-phosphate but negatively regulates arginine biosynthesis [<xref rid="B102-antibiotics-10-00084" ref-type="bibr">102</xref>]. </p><p>Similarly, other TCS have been identified for <italic>S. clavuligerus</italic>. Kwong and colleagues [<xref rid="B104-antibiotics-10-00084" ref-type="bibr">104</xref>] found that the transcription of the transcriptional activator <italic>cvm7p</italic> is controlled by a TCS formed by <italic>snk</italic> and <italic>res2</italic>. Mutants of <italic>res2</italic> and <italic>snk</italic> were incapable to synthesize metabolites of the 5S clavams pathway [<xref rid="B104-antibiotics-10-00084" ref-type="bibr">104</xref>]. Another important two-component regulatory system is associated with the phosphate (Pho) regulon, the unique known regulatory mechanism in response to phosphate starvation in bacteria [<xref rid="B105-antibiotics-10-00084" ref-type="bibr">105</xref>]. The hypothesis of a Pho regulon present in <italic>S. clavuligerus</italic> is supported by the high production of CA under phosphate limitations. Salehghamari et al. [<xref rid="B106-antibiotics-10-00084" ref-type="bibr">106</xref>] predicted the existence of this regulon by the identification of PHO binding sequences in promoter regions of 31 genes of <italic>S. clavuligerus</italic>. </p><p>Likewise, other TCS is the AfsK-AfsR serine/threonine kinase system, which induces the production of secondary metabolism gene clusters in <italic>S. lividans</italic> and <italic>S. coelicolor</italic> [<xref rid="B107-antibiotics-10-00084" ref-type="bibr">107</xref>]. The <italic>asfR-p</italic> is a homologue of <italic>asfR</italic>, the substrate of AfsK from the AfsK-AfsR. Paraluji and colleagues [<xref rid="B108-antibiotics-10-00084" ref-type="bibr">108</xref>] demonstrated the potential of this pleiotropic regulation by overexpressing <italic>asfR-p</italic> in distinct <italic>Streptomyces</italic> bacteria, including <italic>S. clavuligerus</italic>, which showed a CA production of 0.065 g&#x02219;L<sup>&#x02212;1</sup>. </p><p>Recently, it was found that CepRS (cephamicyn regulator/sensor) is a TCS regulator with a key role in the cephamycin C biosynthesis [<xref rid="B109-antibiotics-10-00084" ref-type="bibr">109</xref>]. Although this TCS did not affect the production of CA, this mutant strain (<italic>&#x02206;cepRS</italic>) in combination with the overexpression of CA specific regulators may be an interesting alternative for improving CA production.</p><p>Expression of secondary metabolism in bacteria is also regulated by sigma factors. Sigma factors are proteins that recognize the RNA polymerase and allow the proper union to the gene promoter, leading to the synthesis of a mRNA molecule [<xref rid="B110-antibiotics-10-00084" ref-type="bibr">110</xref>]. Similarly, an anti-sigma factor inhibits the transcription, as they will bind to the RNA polymerase, thus preventing that sigma factors from mediating the binding to the promoter site [<xref rid="B110-antibiotics-10-00084" ref-type="bibr">110</xref>].</p><p>The sigma factor gene, <italic>orf21</italic>, is located downstream of the CA biosynthesis cluster in <italic>S. clavuligerus</italic>. Jnawali et al. [<xref rid="B111-antibiotics-10-00084" ref-type="bibr">111</xref>] disrupted and overexpressed this gene in a <italic>S. clavuligerus</italic> NRRL3585 and found a reduction 10&#x02013;15% in the levels of CA in the <italic>&#x02206;orf21</italic> mutant; while in the same conditions, overexpression of <italic>orf21</italic> exhibited a 1.45-fold increase in CA yields during fermentation. <italic>S. clavuligerus</italic> also encodes <italic>bldG</italic>, an anti-anti-sigma factor, which controls genes (regulated by sigma factors) involved in morphological development and secondary metabolite biosynthesis. Bignell and colleagues [<xref rid="B90-antibiotics-10-00084" ref-type="bibr">90</xref>] found that <italic>bldG</italic> regulates CA biosynthesis by modulating the expression of <italic>ccaR</italic>, and recently, this regulator has been associated with a direct regulatory role in the tunicamycin biosynthesis [<xref rid="B112-antibiotics-10-00084" ref-type="bibr">112</xref>].</p><p>The stringent response is a stress response phenomenon that occurs in bacteria under substrate starvation, e.g., amino acid deprivation, iron restriction, and other stringent conditions [<xref rid="B113-antibiotics-10-00084" ref-type="bibr">113</xref>]. This stress mechanism involves the RelA/SpoT protein system (ppGpp synthase (RelA) and (p)ppGpp synthase/hydrolase (SpoT)), which mediates the synthesis of phosphorylated nucleotides like (p)ppGpp [<xref rid="B24-antibiotics-10-00084" ref-type="bibr">24</xref>,<xref rid="B85-antibiotics-10-00084" ref-type="bibr">85</xref>]. This nucleotide exerts a regulatory role in ribosomal genes via RNA Polymerase binding it is also involved in the morphological differentiation of <italic>S. clavuligerus</italic> [<xref rid="B114-antibiotics-10-00084" ref-type="bibr">114</xref>]. Likewise, a <italic>relA</italic> mutant of <italic>S. clavuligerus</italic> showed reduced capability to yield both CA and cephamycin C [<xref rid="B115-antibiotics-10-00084" ref-type="bibr">115</xref>].</p><p>In addition to the strain design based on overexpression or mutation of regulatory genes, some research efforts have been focused in targeting the primary metabolism. Li and Townsend [<xref rid="B116-antibiotics-10-00084" ref-type="bibr">116</xref>] doubled CA production by deleting the <italic>gap1</italic> gene in a mutant of <italic>S. clavuligerus</italic> NRRL3585, increasing the glyceraldehyde 3-phosphate pool for CA biosynthesis. Jnawali et al. [<xref rid="B117-antibiotics-10-00084" ref-type="bibr">117</xref>] used the last approach along with the overexpression of ccaR and claR to create an overproducer engineered strain. Recently, overexpression of <italic>lysA</italic> in <italic>S. clavuligerus</italic> NRRL 3585, a gene involved in L-lysine biosynthesis (coding for a diaminopimelic acid decarboxylase), showed improvements in the production of CA, cephamycin C and tunicamycin.</p><p>In this decade, it has been also described engineered strains of <italic>S. clavuligerus</italic> perturbing random genes through mutagenesis techniques. Medema and colleagues [<xref rid="B118-antibiotics-10-00084" ref-type="bibr">118</xref>] engineered an industrial strain (DS48802) through an iterative process of mutagenesis and screening of <italic>S. clavuligerus</italic> ATCC 27064. This mutant strain produced CA levels 100 times more than the wild type. Likewise, an improvement in CA yields using mutagenesis induced by ultraviolet on <italic>Streptomyces sp. NRC77</italic> was reported [<xref rid="B119-antibiotics-10-00084" ref-type="bibr">119</xref>]. The authors found a mutant strain after screening <italic>(Streptomyces sp. MU-NRC77</italic>) that was able to produce 0.272 g&#x02219;L<sup>&#x02212;1</sup> of CA in the production medium, while the addition of H<sub>2</sub>O<sub>2</sub> and plant charcoal increased the production up to 0.649 and 0.683 g&#x02219;L<sup>&#x02212;1</sup>, respectively. Recently, Cruz-Hernandez et al. [<xref rid="B120-antibiotics-10-00084" ref-type="bibr">120</xref>] also used UV mutagenesis for enhanced CA titer by <italic>S. clavuligerus</italic>. The authors obtained mutants of <italic>S. clavuligerus</italic> ATCC 27064 via UV radiation, and one of them achieved a CA concentration of 0.500 g&#x02219;L<sup>&#x02212;1</sup>. Although both studies reported an increase of 5.2- and 1.6-fold on CA production compared to wild-type strain, respectively, the titers are too low to be considered in a large-scale process. The summary of studies reporting the highest CA titers using <italic>S. clavuligerus</italic> engineered strains is presented in <xref rid="antibiotics-10-00084-t001" ref-type="table">Table 1</xref>.</p><p>Despite <italic>S. clavuligerus</italic> being the strain commonly used in the large-scale process of CA production, there are other CA-producer <italic>Streptomyces</italic> species, which might be further studied and possibly engineered.</p></sec><sec id="sec5-antibiotics-10-00084"><title>5. Advances in Systems Level Understanding of the CA Production in <italic>S. clavuligerus</italic></title><p>In the recent decade, whole system-level approaches and omics technologies are being developed to explore and understand the existing complex interaction between different biological layers, such as the genome, transcriptome, proteome, and metabolism. A deeper understanding of the BGCs regulation and expression in <italic>S. clavuligerus</italic> is important to improve the CA production in submerged cultures. </p><p>The first draft genome of <italic>S. clavuligerus</italic> was sequenced by two independent research groups in 2010 [<xref rid="B121-antibiotics-10-00084" ref-type="bibr">121</xref>,<xref rid="B122-antibiotics-10-00084" ref-type="bibr">122</xref>]. The genome is composed of a 6.8 Mb chromosome and four linear plasmids named pSCL1 (11 kb), pSCL2 (150 kb), pSCL3 (430 kb), and pSCL4 (1.8 Mb), and a GC% of 72. The global annotation of this genome refers six rRNA operons, 66 tRNA genes, and 7898 protein-coding genes (5700 in the chromosome). The <italic>S. clavuligerus</italic> genome contains a plethora of BGCs that includes secondary metabolites like staurosporine, moenomycin, terpenes, pentalenenes, phytoenes, siderophores, lantibiotics, holomycin, cephamycin C, and CA [<xref rid="B121-antibiotics-10-00084" ref-type="bibr">121</xref>]. Specifically, the gene cluster of CA is situated in the chromosome and there exists a paralog gene cluster located in the pSCL4 plasmid codifying for CA and clavam metabolite production. In 2016, the genome of a <italic>S. clavuligerus</italic> industrial strain (F613-1) was sequenced. The assembly of the genome sequences identified a chromosome and a plasmid. The main differences were reported in the plasmid of F613-1, which contains a smaller number of coding genes compared to the 1.8 Mb megaplasmid of <italic>S. clavuligerus</italic> ATCC 27064 [<xref rid="B123-antibiotics-10-00084" ref-type="bibr">123</xref>]. The significance of these differences needs further investigations.</p><p>Recently, Hwang and colleagues [<xref rid="B124-antibiotics-10-00084" ref-type="bibr">124</xref>] performed a complete systems biology analysis for identifying new regulatory elements and BGCs in <italic>S. clavuligerus</italic> using new generation high-throughput technologies. In this research, the authors sequenced a high-quality genome of <italic>S. clavuligerus</italic> ATCC 27064, and it was used as a template to integrate the ribosome profiling and differential RNA-seq data. In that study, 58 potential BGCs were identified, including CA, 5S clavams, holomycin, tunicamycin, and 14 terpene type and 12 polyketides type BGCs. Furthermore, 2659 Transcription Start Sites (TSSs) and regulatory elements in the whole genome were identified. The same study reported that COG functional categories like coenzymes, secondary metabolites, inorganic ions, carbohydrate, and amino acid metabolism exhibited high differential expression levels during distinct growth phases while categories like signal transduction, replication, and cell division exhibited constitutive expression during all growth phases. Similarly, Lee and colleagues presented a high-quality genome and developed a data mining analysis for identifying secondary metabolite BGCs in thirty <italic>Streptomyces</italic> strains, including improvements in previous genome annotations and the identification of 43 BGCs in <italic>S. clavuligerus</italic> [<xref rid="B125-antibiotics-10-00084" ref-type="bibr">125</xref>]. Similar approaches were performed for other bacteria of the <italic>Streptomyces</italic> genus [<xref rid="B126-antibiotics-10-00084" ref-type="bibr">126</xref>].</p><p>Although the analysis and study of the transcriptome in <italic>S. clavuligerus</italic> have been relevant for identifying regulatory elements in the genome, they are also useful for understanding the up- or downregulation of metabolic pathways involved in CA production at specific nutritional conditions. In 2011, Medema et al. [<xref rid="B118-antibiotics-10-00084" ref-type="bibr">118</xref>] developed the first comparative transcriptome analysis of a <italic>S. clavuligerus</italic> industrial strain (engineered by random mutagenesis) versus a wild type strain. They captured transcript changes in central carbon and secondary metabolism, specifically, upregulation of ammonium and phosphate transporters, and glutamine and glutamate synthase genes. In 2014, &#x000c1;lvarez-&#x000c1;lvarez and co-workers [<xref rid="B127-antibiotics-10-00084" ref-type="bibr">127</xref>] developed a comparative transcriptomic analysis between a <italic>ccaR</italic>-deleted mutant and the wild type strain <italic>S. clavuligerus</italic> ATCC 27064. The authors observed that cephamycin C and CA biosynthetic genes were negatively regulated in the <italic>ccaR</italic> mutant, a gene expression pattern previously identified [<xref rid="B128-antibiotics-10-00084" ref-type="bibr">128</xref>]. Likewise, <italic>blip</italic> and <italic>blp</italic>, two genes encoding &#x003b2;-lactamase inhibitory proteins, were downregulated. The most interesting metabolic phenotype was the overexpression of all the genes involved in holomycin biosynthesis, in agreement with previous studies reporting high holomycin production in <italic>ccaR</italic> mutants [<xref rid="B129-antibiotics-10-00084" ref-type="bibr">129</xref>]. Similar results were found in a <italic>claR</italic> mutant; genes like <italic>hlmI</italic> and <italic>hlmH</italic> were upregulated during the entire fermentation [<xref rid="B130-antibiotics-10-00084" ref-type="bibr">130</xref>]. In contrast, poor regulation of genes in the initial and late steps of CA biosynthesis, and thus no CA production were detected [<xref rid="B130-antibiotics-10-00084" ref-type="bibr">130</xref>]. Recently, the <italic>oppA2</italic> gene (oligopeptide binding protein permease) was identified as essential for CA production [<xref rid="B131-antibiotics-10-00084" ref-type="bibr">131</xref>]. Transcriptional analysis of <italic>oppA2</italic> mutant compared to the wild type strain also allowed identifying upregulation of holomycin genes and no significant expression of cephamycin C and CA biosynthesis clusters. However, the most interesting result was that <italic>oppA2</italic> mutant secreted N-acetylglycyl-clavaminic acid, an intermediate of the CA biosynthesis. The evidence suggests that this peptide probably is bound to the <italic>OppA2</italic> protein forming a multi-enzymatic complex in the final stages of CA biosynthesis [<xref rid="B131-antibiotics-10-00084" ref-type="bibr">131</xref>]. A proteomic study of the same <italic>oppA2</italic> mutant identified high level abundance of rhodanese-like enzyme (<italic>rhlA</italic>, thiosulfate sulfur transferase) [<xref rid="B132-antibiotics-10-00084" ref-type="bibr">132</xref>]. Deletion of this gene showed impairment of holomycin (90%) and lower CA and cephamycin C production.</p><p>Overexpression of non-native transcriptional regulators into <italic>S. clavuligerus</italic> could become an interesting approach for improving antibiotic production in the <italic>Streptomyces</italic> genus. In 2019, Mart&#x000ed;nez-Burgos et al. [<xref rid="B133-antibiotics-10-00084" ref-type="bibr">133</xref>] overexpressed <italic>pimM</italic> in <italic>S. clavuligerus</italic> ATCC 27064, a PAS-LuxR activator of the pimaricin biosynthetic cluster present in <italic>Streptomyces nataliensis</italic>. A comparative transcriptome analysis indicated that overexpression of <italic>pimM</italic> triggers the production of both CA and cephamycin C, by affecting the expression of secondary metabolite gene clusters like SMC10, SMC13, and SMCp5, including the upregulation of CA biosynthesis and cephamycin C clusters [<xref rid="B133-antibiotics-10-00084" ref-type="bibr">133</xref>]. Untargeted metabolic profiling of the <italic>pimM</italic> expression identified antifungal compounds similar to tunicamycin.</p><p>A proteomic analysis comparing the wild type strain of <italic>S. clavuligerus</italic> and two mutants lacking the global regulators <italic>bldA</italic> and <italic>bldG</italic> (<italic>bldA</italic> regulates the morphological development and <italic>bldg</italic> regulates CA and cephamycin C production) was conducted [<xref rid="B134-antibiotics-10-00084" ref-type="bibr">134</xref>]. The authors showed that the <italic>bldA</italic> mutant reduced the CA production by 80%, while in the <italic>bldG</italic> mutant the CA levels were not detected compared to the wild type [<xref rid="B134-antibiotics-10-00084" ref-type="bibr">134</xref>]. The <italic>bldG</italic> mutant exhibited a large percentage of differentially expressed proteins; those classified in functional categories like metabolism, cellular processes, regulation, translation, and energetics. When compared to the wild type, the <italic>bldA</italic> mutant showed a lower percentage of differential expressed proteins in the same categories [<xref rid="B134-antibiotics-10-00084" ref-type="bibr">134</xref>]. The most interesting result of this whole-cell proteomic analysis was the detection of protein regulators (such as BldG, RshA, SigH, BldD, AdsA, BldC, AdpA, AfsA, AbsB, DraK, AfsK, and PhoP) involved in the regulatory cascade of CA biosynthesis [<xref rid="B134-antibiotics-10-00084" ref-type="bibr">134</xref>]. Another whole-cell proteome analysis was developed by &#x000dc;nsald&#x00131; et al. (2017). They performed a proteome-wide study in an industrial CA overproducer strain <italic>(S. clavuligerus</italic> DEPA) [<xref rid="B135-antibiotics-10-00084" ref-type="bibr">135</xref>]. In that case, three CA biosynthetic enzymes were overexpressed: (i) <italic>N</italic><sup>2</sup>-(2-carboxyethyl)-arginine synthase (CEAS2), (ii) clavaldehyde dehydrogenase (Car) (also known as clavulanic acid dehydrogenase (CAD)), and (iii) carboxyethyl-arginine &#x003b2;-lactam synthase (BLS2). The authors identified 33 different ORFs that were underexpressed and 60 ORFs that were overexpressed. A decrease on the expression level of genes associated with methionine biosynthesis and some enzymes of the glycolytic pathway were observed and identified as the main causes for the CA overproduction in the <italic>S. clavuligerus</italic> DEPA strain [<xref rid="B95-antibiotics-10-00084" ref-type="bibr">95</xref>,<xref rid="B135-antibiotics-10-00084" ref-type="bibr">135</xref>]. </p><p>Most previous studies have, at least, one point in common: the genes manipulated are involved, or related, to the clavam pathway. However, the evidence suggests that investigations should not target only the clavam pathway to enhance CA production. Despite the recent advances regarding the cephamycin C and CA gene cluster in <italic>S. clavuligerus</italic>, further research on those pathways and other regulatory pathways must be conducted in order to decipher the complex metabolism of <italic>S. clavuligerus</italic>. In this regard, ChIP-Seq, transcriptomic, and proteomic analysis may contribute to elucidate the mechanisms involved in the &#x0201c;late&#x0201d; steps, especially the genes responsible for the inversion of (3S, 5S)-clavaminic acid into (3R, 5R)-CA, and their regulation and connection with CA biosynthesis. Additionally, more studies focused on the 5S clavam branch are required. For instance, studies related with <italic>cvm6P</italic> (encode a putative aminotransferase responsible for the first reaction of the 5S clavam pathway) and the carbon flux control downstream this bifurcation point, as a strategy to enhance the CA production [<xref rid="B136-antibiotics-10-00084" ref-type="bibr">136</xref>].</p></sec><sec id="sec6-antibiotics-10-00084"><title>6. Genome-Scale Modeling: A Suitable Platform for Improving CA Production</title><p>As previously described, the development of high-throughput techniques has allowed to measure and quantify a high number of cellular molecular constituents from the different biological levels (genome, RNAs, proteins, metabolites, etc.). The analysis of omics data is giving lights about the interrelated or individual relationship of biological levels (genes, proteins, regulators, and metabolites) and the production of specialized metabolites [<xref rid="B137-antibiotics-10-00084" ref-type="bibr">137</xref>,<xref rid="B138-antibiotics-10-00084" ref-type="bibr">138</xref>,<xref rid="B139-antibiotics-10-00084" ref-type="bibr">139</xref>,<xref rid="B140-antibiotics-10-00084" ref-type="bibr">140</xref>]. However, the integration of multiple omics datasets for analyzing the interplay between biological levels is still a challenging task [<xref rid="B141-antibiotics-10-00084" ref-type="bibr">141</xref>,<xref rid="B142-antibiotics-10-00084" ref-type="bibr">142</xref>,<xref rid="B143-antibiotics-10-00084" ref-type="bibr">143</xref>,<xref rid="B144-antibiotics-10-00084" ref-type="bibr">144</xref>,<xref rid="B145-antibiotics-10-00084" ref-type="bibr">145</xref>,<xref rid="B146-antibiotics-10-00084" ref-type="bibr">146</xref>]. Most of the proposed methodologies for multi-omics data integration have been focused on the so-called element-based approaches (correlation, clustering, and multivariate analysis) [<xref rid="B147-antibiotics-10-00084" ref-type="bibr">147</xref>]. These are useful to define correlations or groups in a particular biological level and a specific condition, but not to reveal the molecular mechanisms associated with a specific cell phenotype. However, the use of mathematical-based approaches considering system components, network interaction, and physicochemical properties of the cell, poses as a suitable alternative for multi-omics data integration. Such approaches can be used to infer the interplay between biological levels through the identification of mechanisms governing the cell phenotype.</p><p>A mathematical-based approach that allows studying the metabolic fluxes and phenotypes of a cell under a plethora of nutritional/genetic/regulatory perturbations is the genome-scale metabolic modeling (GEMs) [<xref rid="B148-antibiotics-10-00084" ref-type="bibr">148</xref>,<xref rid="B149-antibiotics-10-00084" ref-type="bibr">149</xref>]. This mathematical platform along with the integration of omics data (genomics, transcriptomics, proteomics, metabolomics, etc.) has demonstrated usefulness in guiding experimental efforts and elucidating mechanisms affecting cell phenotypes in many different cell types [<xref rid="B150-antibiotics-10-00084" ref-type="bibr">150</xref>,<xref rid="B151-antibiotics-10-00084" ref-type="bibr">151</xref>,<xref rid="B152-antibiotics-10-00084" ref-type="bibr">152</xref>,<xref rid="B153-antibiotics-10-00084" ref-type="bibr">153</xref>,<xref rid="B154-antibiotics-10-00084" ref-type="bibr">154</xref>,<xref rid="B155-antibiotics-10-00084" ref-type="bibr">155</xref>,<xref rid="B156-antibiotics-10-00084" ref-type="bibr">156</xref>]. </p><p>Usually, GEMs contain all the biochemical knowledge of a cell through the formulation of mass balances per metabolites and the existing association between genes, proteins/enzymes, and reactions [<xref rid="B157-antibiotics-10-00084" ref-type="bibr">157</xref>]. The stationary mass balance is the simplest mathematical formulation allowing computing carbon fluxes under specific nutritional conditions. The mass balances are represented in a stoichiometric matrix multiplied by an unknown vector of reaction velocities (reaction fluxes), configuring a linear programming problem with an objective function based on some evolution criteria like the maximization of growth or energy production yield [<xref rid="B158-antibiotics-10-00084" ref-type="bibr">158</xref>]. Under this consideration the in silico cells use most of the available nutrients to grow as expected to occur under the appropriated biological conditions [<xref rid="B159-antibiotics-10-00084" ref-type="bibr">159</xref>]. This approach is vastly known as Flux Balance Analysis (FBA) and it is widely used for studying cell metabolism in many areas of research [<xref rid="B160-antibiotics-10-00084" ref-type="bibr">160</xref>,<xref rid="B161-antibiotics-10-00084" ref-type="bibr">161</xref>].</p><p>Application and use of genome-scale metabolic modeling of <italic>Streptomyces</italic> bacteria is currently an active field of study [<xref rid="B138-antibiotics-10-00084" ref-type="bibr">138</xref>,<xref rid="B145-antibiotics-10-00084" ref-type="bibr">145</xref>,<xref rid="B162-antibiotics-10-00084" ref-type="bibr">162</xref>,<xref rid="B163-antibiotics-10-00084" ref-type="bibr">163</xref>,<xref rid="B164-antibiotics-10-00084" ref-type="bibr">164</xref>], including the modeling of <italic>S. clavuligerus</italic> metabolism (<xref ref-type="fig" rid="antibiotics-10-00084-f004">Figure 4</xref>) [<xref rid="B19-antibiotics-10-00084" ref-type="bibr">19</xref>,<xref rid="B43-antibiotics-10-00084" ref-type="bibr">43</xref>,<xref rid="B122-antibiotics-10-00084" ref-type="bibr">122</xref>,<xref rid="B165-antibiotics-10-00084" ref-type="bibr">165</xref>,<xref rid="B166-antibiotics-10-00084" ref-type="bibr">166</xref>]. </p><p>In 2000, Kirk and colleagues [<xref rid="B167-antibiotics-10-00084" ref-type="bibr">167</xref>] published the first reconstructed metabolic model of <italic>S. clavuligerus;</italic> a mathematical model limited to central carbon metabolism, amino acid biosynthesis, anaplerotic reactions, urea cycle, and the specific pathway of CA biosynthesis. This model was used to explore the metabolic adaptation strategies of <italic>S. clavuligerus</italic> during a chemostat culture under phosphate, carbon and nitrogen limitations. The researchers found that anaplerotic metabolism decreases under carbon limitation, limiting the use of alpha-keto glutarate from the TCA cycle to synthesize C5 precursors. Conversely, under phosphate limited conditions the flux through C5 precursors was favored, increasing the CA production. </p><p>In 2010, Medema and colleagues [<xref rid="B122-antibiotics-10-00084" ref-type="bibr">122</xref>] used the annotation information of <italic>S. clavuligerus</italic> ATCC 27064 genome in the reconstruction of the first genome-scale metabolic model of <italic>S. clavuligerus</italic> (iMM864). This model encompasses 1492 reactions, 971 metabolites, and 864 genes; it was used to simulate growth on different nitrogen and carbon sources and evaluate essentiality of the 1.8 Mb megaplasmid identified in <italic>S. clavuligerus</italic> ATCC 27064. Later, the same authors demonstrated that the FBA predicts the metabolic fluxes through the biosynthetic precursors of CA; in line with the gene expression data of the <italic>S. clavuligerus</italic> overproducer strains (<italic>claR/ccaR</italic> overexpression and <italic>&#x02206;gap1</italic>) [<xref rid="B118-antibiotics-10-00084" ref-type="bibr">118</xref>]. </p><p>In 2015, a stoichiometric model of <italic>S. clavuligerus</italic> (containing 100 reactions and 91 metabolites) expanded from the first model was used to explore the effect of nutrients (carbon, nitrogen, and phosphate) and oxygen limitations on CA production [<xref rid="B44-antibiotics-10-00084" ref-type="bibr">44</xref>,<xref rid="B167-antibiotics-10-00084" ref-type="bibr">167</xref>]. The authors found that maximization of ATP yield was the best objective function as it was the most suitable function for predicting CA production. Likewise, they found that during the phosphate limitation, CA production was favored when glutamate flux and the precursors of the urea cycle increased. </p><p>In 2018, two model updates of iMM864 were published. First, the iLT1021 GEM containing 1494 reactions, 1360 metabolites, and 1021 genes, using ATP yield as the best objective function to represent <italic>S. clavuligerus</italic> cultivated in chemostat mode, while growth rate was used as the objective function for the batch cultures [<xref rid="B165-antibiotics-10-00084" ref-type="bibr">165</xref>]. The authors identified the NAD+ synthase, <italic>glyK</italic>, and <italic>idh</italic> genes as the best metabolic targets for improving the CA production. In 2018, Ramirez-Malule and colleagues [<xref rid="B43-antibiotics-10-00084" ref-type="bibr">43</xref>] also improved the iMM864 GEM by including gene&#x02013;reaction associations and gap-filling curation. This model was used to characterize the TCA strategies used by <italic>S. clavuligerus</italic> at four different growth conditions associated with CA production [<xref rid="B43-antibiotics-10-00084" ref-type="bibr">43</xref>]. The authors found that CA biosynthesis correlates positively with accumulation of oxaloacetate, succinate, and acetate, while it correlates negatively with accumulation of malate at different feeding conditions in continuous cultures [<xref rid="B43-antibiotics-10-00084" ref-type="bibr">43</xref>]. Additionally, FBA-fluxes inferred from experimental data predicted that the phosphoenolpyruvate carboxylase activation triggers CA production. In contrast, the activation of the glyoxylate shunt (by isocitrate lyase) matched with carbon limitation conditions and a negative effect on CA titers [<xref rid="B43-antibiotics-10-00084" ref-type="bibr">43</xref>]. </p><p>The last model was updated and curated in 2019, containing 1534 reactions, 1199 metabolites and 871 genes [<xref rid="B166-antibiotics-10-00084" ref-type="bibr">166</xref>]. Although this model was not validated with experimental data, it explored 18 objective functions and metabolic phenotypes of <italic>S. clavuligerus</italic> during production of CA and Cephamycin C.</p><p>Finally, in 2020, a new and independent reconstruction was published [<xref rid="B19-antibiotics-10-00084" ref-type="bibr">19</xref>]. The topologically and thermodynamically curated iDG1237 GEM encompasses 2177 reactions, 1518 metabolites, and 1237 genes. This model was validated with experimental data and used to get insights about the metabolic reprograming strategies of <italic>S. clavuligerus</italic> under high and low shear stress conditions (intracellular nutrient availability). The authors showed that during phosphate-limited and low shear stress conditions the CA production halved due to the existence of overflow metabolism coincident with accumulation of TCA intermediates. These evidences suggest that GEMs constitute valuable platforms for exploring the metabolism of <italic>S. clavuligerus</italic> under different experimental and nutritional conditions. We invite the <italic>S. clavuligerus</italic> community to use these models along with multi-omics datasets for getting further insights about the regulatory links between genes, proteins and metabolism in order to improve CA production at the industrial level.</p></sec><sec id="sec7-antibiotics-10-00084"><title>7. Downstream Processing of CA </title><p>Due to its low molecular weight and its instability in aqueous solution at room temperature diverse processes for CA separation and purification have been employed, e.g., filtration or centrifugation, liquid&#x02013;liquid extraction, and ion exchange chromatography. In addition to the characteristic low productivity of the bioprocess, the product yield is also compromised by the degradation of CA in aqueous phases and the efficiency of the separation steps required for the obtention of potassium clavulanate (the stable commercial form). Several authors have confirmed the degradation of CA in fermentation broths [<xref rid="B67-antibiotics-10-00084" ref-type="bibr">67</xref>,<xref rid="B69-antibiotics-10-00084" ref-type="bibr">69</xref>,<xref rid="B168-antibiotics-10-00084" ref-type="bibr">168</xref>,<xref rid="B169-antibiotics-10-00084" ref-type="bibr">169</xref>,<xref rid="B170-antibiotics-10-00084" ref-type="bibr">170</xref>], synthetic buffer [<xref rid="B68-antibiotics-10-00084" ref-type="bibr">68</xref>,<xref rid="B171-antibiotics-10-00084" ref-type="bibr">171</xref>,<xref rid="B172-antibiotics-10-00084" ref-type="bibr">172</xref>], and pure water [<xref rid="B173-antibiotics-10-00084" ref-type="bibr">173</xref>,<xref rid="B174-antibiotics-10-00084" ref-type="bibr">174</xref>,<xref rid="B175-antibiotics-10-00084" ref-type="bibr">175</xref>]. The CA secreted by <italic>S. clavuligerus</italic> exhibits a high initial reaction rate (~5 h) in aqueous solution (e.g., fermentation broths) followed by a slower degradation rate in the next hours [<xref rid="B168-antibiotics-10-00084" ref-type="bibr">168</xref>,<xref rid="B169-antibiotics-10-00084" ref-type="bibr">169</xref>]. Degradation of CA is considered consequence of susceptibility to nucleophilic attacks at specific points. This acts as a hydrolytic mechanism in two steps: an equilibrium reaction leading to an active intermediate and an irreversible reaction of this intermediate with another CA molecule, thus leading to the degradation product [<xref rid="B67-antibiotics-10-00084" ref-type="bibr">67</xref>,<xref rid="B176-antibiotics-10-00084" ref-type="bibr">176</xref>,<xref rid="B177-antibiotics-10-00084" ref-type="bibr">177</xref>]. As consequence, CA increases its own degradation rate when increasing concentration in the fermentation broth [<xref rid="B68-antibiotics-10-00084" ref-type="bibr">68</xref>,<xref rid="B176-antibiotics-10-00084" ref-type="bibr">176</xref>]. Usually, CA purification starts (after cultivation process) with the removal of the cells from cultivation broth either by centrifugation or filtration. Then, the antibiotic is separated through adsorption, liquid extraction, or both, followed by the clavulanate salt precipitation. Nevertheless, the observed instability of CA makes the efficient recovery necessary to improve the profitability of the CA production process at reduced operation costs.</p><p>One of the most explored alternatives for CA recovery from fermentation broths is the adsorption with selective materials such as ion exchange resins, activated carbon, hydrotalcites, zeolites, and double-layer hydroxides. This technique allows the biomolecules to be selectively adsorbed in solid materials while minimizing the degradation of the product. Forte et al. [<xref rid="B178-antibiotics-10-00084" ref-type="bibr">178</xref>,<xref rid="B179-antibiotics-10-00084" ref-type="bibr">179</xref>] studied the CA recovery from aqueous solutions by using natural and synthetic zeolites, namely, faujasite-type NaX zeolite (13X) and clinoptilolite&#x02013;mordenite zeolite (NZ) and their modified cationic forms (K<sup>+</sup>, Na<sup>+</sup>, Ca<sup>2+</sup>, Ba<sup>2+</sup>, Mg<sup>2+</sup>, Sr<sup>2+</sup>), with aperture diameters ranging 0.062 and 0.150 mm. The 13X&#x000ad;-Na zeolite showed the best CA retention (17.4%) in the equilibrium at a zeolite/liquid ratio of 0.5 mg.g<sup>&#x02212;1</sup> [<xref rid="B178-antibiotics-10-00084" ref-type="bibr">178</xref>]. Higher retention levels have been obtained in separations with quaternary ammonium anionic exchange resins, such as Amberlite IRA 400 and Q Sepharose XL. In this regard, Barboza et al. [<xref rid="B180-antibiotics-10-00084" ref-type="bibr">180</xref>,<xref rid="B181-antibiotics-10-00084" ref-type="bibr">181</xref>] studied the temperature effect on CA adsorption and desorption in flask-scale experiments, showing that CA removal from aqueous solution is very favorable (retention values between 60 and 70%) at temperatures ranging from 5 to 10 &#x000b0;C given the exothermicity of the CA-resin bonding. The desorption process is facilitated by higher temperatures (up to 30 &#x000b0;C) than the adsorption, the equilibrium time is almost doubled and the desorption ratio is about 60% [<xref rid="B180-antibiotics-10-00084" ref-type="bibr">180</xref>,<xref rid="B181-antibiotics-10-00084" ref-type="bibr">181</xref>]. Almeida et al. [<xref rid="B182-antibiotics-10-00084" ref-type="bibr">182</xref>] proposed a simultaneous adsorption/desorption system of CA using sequential stirred tanks, allowing the recycling of the fermentation supernatants and hence, increasing the CA adsorption percentages. Absorption operations in packed columns with IRA 400 operating at a flow rate of 0.3 L&#x02219;h<sup>&#x02212;1</sup> and 10 &#x000b0;C were used, followed by desorption with 2% NaCl at 30 &#x000b0;C. Even though the absorption in fixed beds have provided good results in terms of separation and concentration, CA degradation may occur within the sites of the ion-exchange resin, reducing the overall yield of the process [<xref rid="B183-antibiotics-10-00084" ref-type="bibr">183</xref>]. The rapid CA degradation in aqueous media has implications on the selection of the separation technology, the shorter the time of CA in aqueous solution, the lower its degradation. Furthermore, the complete CA desorption from the ion exchange matrix doubles the adsorption time, increasing the product losses. The layered double hydroxides (LDHs) have been also explored for CA adsorption from aqueous solutions. LDHs are mixed hydroxides with layers of divalent, trivalent cations, and hydroxyl anions capable of anion exchange [<xref rid="B184-antibiotics-10-00084" ref-type="bibr">184</xref>]. The interlayer domain is constituted by water molecules and anions [<xref rid="B184-antibiotics-10-00084" ref-type="bibr">184</xref>]. When using calcined hydrotalcite LDHs containing 70% MgO in a solid&#x02013;liquid ratio of 15.0 g&#x02219;L<sup>&#x02212;1</sup>, complete adsorption of CA was observed [<xref rid="B184-antibiotics-10-00084" ref-type="bibr">184</xref>]. CA adsorption into Zn<sub>2</sub>Cr-NO<sub>3</sub>, Zn<sub>2</sub>Al-NO<sub>3</sub>, and Mg<sub>2</sub>Al-NO<sub>3</sub> LDHs was satisfactory, but the best results were observed for the Zn<sub>2</sub>Cr-NO<sub>3</sub> LDH microencapsulated with calcium alginate, showing a purification factor of about 2.3 and CA recovery between 93 and 99% [<xref rid="B185-antibiotics-10-00084" ref-type="bibr">185</xref>,<xref rid="B186-antibiotics-10-00084" ref-type="bibr">186</xref>].</p><p>Aqueous two-phase systems (ATPS) have been also studied for CA separation from fermentation broths. ATPS are formed when two hydrophilic components are mixed in water above a threshold concentration [<xref rid="B187-antibiotics-10-00084" ref-type="bibr">187</xref>]. Two polymers or a polymer and a salt are commonly used. Those systems are convenient for the purification of bioactive compounds due to the high water content (70&#x02013;90%) in both phases [<xref rid="B187-antibiotics-10-00084" ref-type="bibr">187</xref>]. The use of ATPS for CA recovery from cultivation broths was first reported by Videira and Barros [<xref rid="B188-antibiotics-10-00084" ref-type="bibr">188</xref>]. The authors used the ATPS of polyethylene glycol (PEG) and potassium phosphate for CA extraction. Under the conditions tested, CA showed high affinity to the PEG-rich (top) phase, yielding recoveries ranging from 90 to 99% [<xref rid="B188-antibiotics-10-00084" ref-type="bibr">188</xref>]. The subsequent optimization studies confirmed the high recovery ratio of this technique, using PEG with molecular mass of 400 daltons at pH 6.4 and top/bottom phase volume ratios of 42 and 1.3, respectively [<xref rid="B189-antibiotics-10-00084" ref-type="bibr">189</xref>]. Similar results have been observed when using other PEG based ATPS like those formed by PEG/citrate, PEG/polyacrylate and PEG/cholinium chloride [<xref rid="B187-antibiotics-10-00084" ref-type="bibr">187</xref>,<xref rid="B190-antibiotics-10-00084" ref-type="bibr">190</xref>,<xref rid="B191-antibiotics-10-00084" ref-type="bibr">191</xref>]. Furthermore, Silva et al. [<xref rid="B192-antibiotics-10-00084" ref-type="bibr">192</xref>] used ATPS followed by ion-exchange adsorption for CA separation from complex fermentation broths with high amino acids content. The ATPS-Ion exchange system produced CA recoveries of 100% in both stages, which is higher than the separation reached when using single ion-exchange adsorption. However, the CA degradation rate in ATPS systems remains to be assessed given the susceptibility of CA to hydrolysis via nucleophilic attacks to the carbonyl group [<xref rid="B176-antibiotics-10-00084" ref-type="bibr">176</xref>].</p><p>Viana-Marques and co-workers [<xref rid="B193-antibiotics-10-00084" ref-type="bibr">193</xref>] investigated the application of ATPS in the CA extractive fermentation with a variant of <italic>S. variabilis</italic> in the shake flask and bioreactor scales, taking advantage of the high extraction levels attained with this separation strategy. ATPS 25% PEG 8000 g&#x02219;mol<sup>&#x02212;1</sup> and phosphate salts led to CA productivity of 5.3 mg.(L&#x02219;h)<sup>&#x02212;1</sup> [<xref rid="B193-antibiotics-10-00084" ref-type="bibr">193</xref>]. The CA concentration in the PEG-rich phase was 691 mg&#x02219;L<sup>&#x02212;1</sup>, which was 30% higher than in the cultivation broth [<xref rid="B193-antibiotics-10-00084" ref-type="bibr">193</xref>]. In the bioreactor scale (950 rpm, 3.5 vvm), this strategy allowed a maximum CA production of 434&#x02009;mg&#x02219;L<sup>&#x02212;1</sup> [<xref rid="B194-antibiotics-10-00084" ref-type="bibr">194</xref>]. The authors emphasized that this technology constitutes a low-cost platform to simultaneously produce and recover CA with high yields. Similarly, Lopes-Costa and Colli-Badino employed extractive fermentation using IRA 400 ion-exchange resin, obtaining a CA recovery of 78%; thus, increasing the cumulative CA concentration in 248% compared to the control without product removal [<xref rid="B195-antibiotics-10-00084" ref-type="bibr">195</xref>]. The increase of CA productivity when it is adsorbed from the fermentation broth supports the hypothesis that high CA concentration may inhibit the antibiotic biosynthesis. </p><p>A different approach considers the use of aqueous two-phase micellar systems (ATPMS). Those are micellar solutions that separate spontaneously in two phases: a micelle-rich phase and a micelle&#x02011;poor phase, depending on operating conditions (pH, ionic strength, and temperature) [<xref rid="B196-antibiotics-10-00084" ref-type="bibr">196</xref>]. An ATPMS employing the surfactant n-decyltetraethylene oxide showed preferential partition of proteins towards the micelle-rich phase, but if a denaturation step is applied prior to extraction, the 52% of CA is recovered in this phase [<xref rid="B196-antibiotics-10-00084" ref-type="bibr">196</xref>]. ATPMS formed by the non-ionic surfactant Triton X-114 (0.022%) and an anionic one (1%) allowed a CA recovery of 86.3% at 28 &#x000b0;C [<xref rid="B197-antibiotics-10-00084" ref-type="bibr">197</xref>]. Similarly, ATPMS of dextran sulfate with non-ionic surfactants Triton X-114 or Triton X-100 have been also used for CA purification, yielding CA recoveries of 80 and 50%, respectively [<xref rid="B198-antibiotics-10-00084" ref-type="bibr">198</xref>]. </p><p>Aqueous CA from fermentation broths or concentrated solutions can also be extracted by simple liquid extraction with organic solvents. The evaluation of organic solvents butyl acetate, ethyl acetate, n-butanol, 2-butanol, and methyl isobutyl ketone showed that CA partition coefficient is related to solvent properties like dielectric constant and species solubility [<xref rid="B199-antibiotics-10-00084" ref-type="bibr">199</xref>]. Although CA distribution coefficients for 2-butanol and n-butanol were found to be higher than for the esters and the methyl&#x02011;isobutyl ketone; the high solubility of light alcohols in water makes them impractical for further CA precipitation. For extraction purposes is desirable a water&#x02011;immiscible organic phase, which also reduces the degradation susceptibility of the molecule. Brites and colleagues [<xref rid="B199-antibiotics-10-00084" ref-type="bibr">199</xref>] concluded that ethyl acetate is the best option considering the subsequent precipitation steps required for the formation of clavulanate salts, yielding a CA extraction of 35.6% with partition coefficient of 0.73 in acidic conditions. Furthermore, organic solvent mixtures containing methyl&#x02011;ethyl ketone/ethyl acetate and methyl&#x02011;isobutyl ketone/ethyl acetate allow higher extraction levels of CA from fermentation broths. The equivolumetric mixtures of methyl&#x02011;ethyl ketone/ethyl acetate and ethyl&#x02011;isobutyl ketone/ethyl acetate led to extraction yields of 50 and 44.7%, respectively, which is approximately 30% higher compared to the obtained for single ethyl acetate extraction [<xref rid="B200-antibiotics-10-00084" ref-type="bibr">200</xref>]. </p><p>As CA is marketed in salt form, the direct precipitation from aqueous solutions, either fermentation broths or concentrated solutions, has been studied as a purification alternative. CA extracted via organic solvents can be precipitated in two steps: (i) reaction of CA with an aliphatic amine to form a stable CA-amine salt and (ii) precipitation with potassium 2-ethyl hexanoate [<xref rid="B201-antibiotics-10-00084" ref-type="bibr">201</xref>]. However, CA can be precipitated directly from the organic solvent by addition of potassium 2-ethyl hexanoate without requiring the formation of a stable intermediate [<xref rid="B202-antibiotics-10-00084" ref-type="bibr">202</xref>]. However, slightly higher yield was observed when the amine intermediate is formed (72.4%) compared to the direct precipitation method (69.5%) [<xref rid="B201-antibiotics-10-00084" ref-type="bibr">201</xref>,<xref rid="B202-antibiotics-10-00084" ref-type="bibr">202</xref>].</p></sec><sec id="sec8-antibiotics-10-00084"><title>8. Concluding Remarks</title><p>Genetic modification of genes involved, or related to, the clavam pathway leads to improvement of CA production in <italic>S. clavuligerus.</italic> This pathway constitutes a key point for engineering CA overproducer strains aimed to the large-scale application. Despite the high number of successful studies involving synthetic biology approaches, alternative bioprocessing strategies, identification of genes related to pathway regulation, metabolic modeling, and downstream processing, novel strategies need to be implemented to pave the way to higher CA productivity in the antibiotics industry. Thus, a multidisciplinary research approach combining microbiology, bioprocess engineering, biochemistry, molecular biology, analytical chemistry, and computational biology would help to unravel the intrinsic metabolic complexity of CA biosynthesis. The connection of CA with the reaction-steps in the clavam pathway and its relationship with the biosynthesis and release of other antibiotics like the cephamycins and penicillins should be further studied considering the interaction between the biological layers.</p></sec></body><back><fn-group><fn><p><bold>Publisher&#x02019;s Note:</bold> MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><notes><title>Author Contributions</title><p>Conceptualization, H.R.-M.; methodology, V.A.L.-A., D.G.-R., and H.R.-M.; investigation, V.A.L.-A., D.G.-R., and H.R.-M.; resources, H.R.-M.; writing&#x02014;original draft preparation, V.A.L.-A., D.G.-R., and H.R.-M.; writing&#x02014;review and editing, H.R.-M.; visualization, V.A.L.-A., D.G.-R., and H.R.-M.; supervision, H.R.-M.; project administration, H.R.-M.; funding acquisition, H.R.-M. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Funding</title><p>This research was funded by Universidad del Valle C.I. 21108 and the MinCiencias Postdoctoral Fellowship 848-2019 approved with the project: &#x0201c;Desarrollo de un modelo metab&#x000f3;lico cin&#x000e9;tico a escala del genoma que capture eventos de adaptaci&#x000f3;n metab&#x000f3;lica en <italic>Streptomyces clavuligerus</italic>&#x0201d;.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.</p></notes><ref-list><title>References</title><ref id="B1-antibiotics-10-00084"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>G&#x000f3;mez-R&#x000ed;os</surname><given-names>D.</given-names></name><name><surname>Ram&#x000ed;rez-Malule</surname><given-names>H.</given-names></name></person-group><article-title>Bibliometric analysis of recent research on multidrug and antibiotics resistance (2017&#x02013;2018)</article-title><source>J. Appl. Pharm. Sci.</source><year>2019</year><volume>9</volume><fpage>112</fpage><lpage>116</lpage><pub-id pub-id-type="doi">10.7324/JAPS.2019.90515</pub-id></element-citation></ref><ref id="B2-antibiotics-10-00084"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Landecker</surname><given-names>H.</given-names></name></person-group><article-title>Antibiotic Resistance and the Biology of History</article-title><source>Body Soc.</source><year>2016</year><volume>22</volume><fpage>19</fpage><lpage>52</lpage><pub-id pub-id-type="doi">10.1177/1357034X14561341</pub-id><pub-id pub-id-type="pmid">28458609</pub-id></element-citation></ref><ref id="B3-antibiotics-10-00084"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davies</surname><given-names>J.</given-names></name><name><surname>Davies</surname><given-names>D.</given-names></name></person-group><article-title>Origins and Evolution of Antibiotic Resistance</article-title><source>Microbiol. Mol. Biol. Rev.</source><year>2010</year><volume>74</volume><fpage>417</fpage><lpage>433</lpage><pub-id pub-id-type="doi">10.1128/MMBR.00016-10</pub-id><?supplied-pmid 20805405?><pub-id pub-id-type="pmid">20805405</pub-id></element-citation></ref><ref id="B4-antibiotics-10-00084"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abraham</surname><given-names>E.P.</given-names></name><name><surname>Chain</surname><given-names>E.</given-names></name></person-group><article-title>An enzyme from bacteria able to destroy penicillin</article-title><source>Nature</source><year>1940</year><volume>146</volume><fpage>837</fpage><pub-id pub-id-type="doi">10.1038/146837a0</pub-id></element-citation></ref><ref id="B5-antibiotics-10-00084"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bush</surname><given-names>K.</given-names></name><name><surname>Bradford</surname><given-names>P.A.</given-names></name></person-group><article-title>&#x003b2;-Lactams and &#x003b2;-Lactamase Inhibitors: An Overview</article-title><source>Cold Spring Harb. Perspect. Med.</source><year>2016</year><volume>6</volume><fpage>a025247</fpage><pub-id pub-id-type="doi">10.1101/cshperspect.a025247</pub-id><?supplied-pmid 27329032?><pub-id pub-id-type="pmid">27329032</pub-id></element-citation></ref><ref id="B6-antibiotics-10-00084"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saudagar</surname><given-names>P.S.</given-names></name><name><surname>Survase</surname><given-names>S.A.</given-names></name><name><surname>Singhal</surname><given-names>R.S.</given-names></name></person-group><article-title>Clavulanic acid: A review</article-title><source>Biotechnol. Adv.</source><year>2008</year><volume>26</volume><fpage>335</fpage><lpage>351</lpage><pub-id pub-id-type="doi">10.1016/j.biotechadv.2008.03.002</pub-id><pub-id pub-id-type="pmid">18450406</pub-id></element-citation></ref><ref id="B7-antibiotics-10-00084"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reading</surname><given-names>C.</given-names></name><name><surname>Cole</surname><given-names>M.</given-names></name></person-group><article-title>Clavulanic acid: A beta-lactamase-inhiting beta-lactam from Streptomyces clavuligerus</article-title><source>Antimicrob. Agents Chemother.</source><year>1977</year><volume>11</volume><fpage>852</fpage><lpage>857</lpage><pub-id pub-id-type="doi">10.1128/AAC.11.5.852</pub-id><pub-id pub-id-type="pmid">879738</pub-id></element-citation></ref><ref id="B8-antibiotics-10-00084"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huttner</surname><given-names>A.</given-names></name><name><surname>Bielicki</surname><given-names>J.</given-names></name><name><surname>Clements</surname><given-names>M.N.</given-names></name><name><surname>Frimodt-M&#x000f8;ller</surname><given-names>N.</given-names></name><name><surname>Muller</surname><given-names>A.E.</given-names></name><name><surname>Paccaud</surname><given-names>J.-P.</given-names></name><name><surname>Mouton</surname><given-names>J.W.</given-names></name></person-group><article-title>Oral amoxicillin and amoxicillin&#x02013;clavulanic acid: Properties, indications and usage</article-title><source>Clin. Microbiol. Infect.</source><year>2020</year><pub-id pub-id-type="doi">10.1016/j.cmi.2019.11.028</pub-id></element-citation></ref><ref id="B9-antibiotics-10-00084"><label>9.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Mutlu</surname><given-names>A.</given-names></name></person-group><source>Increasing Clavulanic Acid Production both in Wild Type and Industrial Streptomyces Clavuligerus Strains by Amplification of Positive Regulator claR Gene</source><publisher-name>Middle East Technical University</publisher-name><publisher-loc>&#x000c7;ankaya/Ankara, Turkey</publisher-loc><year>2012</year></element-citation></ref><ref id="B10-antibiotics-10-00084"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Viana Marques</surname><given-names>D.A.</given-names></name><name><surname>Feitosa Machado</surname><given-names>S.E.</given-names></name><name><surname>Santos Ebinuma</surname><given-names>V.C.</given-names></name><name><surname>de Lima Duarte</surname><given-names>C.A.</given-names></name><name><surname>Converti</surname><given-names>A.</given-names></name><name><surname>Porto</surname><given-names>A.L.F.</given-names></name></person-group><article-title>Production of &#x003b2; -Lactamase Inhibitors by Streptomyces Species</article-title><source>Antibiotics</source><year>2018</year><volume>7</volume><elocation-id>61</elocation-id><pub-id pub-id-type="doi">10.3390/antibiotics7030061</pub-id></element-citation></ref><ref id="B11-antibiotics-10-00084"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nagarajan</surname><given-names>R.</given-names></name><name><surname>Boeck</surname><given-names>L.D.</given-names></name><name><surname>Gorman</surname><given-names>M.</given-names></name><name><surname>Hamill</surname><given-names>R.L.</given-names></name><name><surname>Higgens</surname><given-names>C.E.</given-names></name><name><surname>Hoehn</surname><given-names>M.M.</given-names></name><name><surname>Stark</surname><given-names>W.M.</given-names></name><name><surname>Whitney</surname><given-names>J.G.</given-names></name></person-group><article-title>&#x003b2;-Lactam antibiotics from Streptomyces</article-title><source>J. Am. Chem. Soc.</source><year>1971</year><volume>93</volume><fpage>2308</fpage><lpage>2310</lpage><pub-id pub-id-type="doi">10.1021/ja00738a035</pub-id><pub-id pub-id-type="pmid">5553073</pub-id></element-citation></ref><ref id="B12-antibiotics-10-00084"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Higgens</surname><given-names>C.E.</given-names></name><name><surname>Kastner</surname><given-names>R.E.</given-names></name></person-group><article-title>Streptomyces Clavuligerus sp.nov. a B-Lactam Antibiotic Producer</article-title><source>Int. J. Syst. Bacteriol.</source><year>1971</year><volume>21</volume><fpage>326</fpage><lpage>331</lpage><pub-id pub-id-type="doi">10.1099/00207713-21-4-326</pub-id></element-citation></ref><ref id="B13-antibiotics-10-00084"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Howarth</surname><given-names>T.T.</given-names></name><name><surname>Brown</surname><given-names>A.G.</given-names></name><name><surname>King</surname><given-names>T.J.</given-names></name></person-group><article-title>Clavulanic acid, a novel &#x003b2;-lactam isolated from Streptomyces clavuligerus; X-ray crystal structure analysis</article-title><source>J. Chem. Soc. Chem. Commun.</source><year>1976</year><fpage>266b</fpage><lpage>267b</lpage><pub-id pub-id-type="doi">10.1039/C3976000266B</pub-id></element-citation></ref><ref id="B14-antibiotics-10-00084"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clardy</surname><given-names>J.</given-names></name><name><surname>Fischbach</surname><given-names>M.A.</given-names></name><name><surname>Currie</surname><given-names>C.R.</given-names></name></person-group><article-title>The natural history of antibiotics</article-title><source>Curr. Biol.</source><year>2009</year><volume>19</volume><fpage>R437</fpage><lpage>R441</lpage><pub-id pub-id-type="doi">10.1016/j.cub.2009.04.001</pub-id><?supplied-pmid 19515346?><pub-id pub-id-type="pmid">19515346</pub-id></element-citation></ref><ref id="B15-antibiotics-10-00084"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Watve</surname><given-names>M.G.</given-names></name><name><surname>Tickoo</surname><given-names>R.</given-names></name><name><surname>Jog</surname><given-names>M.M.</given-names></name><name><surname>Bhole</surname><given-names>B.D.</given-names></name></person-group><article-title>How many antibiotics are produced by the genus Streptomyces?</article-title><source>Arch. Microbiol.</source><year>2001</year><volume>176</volume><fpage>386</fpage><lpage>390</lpage><pub-id pub-id-type="doi">10.1007/s002030100345</pub-id><?supplied-pmid 11702082?><pub-id pub-id-type="pmid">11702082</pub-id></element-citation></ref><ref id="B16-antibiotics-10-00084"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>J.</given-names></name><name><surname>Zhang</surname><given-names>J.</given-names></name><name><surname>Zhuo</surname><given-names>J.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Tian</surname><given-names>Y.</given-names></name><name><surname>Tan</surname><given-names>H.</given-names></name></person-group><article-title>Activation and mechanism of a cryptic oviedomycin gene cluster via the disruption of a global regulatory gene, adpA, in Streptomyces ansochromogenes</article-title><source>J. Biol. Chem.</source><year>2017</year><volume>292</volume><fpage>19708</fpage><lpage>19720</lpage><pub-id pub-id-type="doi">10.1074/jbc.M117.809145</pub-id><pub-id pub-id-type="pmid">28972184</pub-id></element-citation></ref><ref id="B17-antibiotics-10-00084"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peng</surname><given-names>Q.</given-names></name><name><surname>Gao</surname><given-names>G.</given-names></name><name><surname>L&#x000fc;</surname><given-names>J.</given-names></name><name><surname>Long</surname><given-names>Q.</given-names></name><name><surname>Chen</surname><given-names>X.</given-names></name><name><surname>Zhang</surname><given-names>F.</given-names></name><name><surname>Xu</surname><given-names>M.</given-names></name><name><surname>Liu</surname><given-names>K.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Deng</surname><given-names>Z.</given-names></name><etal/></person-group><article-title>Engineered streptomyces lividans strains for optimal identification and expression of cryptic biosynthetic gene clusters</article-title><source>Front. Microbiol.</source><year>2018</year><volume>9</volume><pub-id pub-id-type="doi">10.3389/fmicb.2018.03042</pub-id></element-citation></ref><ref id="B18-antibiotics-10-00084"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nguyen</surname><given-names>H.T.</given-names></name><name><surname>Pham</surname><given-names>V.T.T.</given-names></name><name><surname>Nguyen</surname><given-names>C.T.</given-names></name><name><surname>Pokhrel</surname><given-names>A.R.</given-names></name><name><surname>Kim</surname><given-names>T.S.</given-names></name><name><surname>Kim</surname><given-names>D.H.</given-names></name><name><surname>Na</surname><given-names>K.</given-names></name><name><surname>Yamaguchi</surname><given-names>T.</given-names></name><name><surname>Sohng</surname><given-names>J.K.</given-names></name></person-group><article-title>Exploration of cryptic organic photosensitive compound as Zincphyrin IV in Streptomyces venezuelae ATCC 15439</article-title><source>Appl. Microbiol. Biotechnol.</source><year>2020</year><volume>104</volume><fpage>713</fpage><lpage>724</lpage><pub-id pub-id-type="doi">10.1007/s00253-019-10262-x</pub-id><pub-id pub-id-type="pmid">31820068</pub-id></element-citation></ref><ref id="B19-antibiotics-10-00084"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>G&#x000f3;mez-R&#x000ed;os</surname><given-names>D.</given-names></name><name><surname>L&#x000f3;pez-Agudelo</surname><given-names>V.A.</given-names></name><name><surname>Ram&#x000ed;rez-Malule</surname><given-names>H.</given-names></name><name><surname>Neubauer</surname><given-names>P.</given-names></name><name><surname>Junne</surname><given-names>S.</given-names></name><name><surname>Ochoa</surname><given-names>S.</given-names></name><name><surname>R&#x000ed;os-Estepa</surname><given-names>R.</given-names></name></person-group><article-title>A Genome-Scale Insight into the Effect of Shear Stress During the Fed-Batch Production of Clavulanic Acid by Streptomyces Clavuligerus</article-title><source>Microorganisms</source><year>2020</year><volume>8</volume><elocation-id>1255</elocation-id><pub-id pub-id-type="doi">10.3390/microorganisms8091255</pub-id></element-citation></ref><ref id="B20-antibiotics-10-00084"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Esnault</surname><given-names>C.</given-names></name><name><surname>Dulermo</surname><given-names>T.</given-names></name><name><surname>Smirnov</surname><given-names>A.</given-names></name><name><surname>Askora</surname><given-names>A.</given-names></name><name><surname>David</surname><given-names>M.</given-names></name><name><surname>Deniset-Besseau</surname><given-names>A.</given-names></name><name><surname>Holland</surname><given-names>I.B.</given-names></name><name><surname>Virolle</surname><given-names>M.J.</given-names></name></person-group><article-title>Strong antibiotic production is correlated with highly active oxidative metabolism in Streptomyces coelicolor M145</article-title><source>Sci. Rep.</source><year>2017</year><volume>7</volume><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1038/s41598-017-00259-9</pub-id><pub-id pub-id-type="pmid">28127051</pub-id></element-citation></ref><ref id="B21-antibiotics-10-00084"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Millan-Oropeza</surname><given-names>A.</given-names></name><name><surname>Henry</surname><given-names>C.</given-names></name><name><surname>Lejeune</surname><given-names>C.</given-names></name><name><surname>David</surname><given-names>M.</given-names></name><name><surname>Virolle</surname><given-names>M.-J.</given-names></name></person-group><article-title>Expression of genes of the Pho regulon is altered in Streptomyces coelicolor</article-title><source>Sci. Rep.</source><year>2020</year><volume>10</volume><fpage>8492</fpage><pub-id pub-id-type="doi">10.1038/s41598-020-65087-w</pub-id><pub-id pub-id-type="pmid">32444655</pub-id></element-citation></ref><ref id="B22-antibiotics-10-00084"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cho</surname><given-names>H.</given-names></name><name><surname>Uehara</surname><given-names>T.</given-names></name><name><surname>Bernhardt</surname><given-names>T.G.</given-names></name></person-group><article-title>Beta-Lactam Antibiotics Induce a Lethal Malfunctioning of the Bacterial Cell Wall Synthesis Machinery</article-title><source>Cell</source><year>2014</year><volume>159</volume><fpage>1300</fpage><lpage>1311</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2014.11.017</pub-id><?supplied-pmid 25480295?><pub-id pub-id-type="pmid">25480295</pub-id></element-citation></ref><ref id="B23-antibiotics-10-00084"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Virolle</surname><given-names>M.-J.</given-names></name></person-group><article-title>A Challenging View: Antibiotics Play a Role in the Regulation of the Energetic Metabolism of the Producing Bacteria</article-title><source>Antibiotics</source><year>2020</year><volume>9</volume><elocation-id>83</elocation-id><pub-id pub-id-type="doi">10.3390/antibiotics9020083</pub-id><?supplied-pmid 32069930?><pub-id pub-id-type="pmid">32069930</pub-id></element-citation></ref><ref id="B24-antibiotics-10-00084"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paradkar</surname><given-names>A.</given-names></name></person-group><article-title>Clavulanic acid production by Streptomyces clavuligerus: Biogenesis, regulation and strain improvement</article-title><source>J. Antibiot.</source><year>2013</year><volume>66</volume><fpage>411</fpage><lpage>420</lpage><pub-id pub-id-type="doi">10.1038/ja.2013.26</pub-id><?supplied-pmid 23612724?><pub-id pub-id-type="pmid">23612724</pub-id></element-citation></ref><ref id="B25-antibiotics-10-00084"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jensen</surname><given-names>S.E.</given-names></name></person-group><article-title>Biosynthesis of clavam metabolites</article-title><source>J. Ind. Microbiol. Biotechnol.</source><year>2012</year><volume>39</volume><fpage>1407</fpage><lpage>1419</lpage><pub-id pub-id-type="doi">10.1007/s10295-012-1191-0</pub-id><pub-id pub-id-type="pmid">22948564</pub-id></element-citation></ref><ref id="B26-antibiotics-10-00084"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hamed</surname><given-names>R.B.</given-names></name><name><surname>Gomez-Castellanos</surname><given-names>J.R.</given-names></name><name><surname>Henry</surname><given-names>L.</given-names></name><name><surname>Ducho</surname><given-names>C.</given-names></name><name><surname>McDonough</surname><given-names>M.A.</given-names></name><name><surname>Schofield</surname><given-names>C.J.</given-names></name></person-group><article-title>The enzymes of &#x003b2;-lactam biosynthesis</article-title><source>Nat. Prod. Rep.</source><year>2013</year><volume>30</volume><fpage>21</fpage><lpage>107</lpage><pub-id pub-id-type="doi">10.1039/C2NP20065A</pub-id><pub-id pub-id-type="pmid">23135477</pub-id></element-citation></ref><ref id="B27-antibiotics-10-00084"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bachmann</surname><given-names>B.</given-names></name><name><surname>Li</surname><given-names>R.</given-names></name><name><surname>Townsend</surname><given-names>C.</given-names></name></person-group><article-title>beta-Lactam synthetase: A new biosynthetic enzyme</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>1998</year><volume>95</volume><fpage>9082</fpage><lpage>9086</lpage><pub-id pub-id-type="doi">10.1073/pnas.95.16.9082</pub-id><pub-id pub-id-type="pmid">9689037</pub-id></element-citation></ref><ref id="B28-antibiotics-10-00084"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bachmann</surname><given-names>B.O.</given-names></name><name><surname>Townsend</surname><given-names>C.A.</given-names></name></person-group><article-title>Kinetic mechanism of the &#x003b2;-lactam synthetase of streptomyces clavuligerus</article-title><source>Biochemistry</source><year>2000</year><volume>39</volume><fpage>11187</fpage><lpage>11193</lpage><pub-id pub-id-type="doi">10.1021/bi000709i</pub-id><pub-id pub-id-type="pmid">10985764</pub-id></element-citation></ref><ref id="B29-antibiotics-10-00084"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tahlan</surname><given-names>K.</given-names></name><name><surname>Park</surname><given-names>H.U.</given-names></name><name><surname>Wong</surname><given-names>A.</given-names></name><name><surname>Beatty</surname><given-names>P.H.</given-names></name><name><surname>Jensen</surname><given-names>S.E.</given-names></name></person-group><article-title>Two Sets of Paralogous Genes Encode the Enzymes Involved in the Early Stages of Clavulanic Acid and Clavam Metabolite Biosynthesis in Streptomyces clavuligerus</article-title><source>Antimicrob. Agents Chemother.</source><year>2004</year><volume>48</volume><fpage>930</fpage><lpage>939</lpage><pub-id pub-id-type="doi">10.1128/AAC.48.3.930-939.2004</pub-id><pub-id pub-id-type="pmid">14982786</pub-id></element-citation></ref><ref id="B30-antibiotics-10-00084"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salowe</surname><given-names>S.P.</given-names></name><name><surname>Marsh</surname><given-names>E.N.</given-names></name><name><surname>Townsend</surname><given-names>C.A.</given-names></name></person-group><article-title>Purification and characterization of clavaminate synthase from Streptomyces clavuligerus: An unusual oxidative enzyme in natural product biosynthesis</article-title><source>Biochemistry</source><year>1990</year><volume>29</volume><fpage>6499</fpage><lpage>6508</lpage><pub-id pub-id-type="doi">10.1021/bi00479a023</pub-id><pub-id pub-id-type="pmid">2207091</pub-id></element-citation></ref><ref id="B31-antibiotics-10-00084"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Busby</surname><given-names>R.W.</given-names></name><name><surname>Chang</surname><given-names>M.D.-T.</given-names></name><name><surname>Busby</surname><given-names>R.C.</given-names></name><name><surname>Wimp</surname><given-names>J.</given-names></name><name><surname>Townsend</surname><given-names>C.A.</given-names></name></person-group><article-title>Expression and Purification of Two Isozymes of Clavaminate Synthase and Initial Characterization of the Iron Binding Site</article-title><source>J. Biol. Chem.</source><year>1995</year><volume>270</volume><fpage>4262</fpage><lpage>4269</lpage><pub-id pub-id-type="doi">10.1074/jbc.270.9.4262</pub-id><pub-id pub-id-type="pmid">7876185</pub-id></element-citation></ref><ref id="B32-antibiotics-10-00084"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Z.</given-names></name><name><surname>Ren</surname><given-names>J.S.</given-names></name><name><surname>Harlos</surname><given-names>K.</given-names></name><name><surname>McKinnon</surname><given-names>C.H.</given-names></name><name><surname>Clifton</surname><given-names>I.J.</given-names></name><name><surname>Schofield</surname><given-names>C.J.</given-names></name></person-group><article-title>Crystal structure of a clavaminate synthase-Fe(II)-2-oxoglutarate-substrate-NO complex: Evidence for metal centered rearrangements</article-title><source>FEBS Lett.</source><year>2002</year><volume>517</volume><fpage>7</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1016/S0014-5793(02)02520-6</pub-id><pub-id pub-id-type="pmid">12062399</pub-id></element-citation></ref><ref id="B33-antibiotics-10-00084"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Caines</surname><given-names>M.E.C.</given-names></name><name><surname>Elkins</surname><given-names>J.M.</given-names></name><name><surname>Hewitson</surname><given-names>K.S.</given-names></name><name><surname>Schofield</surname><given-names>C.J.</given-names></name></person-group><article-title>Crystal Structure and Mechanistic Implications of N 2-(2-Carboxyethyl)arginine Synthase, the First Enzyme in the Clavulanic Acid Biosynthesis Pathway</article-title><source>J. Biol. Chem.</source><year>2004</year><volume>279</volume><fpage>5685</fpage><lpage>5692</lpage><pub-id pub-id-type="doi">10.1074/jbc.M310803200</pub-id><?supplied-pmid 14623876?><pub-id pub-id-type="pmid">14623876</pub-id></element-citation></ref><ref id="B34-antibiotics-10-00084"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>T.K.</given-names></name><name><surname>Busby</surname><given-names>R.W.</given-names></name><name><surname>Houston</surname><given-names>T.A.</given-names></name><name><surname>Mcilwaine</surname><given-names>D.B.</given-names></name><name><surname>Egan</surname><given-names>L.A.</given-names></name><name><surname>Townsend</surname><given-names>C.A.</given-names></name><name><surname>Wu</surname><given-names>T.</given-names></name><name><surname>Busby</surname><given-names>R.W.</given-names></name><name><surname>Houston</surname><given-names>T.A.</given-names></name><name><surname>Ilwaine</surname><given-names>D.B.M.C.</given-names></name><etal/></person-group><article-title>Identification, Cloning, Sequencing, and overexpression of the gene encoding proclavaminate amidino hydrolase and characterization of protein function in clavulanic acid biosynthesis</article-title><source>J. Bacteriol.</source><year>1995</year><volume>177</volume><fpage>3714</fpage><lpage>3720</lpage><pub-id pub-id-type="doi">10.1128/JB.177.13.3714-3720.1995</pub-id><?supplied-pmid 7601835?><pub-id pub-id-type="pmid">7601835</pub-id></element-citation></ref><ref id="B35-antibiotics-10-00084"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shrestha</surname><given-names>B.</given-names></name><name><surname>Dhakal</surname><given-names>D.</given-names></name><name><surname>Darsandhari</surname><given-names>S.</given-names></name><name><surname>Pandey</surname><given-names>R.P.</given-names></name><name><surname>Pokhrel</surname><given-names>A.R.</given-names></name><name><surname>Jnawali</surname><given-names>H.N.</given-names></name><name><surname>Sohng</surname><given-names>J.K.</given-names></name></person-group><article-title>Heterologous production of clavulanic acid intermediates in Streptomyces venezuelae</article-title><source>Biotechnol. Bioprocess. Eng.</source><year>2017</year><volume>22</volume><fpage>359</fpage><lpage>365</lpage><pub-id pub-id-type="doi">10.1007/s12257-017-0187-z</pub-id></element-citation></ref><ref id="B36-antibiotics-10-00084"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ramirez-Malule</surname><given-names>H.</given-names></name><name><surname>Restrepo</surname><given-names>A.</given-names></name><name><surname>Cardona</surname><given-names>W.</given-names></name><name><surname>Junne</surname><given-names>S.</given-names></name><name><surname>Neubauer</surname><given-names>P.</given-names></name><name><surname>Rios-Estepa</surname><given-names>R.</given-names></name></person-group><article-title>Inversion of the stereochemical configuration (3S, 5S)-clavaminic acid into (3R, 5R)-clavulanic acid: A computationally-assisted approach based on experimental evidence</article-title><source>J. Theor. Biol.</source><year>2016</year><volume>395</volume><fpage>40</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.1016/j.jtbi.2016.01.028</pub-id><pub-id pub-id-type="pmid">26835563</pub-id></element-citation></ref><ref id="B37-antibiotics-10-00084"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arulanantham</surname><given-names>H.</given-names></name><name><surname>Kershaw</surname><given-names>N.J.</given-names></name><name><surname>Hewitson</surname><given-names>K.S.</given-names></name><name><surname>Hughes</surname><given-names>C.E.</given-names></name><name><surname>Thirkettle</surname><given-names>J.E.</given-names></name><name><surname>Schofield</surname><given-names>C.J.</given-names></name></person-group><article-title>ORF17 from the clavulanic acid biosynthesis gene cluster catalyzes the ATP-dependent formation of N-glycyl-clavaminic acid</article-title><source>J. Biol. Chem.</source><year>2006</year><volume>281</volume><fpage>279</fpage><lpage>287</lpage><pub-id pub-id-type="doi">10.1074/jbc.M507711200</pub-id><pub-id pub-id-type="pmid">16251194</pub-id></element-citation></ref><ref id="B38-antibiotics-10-00084"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>MacKenzie</surname><given-names>A.K.</given-names></name><name><surname>Kershaw</surname><given-names>N.J.</given-names></name><name><surname>Hernandez</surname><given-names>H.</given-names></name><name><surname>Robinson</surname><given-names>C.V.</given-names></name><name><surname>Schofield</surname><given-names>C.J.</given-names></name><name><surname>Andersson</surname><given-names>I.</given-names></name></person-group><article-title>Clavulanic Acid Dehydrogenase: Structural and Biochemical Analysis of the Final Step in the Biosynthesis of the &#x003b2;-Lactamase Inhibitor Clavulanic Acid</article-title><source>Biochemistry</source><year>2007</year><volume>46</volume><fpage>1523</fpage><lpage>1533</lpage><pub-id pub-id-type="doi">10.1021/bi061978x</pub-id><pub-id pub-id-type="pmid">17279617</pub-id></element-citation></ref><ref id="B39-antibiotics-10-00084"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>G&#x000f3;mez</surname><given-names>S.</given-names></name><name><surname>Ram&#x000ed;rez-Malule</surname><given-names>H.</given-names></name><name><surname>Cardona-G</surname><given-names>W.</given-names></name><name><surname>Osorio</surname><given-names>E.</given-names></name><name><surname>Restrepo</surname><given-names>A.</given-names></name></person-group><article-title>Double-Ring Epimerization in the Biosynthesis of Clavulanic Acid</article-title><source>J. Phys. Chem. A</source><year>2020</year><volume>124</volume><fpage>9413</fpage><lpage>9426</lpage><pub-id pub-id-type="doi">10.1021/acs.jpca.0c05427</pub-id><pub-id pub-id-type="pmid">33135896</pub-id></element-citation></ref><ref id="B40-antibiotics-10-00084"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zelyas</surname><given-names>N.J.</given-names></name><name><surname>Cai</surname><given-names>H.</given-names></name><name><surname>Kwong</surname><given-names>T.</given-names></name><name><surname>Jensen</surname><given-names>S.E.</given-names></name></person-group><article-title>Alanylclavam biosynthetic genes are clustered together with one group of clavulanic acid biosynthetic genes in Streptomyces clavuligerus</article-title><source>J. Bacteriol.</source><year>2008</year><volume>190</volume><fpage>7957</fpage><lpage>7965</lpage><pub-id pub-id-type="doi">10.1128/JB.00698-08</pub-id><pub-id pub-id-type="pmid">18931110</pub-id></element-citation></ref><ref id="B41-antibiotics-10-00084"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nobary</surname><given-names>S.G.</given-names></name><name><surname>Jensen</surname><given-names>S.E.</given-names></name></person-group><article-title>A comparison of the clavam biosynthetic gene clusters in Streptomyces antibioticus T&#x000fc;1718 and Streptomyces clavuligerus</article-title><source>Can. J. Microbiol.</source><year>2012</year><volume>58</volume><fpage>413</fpage><lpage>425</lpage><pub-id pub-id-type="doi">10.1139/w2012-012</pub-id><pub-id pub-id-type="pmid">22435762</pub-id></element-citation></ref><ref id="B42-antibiotics-10-00084"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bushell</surname><given-names>M.E.</given-names></name><name><surname>Kirk</surname><given-names>S.</given-names></name><name><surname>Zhao</surname><given-names>H.-J.</given-names></name><name><surname>Avignone-Rossa</surname><given-names>C.A.</given-names></name></person-group><article-title>Manipulation of the physiology of clavulanic acid biosynthesis with the aid of metabolic flux analysis</article-title><source>Enzyme Microb. Technol.</source><year>2006</year><volume>39</volume><fpage>149</fpage><lpage>157</lpage><pub-id pub-id-type="doi">10.1016/j.enzmictec.2006.01.017</pub-id></element-citation></ref><ref id="B43-antibiotics-10-00084"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ramirez-Malule</surname><given-names>H.</given-names></name><name><surname>Junne</surname><given-names>S.</given-names></name><name><surname>Nicol&#x000e1;s Cruz-Bournazou</surname><given-names>M.</given-names></name><name><surname>Neubauer</surname><given-names>P.</given-names></name><name><surname>R&#x000ed;os-Estepa</surname><given-names>R.</given-names></name></person-group><article-title>Streptomyces clavuligerus shows a strong association between TCA cycle intermediate accumulation and clavulanic acid biosynthesis</article-title><source>Appl. Microbiol. Biotechnol.</source><year>2018</year><volume>102</volume><fpage>4009</fpage><lpage>4023</lpage><pub-id pub-id-type="doi">10.1007/s00253-018-8841-8</pub-id><?supplied-pmid 29523936?><pub-id pub-id-type="pmid">29523936</pub-id></element-citation></ref><ref id="B44-antibiotics-10-00084"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>S&#x000e1;nchez</surname><given-names>C.</given-names></name><name><surname>Quintero</surname><given-names>J.C.</given-names></name><name><surname>Ochoa</surname><given-names>S.</given-names></name></person-group><article-title>Flux balance analysis in the production of clavulanic acid by Streptomyces clavuligerus</article-title><source>Biotechnol. Prog.</source><year>2015</year><volume>31</volume><fpage>1226</fpage><lpage>1236</lpage><pub-id pub-id-type="doi">10.1002/btpr.2132</pub-id><?supplied-pmid 26171767?><pub-id pub-id-type="pmid">26171767</pub-id></element-citation></ref><ref id="B45-antibiotics-10-00084"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cavallieri</surname><given-names>A.P.</given-names></name><name><surname>Baptista</surname><given-names>A.S.</given-names></name><name><surname>Leite</surname><given-names>C.A.</given-names></name><name><surname>da Costa Araujo</surname><given-names>M.L.G.</given-names></name></person-group><article-title>A case study in flux balance analysis: Lysine, a cephamycin C precursor, can also increase clavulanic acid production</article-title><source>Biochem. Eng. J.</source><year>2016</year><volume>112</volume><fpage>42</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.1016/j.bej.2016.03.012</pub-id></element-citation></ref><ref id="B46-antibiotics-10-00084"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kenig</surname><given-names>M.</given-names></name><name><surname>Reading</surname><given-names>C.</given-names></name></person-group><article-title>Holomycin and an antibiotic (mm 19290) related to tunicamycin, metabolites of streptomyces clavuligerus</article-title><source>J. Antibiot.</source><year>1979</year><volume>32</volume><fpage>549</fpage><lpage>554</lpage><pub-id pub-id-type="doi">10.7164/antibiotics.32.549</pub-id><?supplied-pmid 468729?><pub-id pub-id-type="pmid">468729</pub-id></element-citation></ref><ref id="B47-antibiotics-10-00084"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Antonio</surname><given-names>T.</given-names></name><name><surname>Bell&#x000e3;o</surname><given-names>C.</given-names></name><name><surname>Corr&#x000ea;a</surname><given-names>T.</given-names></name><name><surname>Cavallieri</surname><given-names>A.P.</given-names></name><name><surname>Badino</surname><given-names>A.C.</given-names></name><name><surname>da Costa Araujo</surname><given-names>M.L.G.</given-names></name></person-group><article-title>Evaluation of different media for the production of cephalosporins by streptomyces clavuligerus ATCC 27064</article-title><source>Braz. Arch. Biol. Technol.</source><year>2012</year><volume>55</volume><fpage>819</fpage><lpage>825</lpage><pub-id pub-id-type="doi">10.1590/S1516-89132012000600003</pub-id></element-citation></ref><ref id="B48-antibiotics-10-00084"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goo</surname><given-names>K.S.</given-names></name><name><surname>Chua</surname><given-names>C.S.</given-names></name><name><surname>Sim</surname><given-names>T.S.</given-names></name></person-group><article-title>Directed evolution and rational approaches to improving Streptomyces clavuligerus deacetoxycephalosporin C synthase for cephalosporin production</article-title><source>J. Ind. Microbiol. Biotechnol.</source><year>2009</year><volume>36</volume><fpage>619</fpage><lpage>633</lpage><pub-id pub-id-type="doi">10.1007/s10295-009-0549-4</pub-id><pub-id pub-id-type="pmid">19277744</pub-id></element-citation></ref><ref id="B49-antibiotics-10-00084"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>&#x000d6;ster</surname><given-names>L.M.</given-names></name><name><surname>Lester</surname><given-names>D.R.</given-names></name><name><surname>van Scheltinga</surname><given-names>A.T.</given-names></name><name><surname>Svenda</surname><given-names>M.</given-names></name><name><surname>van Lun</surname><given-names>M.</given-names></name><name><surname>G&#x000e9;n&#x000e9;reux</surname><given-names>C.</given-names></name><name><surname>Andersson</surname><given-names>I.</given-names></name></person-group><article-title>Insights into Cephamycin Biosynthesis: The Crystal Structure of CmcI from Streptomyces clavuligerus</article-title><source>J. Mol. Biol.</source><year>2006</year><volume>358</volume><fpage>546</fpage><lpage>558</lpage><pub-id pub-id-type="doi">10.1016/j.jmb.2006.02.004</pub-id><pub-id pub-id-type="pmid">16527306</pub-id></element-citation></ref><ref id="B50-antibiotics-10-00084"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liras</surname><given-names>P.</given-names></name></person-group><article-title>Holomycin, a dithiolopyrrolone compound produced by Streptomyces clavuligerus</article-title><source>Appl. Microbiol. Biotechnol.</source><year>2014</year><volume>98</volume><fpage>1023</fpage><lpage>1030</lpage><pub-id pub-id-type="doi">10.1007/s00253-013-5410-z</pub-id><pub-id pub-id-type="pmid">24323287</pub-id></element-citation></ref><ref id="B51-antibiotics-10-00084"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sim</surname><given-names>J.</given-names></name><name><surname>Sim</surname><given-names>T.S.</given-names></name></person-group><article-title>In vitro conversion of penicillin G and ampicillin by recombinant Streptomyces clavuligerus NRRL 3585 deacetoxycephalosporin C synthase</article-title><source>Enzyme Microb. Technol.</source><year>2001</year><volume>29</volume><fpage>240</fpage><lpage>245</lpage><pub-id pub-id-type="doi">10.1016/S0141-0229(01)00377-5</pub-id></element-citation></ref><ref id="B52-antibiotics-10-00084"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Law</surname><given-names>K.H.</given-names></name><name><surname>Tsang</surname><given-names>M.W.</given-names></name><name><surname>Wong</surname><given-names>Y.K.</given-names></name><name><surname>Tsang</surname><given-names>M.S.</given-names></name><name><surname>Lau</surname><given-names>P.Y.</given-names></name><name><surname>Wong</surname><given-names>K.Y.</given-names></name><name><surname>Ho</surname><given-names>K.P.</given-names></name><name><surname>Leung</surname><given-names>Y.C.</given-names></name></person-group><article-title>Efficient production of secretory streptomyces clavuligerus &#x003b2;-lactamase inhibitory protein (Blip) in pichia pastoris</article-title><source>AMB Express</source><year>2018</year><volume>8</volume><fpage>1</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.1186/s13568-018-0586-3</pub-id><?supplied-pmid 29679312?><pub-id pub-id-type="pmid">29302756</pub-id></element-citation></ref><ref id="B53-antibiotics-10-00084"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paradkar</surname><given-names>A.S.</given-names></name><name><surname>Petrich</surname><given-names>A.K.</given-names></name><name><surname>Leskiw</surname><given-names>B.K.</given-names></name><name><surname>Aidoo</surname><given-names>K.A.</given-names></name><name><surname>Jensen</surname><given-names>S.E.</given-names></name></person-group><article-title>Transcriptional analysis and heterologous expression of the gene encoding &#x003b2;-lactamase inhibitor protein (BLIP) from Streptomyces clavuligerus</article-title><source>Gene</source><year>1994</year><volume>144</volume><fpage>31</fpage><lpage>36</lpage><pub-id pub-id-type="doi">10.1016/0378-1119(94)90199-6</pub-id><pub-id pub-id-type="pmid">7517906</pub-id></element-citation></ref><ref id="B54-antibiotics-10-00084"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Doran</surname><given-names>J.L.</given-names></name><name><surname>Leskiw</surname><given-names>B.K.</given-names></name><name><surname>Aippersbach</surname><given-names>S.</given-names></name><name><surname>Jensen</surname><given-names>S.E.</given-names></name></person-group><article-title>Isolation and Characterization of a &#x003b2;-Lactamase-Inhibitory Protein from Streptomyces Clavuligerus and Cloning and Analysis of the Corresponding Gene</article-title><source>J. Bacteriol.</source><year>1990</year><volume>172</volume><fpage>4909</fpage><lpage>4918</lpage><pub-id pub-id-type="doi">10.1128/JB.172.9.4909-4918.1990</pub-id><?supplied-pmid 2203736?><pub-id pub-id-type="pmid">2203736</pub-id></element-citation></ref><ref id="B55-antibiotics-10-00084"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ser</surname><given-names>H.-L.</given-names></name><name><surname>Law</surname><given-names>J.W.-F.</given-names></name><name><surname>Chaiyakunapruk</surname><given-names>N.</given-names></name><name><surname>Jacob</surname><given-names>S.A.</given-names></name><name><surname>Palanisamy</surname><given-names>U.D.</given-names></name><name><surname>Chan</surname><given-names>K.-G.</given-names></name><name><surname>Goh</surname><given-names>B.-H.</given-names></name><name><surname>Lee</surname><given-names>L.-H.</given-names></name></person-group><article-title>Fermentation Conditions that Affect Clavulanic Acid Production in Streptomyces clavuligerus: A Systematic Review</article-title><source>Front. Microbiol.</source><year>2016</year><volume>7</volume><fpage>522</fpage><pub-id pub-id-type="doi">10.3389/fmicb.2016.00522</pub-id><?supplied-pmid 27148211?><pub-id pub-id-type="pmid">27148211</pub-id></element-citation></ref><ref id="B56-antibiotics-10-00084"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sanches Henao</surname><given-names>C.P.</given-names></name><name><surname>Gomez Grimaldos</surname><given-names>N.A.</given-names></name><name><surname>Quintero Diaz</surname><given-names>J.C.</given-names></name></person-group><article-title>Producci&#x000f3;n de acido clavul&#x000e1;nico por fermentaci&#x000f3;n de streptomyces clavuligerus: Evaluaci&#x000f3;n de diferentes medios de cultivo y modelado matem&#x000e1;tico</article-title><source>Dyna</source><year>2012</year><volume>79</volume><fpage>158</fpage><lpage>165</lpage></element-citation></ref><ref id="B57-antibiotics-10-00084"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bell&#x000e3;o</surname><given-names>C.</given-names></name><name><surname>Antonio</surname><given-names>T.</given-names></name><name><surname>Araujo</surname><given-names>M.L.G.C.</given-names></name><name><surname>Badino</surname><given-names>A.C.</given-names></name></person-group><article-title>Production of clavulanic acid and cephamycin c by streptomyces clavuligerus under different fed-batch conditions</article-title><source>Braz. J. Chem. Eng.</source><year>2013</year><volume>30</volume><fpage>257</fpage><lpage>266</lpage><pub-id pub-id-type="doi">10.1590/S0104-66322013000200004</pub-id></element-citation></ref><ref id="B58-antibiotics-10-00084"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saudagar</surname><given-names>P.S.</given-names></name><name><surname>Singhal</surname><given-names>R.S.</given-names></name></person-group><article-title>Optimization of nutritional requirements and feeding strategies for clavulanic acid production by Streptomyces clavuligerus</article-title><source>Bioresour. Technol.</source><year>2007</year><volume>98</volume><fpage>2010</fpage><lpage>2017</lpage><pub-id pub-id-type="doi">10.1016/j.biortech.2006.08.003</pub-id><pub-id pub-id-type="pmid">17011778</pub-id></element-citation></ref><ref id="B59-antibiotics-10-00084"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bussari</surname><given-names>B.</given-names></name><name><surname>Saudagar</surname><given-names>P.S.</given-names></name><name><surname>Shaligram</surname><given-names>N.S.</given-names></name><name><surname>Survase</surname><given-names>S.A.</given-names></name><name><surname>Singhal</surname><given-names>R.S.</given-names></name></person-group><article-title>Production of cephamycin C by Streptomyces clavuligerus NT4 using solid-state fermentation</article-title><source>J. Ind. Microbiol. Biotechnol.</source><year>2008</year><volume>35</volume><fpage>49</fpage><lpage>58</lpage><pub-id pub-id-type="doi">10.1007/s10295-007-0265-x</pub-id><pub-id pub-id-type="pmid">17940818</pub-id></element-citation></ref><ref id="B60-antibiotics-10-00084"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>da Silva Rodrigues</surname><given-names>K.C.</given-names></name><name><surname>de Souza</surname><given-names>A.T.</given-names></name><name><surname>Badino</surname><given-names>A.C.</given-names></name><name><surname>Pedrolli</surname><given-names>D.B.</given-names></name><name><surname>Cerri</surname><given-names>M.O.</given-names></name></person-group><article-title>Biotechnology and Industrial Microbiology Screening of medium constituents for clavulanic acid production by Streptomyces clavuligerus</article-title><source>Braz. J. Microbiol.</source><year>2018</year><volume>49</volume><fpage>832</fpage><lpage>839</lpage><pub-id pub-id-type="doi">10.1016/j.bjm.2018.01.006</pub-id><pub-id pub-id-type="pmid">29588197</pub-id></element-citation></ref><ref id="B61-antibiotics-10-00084"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Neto</surname><given-names>A.B.</given-names></name><name><surname>Hirata</surname><given-names>D.B.</given-names></name><name><surname>Cassiano Filho</surname><given-names>L.C.M.</given-names></name><name><surname>Bell&#x000e3;o</surname><given-names>C.</given-names></name><name><surname>Badino</surname><given-names>A.C.</given-names><suffix>Jr.</suffix></name><name><surname>Hokka</surname><given-names>C.O.</given-names></name></person-group><article-title>A study on clavulanic acid production by Streptomyces clavuligerus in batch, FED-batch and continuous processes</article-title><source>Braz. J. Chem. Eng.</source><year>2005</year><volume>22</volume><fpage>557</fpage><lpage>563</lpage><pub-id pub-id-type="doi">10.1590/S0104-66322005000400008</pub-id></element-citation></ref><ref id="B62-antibiotics-10-00084"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Teodoro</surname><given-names>J.C.</given-names></name><name><surname>Araujo</surname><given-names>M.L.G.C.</given-names></name><name><surname>Hokka</surname><given-names>C.O.</given-names></name><name><surname>Badino</surname><given-names>A.C.</given-names></name></person-group><article-title>Influence of glycerol and ornithine feeding on clavulanic acid production by Streptomyces clavuligerus</article-title><source>Braz. J. Chem. Eng.</source><year>2010</year><volume>27</volume><fpage>499</fpage><lpage>506</lpage><pub-id pub-id-type="doi">10.1590/S0104-66322010000400001</pub-id></element-citation></ref><ref id="B63-antibiotics-10-00084"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Domingues</surname><given-names>L.C.G.</given-names></name><name><surname>Teodoro</surname><given-names>J.C.</given-names></name><name><surname>Hokka</surname><given-names>C.O.</given-names></name><name><surname>Badino</surname><given-names>A.C.</given-names></name><name><surname>Araujo</surname><given-names>M.L.G.C.</given-names></name></person-group><article-title>Optimisation of the glycerol-to-ornithine molar ratio in the feed medium for the continuous production of clavulanic acid by Streptomyces clavuligerus</article-title><source>Biochem. Eng. J.</source><year>2010</year><volume>53</volume><fpage>7</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.1016/j.bej.2009.05.006</pub-id></element-citation></ref><ref id="B64-antibiotics-10-00084"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salem-Bekhit</surname><given-names>M.M.</given-names></name><name><surname>Alanazi</surname><given-names>F.K.</given-names></name><name><surname>Alsarra</surname><given-names>I.A.</given-names></name></person-group><article-title>Improvement and enhancement of clavulanic acid production in Streptomyces clavuligerus using vegetable oils</article-title><source>Afr. J. Biotechnol.</source><year>2010</year><volume>9</volume><fpage>6806</fpage><lpage>6812</lpage></element-citation></ref><ref id="B65-antibiotics-10-00084"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Young</surname><given-names>T.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Efthimiou</surname><given-names>G.</given-names></name></person-group><article-title>Olive Pomace Oil can be Used as an Alternative Carbon Source for Clavulanic Acid Production by Streptomyces clavuligerus</article-title><source>Waste Biomass Valoriz.</source><year>2019</year><pub-id pub-id-type="doi">10.1007/s12649-019-00719-5</pub-id></element-citation></ref><ref id="B66-antibiotics-10-00084"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>S.-J.</given-names></name><name><surname>Kim</surname><given-names>J.-O.</given-names></name><name><surname>Shin</surname><given-names>C.-H.</given-names></name><name><surname>Park</surname><given-names>H.W.</given-names></name><name><surname>Kim</surname><given-names>C.-W.</given-names></name></person-group><article-title>An approach to strain improvement and enhanced production of clavulanic acid in Streptomyces clavuligerus</article-title><source>Biosci. Biotechnol. Biochem.</source><year>2009</year><volume>73</volume><fpage>160</fpage><lpage>164</lpage><pub-id pub-id-type="doi">10.1271/bbb.80569</pub-id><pub-id pub-id-type="pmid">19129630</pub-id></element-citation></ref><ref id="B67-antibiotics-10-00084"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carvalho</surname><given-names>V.</given-names></name><name><surname>Brand&#x000e3;o</surname><given-names>J.F.</given-names></name><name><surname>Brand&#x000e3;o</surname><given-names>R.</given-names></name><name><surname>Rangel-yagui</surname><given-names>C.O.</given-names></name><name><surname>Couto</surname><given-names>J.A.</given-names></name><name><surname>Converti</surname><given-names>A.</given-names></name><name><surname>Pessoa</surname><given-names>A.</given-names></name></person-group><article-title>Stability of clavulanic acid under variable pH, ionic strength and temperature conditions. A new kinetic approach</article-title><source>Biochem. Eng. J.</source><year>2009</year><volume>45</volume><fpage>89</fpage><lpage>93</lpage><pub-id pub-id-type="doi">10.1016/j.bej.2009.02.013</pub-id></element-citation></ref><ref id="B68-antibiotics-10-00084"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brethauer</surname><given-names>S.</given-names></name><name><surname>Held</surname><given-names>M.</given-names></name><name><surname>Panke</surname><given-names>S.</given-names></name></person-group><article-title>Clavulanic Acid Decomposition Is Catalyzed by the Compound Itself and by Its Decomposition Products</article-title><source>J. Pharm. Sci.</source><year>2008</year><volume>97</volume><fpage>3451</fpage><lpage>3455</lpage><pub-id pub-id-type="doi">10.1002/jps.21225</pub-id><pub-id pub-id-type="pmid">17969123</pub-id></element-citation></ref><ref id="B69-antibiotics-10-00084"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marques</surname><given-names>D.A.V.</given-names></name><name><surname>Oliveira</surname><given-names>R.P.S.</given-names></name><name><surname>Perego</surname><given-names>P.</given-names></name><name><surname>Porto</surname><given-names>A.L.F.</given-names></name><name><surname>Pessoa</surname><given-names>A.</given-names></name><name><surname>Converti</surname><given-names>A.</given-names></name></person-group><article-title>Kinetic and thermodynamic investigation on clavulanic acid formation and degradation during glycerol fermentation by Streptomyces DAUFPE 3060</article-title><source>Enzyme Microb. Technol.</source><year>2009</year><volume>45</volume><fpage>169</fpage><lpage>173</lpage><pub-id pub-id-type="doi">10.1016/j.enzmictec.2009.03.005</pub-id></element-citation></ref><ref id="B70-antibiotics-10-00084"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rodrigues</surname><given-names>K.C.S.</given-names></name><name><surname>Costa</surname><given-names>C.L.L.</given-names></name><name><surname>Badino</surname><given-names>A.C.</given-names></name><name><surname>Pedrolli</surname><given-names>D.B.</given-names></name><name><surname>Pereira</surname><given-names>J.F.B.</given-names></name><name><surname>Cerri</surname><given-names>M.O.</given-names></name></person-group><article-title>Application of Acid and Cold Stresses to Enhance the Production of Clavulanic Acid by Streptomyces clavuligerus</article-title><source>Appl. Biochem. Biotechnol.</source><year>2019</year><volume>188</volume><fpage>706</fpage><lpage>719</lpage><pub-id pub-id-type="doi">10.1007/s12010-019-02953-y</pub-id><pub-id pub-id-type="pmid">30680701</pub-id></element-citation></ref><ref id="B71-antibiotics-10-00084"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Costa</surname><given-names>C.L.L.</given-names></name><name><surname>Badino</surname><given-names>A.C.</given-names></name></person-group><article-title>Production of clavulanic acid by Streptomyces clavuligerus in batch cultures without and with glycerol pulses under different temperature conditions</article-title><source>Biochem. Eng. J.</source><year>2012</year><volume>69</volume><fpage>1</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1016/j.bej.2012.08.005</pub-id></element-citation></ref><ref id="B72-antibiotics-10-00084"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yepes-Garc&#x000ed;a</surname><given-names>J.</given-names></name><name><surname>Caicedo-Montoya</surname><given-names>C.</given-names></name><name><surname>Pinilla</surname><given-names>L.</given-names></name><name><surname>Toro</surname><given-names>L.F.</given-names></name><name><surname>R&#x000ed;os-Estepa</surname><given-names>R.</given-names></name></person-group><article-title>Morphological differentiation of streptomyces clavuligerus exposed to diverse environmental conditions and its relationship with clavulanic acid biosynthesis</article-title><source>Processes</source><year>2020</year><volume>8</volume><elocation-id>1038</elocation-id><pub-id pub-id-type="doi">10.3390/pr8091038</pub-id></element-citation></ref><ref id="B73-antibiotics-10-00084"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yag&#x000fc;e</surname><given-names>P.</given-names></name><name><surname>L&#x000f3;pez-Garc&#x000ed;a</surname><given-names>M.T.</given-names></name><name><surname>Rioseras</surname><given-names>B.</given-names></name><name><surname>S&#x000e1;nchez</surname><given-names>J.</given-names></name><name><surname>Manteca</surname><given-names>&#x000c1;.</given-names></name></person-group><article-title>Pre-sporulation stages of Streptomyces differentiation: State-of-the-art and future perspectives</article-title><source>FEMS Microbiol. Lett.</source><year>2013</year><volume>342</volume><pub-id pub-id-type="doi">10.1111/1574-6968.12128</pub-id><?supplied-pmid 23496097?><pub-id pub-id-type="pmid">23496097</pub-id></element-citation></ref><ref id="B74-antibiotics-10-00084"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yag&#x000fc;e</surname><given-names>P.</given-names></name><name><surname>Lopez-Garcia</surname><given-names>M.T.</given-names></name><name><surname>Rioseras</surname><given-names>B.</given-names></name><name><surname>Sanchez</surname><given-names>J.</given-names></name><name><surname>Manteca</surname><given-names>A.</given-names></name></person-group><article-title>New insights on the development of Streptomyces and their relationships with secondary metabolite production</article-title><source>Curr. Trends Microbiol.</source><year>2012</year><volume>8</volume><fpage>65</fpage><lpage>73</lpage><?supplied-pmid 24707121?><pub-id pub-id-type="pmid">24707121</pub-id></element-citation></ref><ref id="B75-antibiotics-10-00084"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Olmos</surname><given-names>E.</given-names></name><name><surname>Mehmood</surname><given-names>N.</given-names></name><name><surname>Haj Husein</surname><given-names>L.</given-names></name><name><surname>Goergen</surname><given-names>J.L.</given-names></name><name><surname>Fick</surname><given-names>M.</given-names></name><name><surname>Delaunay</surname><given-names>S.</given-names></name></person-group><article-title>Effects of bioreactor hydrodynamics on the physiology of Streptomyces</article-title><source>Bioprocess. Biosyst. Eng.</source><year>2013</year><volume>36</volume><fpage>259</fpage><lpage>272</lpage><pub-id pub-id-type="doi">10.1007/s00449-012-0794-1</pub-id><?supplied-pmid 22923137?><pub-id pub-id-type="pmid">22923137</pub-id></element-citation></ref><ref id="B76-antibiotics-10-00084"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alok</surname><given-names>S.</given-names></name></person-group><article-title>Effect of Different Impellers and Baffles on Aerobic Stirred Tank Fermenter using Computational Fluid Dynamics</article-title><source>J. Bioprocess. Biotech.</source><year>2014</year><volume>4</volume><fpage>1</fpage><pub-id pub-id-type="doi">10.4172/2155-9821.1000184</pub-id></element-citation></ref><ref id="B77-antibiotics-10-00084"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hristov</surname><given-names>H.V.</given-names></name><name><surname>Mann</surname><given-names>R.</given-names></name><name><surname>Lossev</surname><given-names>V.</given-names></name><name><surname>Vlaev</surname><given-names>S.D.</given-names></name></person-group><article-title>A simplified CFD for three-dimensional analysis of fluid mixing, mass transfer and bioreaction in a fermenter equipped with triple novel geometry impellers</article-title><source>Food Bioprod. Process.</source><year>2004</year><volume>82</volume><fpage>21</fpage><lpage>34</lpage><pub-id pub-id-type="doi">10.1205/096030804322985281</pub-id></element-citation></ref><ref id="B78-antibiotics-10-00084"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jin</surname><given-names>B.</given-names></name><name><surname>van Leeuwen</surname><given-names>J.H.</given-names></name><name><surname>Doelle</surname><given-names>H.W.</given-names></name><name><surname>Yu</surname><given-names>Q.M.</given-names></name></person-group><article-title>The influence of geometry on hydrodynamic and mass transfer characteristics in an external airlift reactor for the cultivation of filamentous fungi</article-title><source>World J. Microbiol. Biotechnol.</source><year>1999</year><volume>15</volume><fpage>83</fpage><lpage>90</lpage><pub-id pub-id-type="doi">10.1023/A:1008822612406</pub-id></element-citation></ref><ref id="B79-antibiotics-10-00084"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>G&#x000f3;mez-R&#x000ed;os</surname><given-names>D.</given-names></name><name><surname>Junne</surname><given-names>S.</given-names></name><name><surname>Neubauer</surname><given-names>P.</given-names></name><name><surname>Ochoa</surname><given-names>S.</given-names></name><name><surname>R&#x000ed;os-Estepa</surname><given-names>R.</given-names></name><name><surname>Ram&#x000ed;rez-Malule</surname><given-names>H.</given-names></name></person-group><article-title>Characterization of the Metabolic Response of Streptomyces clavuligerus to Shear Stress in Stirred Tanks and Single-Use 2D Rocking Motion Bioreactors for Clavulanic Acid Production</article-title><source>Antibiotics</source><year>2019</year><volume>8</volume><elocation-id>168</elocation-id><pub-id pub-id-type="doi">10.3390/antibiotics8040168</pub-id></element-citation></ref><ref id="B80-antibiotics-10-00084"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xia</surname><given-names>X.</given-names></name><name><surname>Lin</surname><given-names>S.</given-names></name><name><surname>Xia</surname><given-names>X.X.</given-names></name><name><surname>Cong</surname><given-names>F.S.</given-names></name><name><surname>Zhong</surname><given-names>J.J.</given-names></name></person-group><article-title>Significance of agitation-induced shear stress on mycelium morphology and lavendamycin production by engineered Streptomyces flocculus</article-title><source>Appl. Microbiol. Biotechnol.</source><year>2014</year><volume>98</volume><fpage>4399</fpage><lpage>4407</lpage><pub-id pub-id-type="doi">10.1007/s00253-014-5555-4</pub-id><pub-id pub-id-type="pmid">24522728</pub-id></element-citation></ref><ref id="B81-antibiotics-10-00084"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>Y.-H.</given-names></name><name><surname>Hwang</surname><given-names>S.-C.J.</given-names></name><name><surname>Gong</surname><given-names>J.T.</given-names></name><name><surname>Wu</surname><given-names>J.-Y.</given-names></name><name><surname>Chen</surname><given-names>K.-C.</given-names></name></person-group><article-title>Using Redox Potential to Detect Microbial Activities During Clavulanic Acid Biosynthesis in Streptomyces clavuligerus</article-title><source>Biotechnol. Lett.</source><year>2005</year><volume>27</volume><fpage>1791</fpage><lpage>1795</lpage><pub-id pub-id-type="doi">10.1007/s10529-005-3727-0</pub-id><pub-id pub-id-type="pmid">16314972</pub-id></element-citation></ref><ref id="B82-antibiotics-10-00084"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rosa</surname><given-names>J.C.</given-names></name><name><surname>Baptista Neto</surname><given-names>A.</given-names></name><name><surname>Hokka</surname><given-names>C.O.</given-names></name><name><surname>Badino</surname><given-names>A.C.</given-names></name></person-group><article-title>Influence of dissolved oxygen and shear conditions on clavulanic acid production by Streptomyces clavuligerus</article-title><source>Bioprocess. Biosyst. Eng.</source><year>2005</year><volume>27</volume><fpage>99</fpage><lpage>104</lpage><pub-id pub-id-type="doi">10.1007/s00449-004-0386-9</pub-id><pub-id pub-id-type="pmid">15592878</pub-id></element-citation></ref><ref id="B83-antibiotics-10-00084"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bentley</surname><given-names>P.H.</given-names></name><name><surname>Brooks</surname><given-names>G.</given-names></name><name><surname>Gilpin</surname><given-names>M.L.</given-names></name><name><surname>Hunt</surname><given-names>E.</given-names></name></person-group><article-title>A new total synthesis of (&#x000b1;)-clavulanic acid</article-title><source>Tetrahedron Lett.</source><year>1979</year><volume>20</volume><fpage>1889</fpage><lpage>1890</lpage><pub-id pub-id-type="doi">10.1016/S0040-4039(01)86869-6</pub-id></element-citation></ref><ref id="B84-antibiotics-10-00084"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bentley</surname><given-names>P.H.</given-names></name><name><surname>Berry</surname><given-names>P.D.</given-names></name><name><surname>Brooks</surname><given-names>G.</given-names></name><name><surname>Gilpin</surname><given-names>M.L.</given-names></name><name><surname>Hunt</surname><given-names>E.</given-names></name><name><surname>Zomaya</surname><given-names>I.I.</given-names></name></person-group><article-title>Total synthesis of (&#x000b1;)-clavulanic acid</article-title><source>J. Chem. Soc. Chem. Commun.</source><year>1977</year><fpage>748</fpage><lpage>749</lpage><pub-id pub-id-type="doi">10.1039/C39770000748</pub-id></element-citation></ref><ref id="B85-antibiotics-10-00084"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liras</surname><given-names>P.</given-names></name><name><surname>Gomez-Escribano</surname><given-names>J.P.</given-names></name><name><surname>Santamarta</surname><given-names>I.</given-names></name></person-group><article-title>Regulatory mechanisms controlling antibiotic production in Streptomyces clavuligerus</article-title><source>J. Ind. Microbiol. Biotechnol.</source><year>2008</year><volume>35</volume><fpage>667</fpage><lpage>676</lpage><pub-id pub-id-type="doi">10.1007/s10295-008-0351-8</pub-id><?supplied-pmid 18446393?><pub-id pub-id-type="pmid">18446393</pub-id></element-citation></ref><ref id="B86-antibiotics-10-00084"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>J.</given-names></name><name><surname>Shi</surname><given-names>J.</given-names></name><name><surname>Molle</surname><given-names>V.</given-names></name><name><surname>Sohlberg</surname><given-names>B.</given-names></name><name><surname>Weaver</surname><given-names>D.</given-names></name><name><surname>Bibb</surname><given-names>M.J.</given-names></name><name><surname>Karoonuthaisiri</surname><given-names>N.</given-names></name><name><surname>Lih</surname><given-names>C.J.</given-names></name><name><surname>Kao</surname><given-names>C.M.</given-names></name><name><surname>Buttner</surname><given-names>M.J.</given-names></name><etal/></person-group><article-title>Cross-regulation among disparate antibiotic biosynthetic pathways of Streptomyces coelicolor</article-title><source>Mol. Microbiol.</source><year>2005</year><volume>58</volume><fpage>1276</fpage><lpage>1287</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2958.2005.04879.x</pub-id><?supplied-pmid 16313616?><pub-id pub-id-type="pmid">16313616</pub-id></element-citation></ref><ref id="B87-antibiotics-10-00084"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>K.</given-names></name><name><surname>Mohsin</surname><given-names>A.</given-names></name><name><surname>Dai</surname><given-names>Y.</given-names></name><name><surname>Ali</surname><given-names>M.F.</given-names></name><name><surname>Chen</surname><given-names>Z.</given-names></name><name><surname>Zhuang</surname><given-names>Y.</given-names></name><name><surname>Chu</surname><given-names>J.</given-names></name><name><surname>Guo</surname><given-names>M.</given-names></name></person-group><article-title>Role of a Two-Component Signal Transduction System RspA1/A2 in Regulating the Biosynthesis of Salinomycin in Streptomyces albus</article-title><source>Appl. Biochem. Biotechnol.</source><year>2020</year><fpage>1</fpage><lpage>15</lpage><pub-id pub-id-type="doi">10.1007/s12010-020-03357-z</pub-id><?supplied-pmid 32524351?><pub-id pub-id-type="pmid">32524351</pub-id></element-citation></ref><ref id="B88-antibiotics-10-00084"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>F.</given-names></name><name><surname>Hou</surname><given-names>Y.</given-names></name><name><surname>Zhang</surname><given-names>H.</given-names></name><name><surname>Chu</surname><given-names>Y.</given-names></name><name><surname>Xia</surname><given-names>H.</given-names></name><name><surname>Tian</surname><given-names>Y.</given-names></name></person-group><article-title>Regulatory genes and their roles for improvement of antibiotic biosynthesis in Streptomyces</article-title><source>3 Biotech</source><year>2017</year><volume>7</volume><fpage>250</fpage><pub-id pub-id-type="doi">10.1007/s13205-017-0875-6</pub-id></element-citation></ref><ref id="B89-antibiotics-10-00084"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>P&#x000e9;rez-Redondo</surname><given-names>R.</given-names></name><name><surname>Rodr&#x000ed;guez-Garc&#x000ed;a</surname><given-names>A.</given-names></name><name><surname>Mart&#x000ed;n</surname><given-names>J.F.</given-names></name><name><surname>Liras</surname><given-names>P.</given-names></name></person-group><article-title>The claR gene of Streptomyces clavuligerus, encoding a LysR-type regulatory protein controlling clavulanic acid biosynthesis, is linked to the clavulanate-9-aldehyde reductase (car) gene</article-title><source>Gene</source><year>1998</year><volume>211</volume><fpage>311</fpage><lpage>321</lpage><pub-id pub-id-type="doi">10.1016/S0378-1119(98)00106-1</pub-id><pub-id pub-id-type="pmid">9602162</pub-id></element-citation></ref><ref id="B90-antibiotics-10-00084"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bignell</surname><given-names>D.R.D.</given-names></name><name><surname>Tahlan</surname><given-names>K.</given-names></name><name><surname>Colvin</surname><given-names>K.R.</given-names></name><name><surname>Jensen</surname><given-names>S.E.</given-names></name><name><surname>Leskiw</surname><given-names>B.K.</given-names></name></person-group><article-title>Expression of ccaR, Encoding the Positive Activator of Cephamycin C and Clavulanic Acid Production in Streptomyces clavuligerus, Is Dependent on bldG</article-title><source>Antimicrob. Agents Chemother.</source><year>2005</year><volume>49</volume><fpage>1529</fpage><lpage>1541</lpage><pub-id pub-id-type="doi">10.1128/AAC.49.4.1529-1541.2005</pub-id><pub-id pub-id-type="pmid">15793135</pub-id></element-citation></ref><ref id="B91-antibiotics-10-00084"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kurt</surname><given-names>A.</given-names></name><name><surname>&#x000c1;lvarez-&#x000c1;lvarez</surname><given-names>R.</given-names></name><name><surname>Liras</surname><given-names>P.</given-names></name><name><surname>&#x000d6;zcengiz</surname><given-names>G.</given-names></name></person-group><article-title>Role of the cmcH-ccaR intergenic region and ccaR overexpression in cephamycin C biosynthesis in Streptomyces clavuligerus</article-title><source>Appl. Microbiol. Biotechnol.</source><year>2013</year><volume>97</volume><fpage>5869</fpage><lpage>5880</lpage><pub-id pub-id-type="doi">10.1007/s00253-013-4721-4</pub-id><pub-id pub-id-type="pmid">23361841</pub-id></element-citation></ref><ref id="B92-antibiotics-10-00084"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pinilla</surname><given-names>L.</given-names></name><name><surname>Toro</surname><given-names>L.F.</given-names></name><name><surname>Laing</surname><given-names>E.</given-names></name><name><surname>Alzate</surname><given-names>J.F.</given-names></name><name><surname>R&#x000ed;os-Estepa</surname><given-names>R.</given-names></name></person-group><article-title>Comparative transcriptome analysis of streptomyces clavuligerus in response to favorable and restrictive nutritional conditions</article-title><source>Antibiotics</source><year>2019</year><volume>8</volume><elocation-id>96</elocation-id><pub-id pub-id-type="doi">10.3390/antibiotics8030096</pub-id><?supplied-pmid 31330947?><pub-id pub-id-type="pmid">31330947</pub-id></element-citation></ref><ref id="B93-antibiotics-10-00084"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>P&#x000e9;rez-Llarena</surname><given-names>F.J.</given-names></name><name><surname>Liras</surname><given-names>P.</given-names></name><name><surname>Rodr&#x000ed;guez-Garc&#x000ed;a</surname><given-names>A.</given-names></name><name><surname>Mart&#x000ed;n</surname><given-names>J.F.</given-names></name></person-group><article-title>A regulatory gene (ccaR) required for cephamycin and clavulanic acid production in Streptomyces clavuligerus: Amplification results in overproduction of both beta-lactam Compounds</article-title><source>J. Bacteriol.</source><year>1997</year><volume>179</volume><fpage>2053</fpage><lpage>2059</lpage><pub-id pub-id-type="doi">10.1128/JB.179.6.2053-2059.1997</pub-id><?supplied-pmid 9068654?><pub-id pub-id-type="pmid">9068654</pub-id></element-citation></ref><ref id="B94-antibiotics-10-00084"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alexander</surname><given-names>D.C.</given-names></name><name><surname>Jensen</surname><given-names>S.E.</given-names></name></person-group><article-title>Investigation of the Streptomyces clavuligerus Cephamycin C Gene Cluster and Its Regulation by the CcaR Protein</article-title><source>J. Bacteriol.</source><year>1998</year><volume>180</volume><fpage>4068</fpage><lpage>4079</lpage><pub-id pub-id-type="doi">10.1128/JB.180.16.4068-4079.1998</pub-id><?supplied-pmid 9696752?><pub-id pub-id-type="pmid">9696752</pub-id></element-citation></ref><ref id="B95-antibiotics-10-00084"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kurt Kizildo&#x0011f;an</surname><given-names>A.</given-names></name><name><surname>Vanli Jaccard</surname><given-names>G.</given-names></name><name><surname>Mutlu</surname><given-names>A.</given-names></name><name><surname>Sertdemir</surname><given-names>&#x00130;.</given-names></name><name><surname>&#x000d6;zcengiz</surname><given-names>G.</given-names></name></person-group><article-title>Genetic engineering of an industrial strain of Streptomyces clavuligerus for further enhancement of clavulanic acid production</article-title><source>Turk. J. Biol.</source><year>2017</year><volume>41</volume><fpage>342</fpage><lpage>353</lpage><pub-id pub-id-type="doi">10.3906/biy-1608-17</pub-id></element-citation></ref><ref id="B96-antibiotics-10-00084"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qin</surname><given-names>R.</given-names></name><name><surname>Zhong</surname><given-names>C.</given-names></name><name><surname>Zong</surname><given-names>G.</given-names></name><name><surname>Fu</surname><given-names>J.</given-names></name><name><surname>Pang</surname><given-names>X.</given-names></name><name><surname>Cao</surname><given-names>G.</given-names></name></person-group><article-title>Improvement of clavulanic acid production in Streptomyces clavuligerus F613-1 by using a claR-neo reporter strategy</article-title><source>Electron. J. Biotechnol.</source><year>2017</year><volume>28</volume><fpage>41</fpage><lpage>46</lpage><pub-id pub-id-type="doi">10.1016/j.ejbt.2017.05.002</pub-id></element-citation></ref><ref id="B97-antibiotics-10-00084"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cho</surname><given-names>H.S.</given-names></name><name><surname>Jo</surname><given-names>J.C.</given-names></name><name><surname>Shin</surname><given-names>C.-H.</given-names></name><name><surname>Lee</surname><given-names>N.</given-names></name><name><surname>Choi</surname><given-names>J.-S.</given-names></name><name><surname>Cho</surname><given-names>B.-K.</given-names></name><name><surname>Roe</surname><given-names>J.-H.</given-names></name><name><surname>Kim</surname><given-names>C.-W.</given-names></name><name><surname>Kwon</surname><given-names>H.J.</given-names></name><name><surname>Yoon</surname><given-names>Y.J.</given-names></name></person-group><article-title>Improved production of clavulanic acid by reverse engineering and overexpression of the regulatory genes in an industrial Streptomyces clavuligerus strain</article-title><source>J. Ind. Microbiol. Biotechnol.</source><year>2019</year><volume>46</volume><fpage>1205</fpage><lpage>1215</lpage><pub-id pub-id-type="doi">10.1007/s10295-019-02196-0</pub-id><pub-id pub-id-type="pmid">31165280</pub-id></element-citation></ref><ref id="B98-antibiotics-10-00084"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Santamarta</surname><given-names>I.</given-names></name><name><surname>L&#x000f3;pez-Garc&#x000ed;a</surname><given-names>M.T.</given-names></name><name><surname>P&#x000e9;rez-Redondo</surname><given-names>R.</given-names></name><name><surname>Koekman</surname><given-names>B.</given-names></name><name><surname>Mart&#x000ed;n</surname><given-names>J.F.</given-names></name><name><surname>Liras</surname><given-names>P.</given-names></name></person-group><article-title>Connecting primary and secondary metabolism: AreB, an IclR-like protein, binds the AREccaR sequence of S. clavuligerus and modulates leucine biosynthesis and cephamycin C and clavulanic acid production</article-title><source>Mol. Microbiol.</source><year>2007</year><volume>66</volume><fpage>511</fpage><lpage>524</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2958.2007.05937.x</pub-id><pub-id pub-id-type="pmid">17877708</pub-id></element-citation></ref><ref id="B99-antibiotics-10-00084"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>L&#x000f3;pez-Garc&#x000ed;a</surname><given-names>M.T.</given-names></name><name><surname>Santamarta</surname><given-names>I.</given-names></name><name><surname>Liras</surname><given-names>P.</given-names></name></person-group><article-title>Morphological differentiation and clavulanic acid formation are affected in a Streptomyces clavuligerus adpA-deleted mutant</article-title><source>Microbiology</source><year>2010</year><volume>156</volume><fpage>2354</fpage><lpage>2365</lpage><pub-id pub-id-type="doi">10.1099/mic.0.035956-0</pub-id><pub-id pub-id-type="pmid">20447998</pub-id></element-citation></ref><ref id="B100-antibiotics-10-00084"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mascher</surname><given-names>T.</given-names></name><name><surname>Helmann</surname><given-names>J.D.</given-names></name><name><surname>Unden</surname><given-names>G.</given-names></name></person-group><article-title>Stimulus Perception in Bacterial Signal-Transducing Histidine Kinases</article-title><source>Microbiol. Mol. Biol. Rev.</source><year>2006</year><volume>70</volume><fpage>910</fpage><lpage>938</lpage><pub-id pub-id-type="doi">10.1128/MMBR.00020-06</pub-id><pub-id pub-id-type="pmid">17158704</pub-id></element-citation></ref><ref id="B101-antibiotics-10-00084"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Papon</surname><given-names>N.</given-names></name><name><surname>Stock</surname><given-names>A.M.</given-names></name></person-group><article-title>Two-component systems</article-title><source>Curr. Biol.</source><year>2019</year><volume>29</volume><fpage>R724</fpage><lpage>R725</lpage><pub-id pub-id-type="doi">10.1016/j.cub.2019.06.010</pub-id><pub-id pub-id-type="pmid">31386843</pub-id></element-citation></ref><ref id="B102-antibiotics-10-00084"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fu</surname><given-names>J.</given-names></name><name><surname>Qin</surname><given-names>R.</given-names></name><name><surname>Zong</surname><given-names>G.</given-names></name><name><surname>Liu</surname><given-names>C.</given-names></name><name><surname>Kang</surname><given-names>N.</given-names></name><name><surname>Zhong</surname><given-names>C.</given-names></name><name><surname>Cao</surname><given-names>G.</given-names></name></person-group><article-title>The CagRS Two-Component System Regulates Clavulanic Acid Metabolism via Multiple Pathways in Streptomyces clavuligerus F613-1</article-title><source>Front. Microbiol.</source><year>2019</year><volume>10</volume><fpage>1</fpage><lpage>17</lpage><pub-id pub-id-type="doi">10.3389/fmicb.2019.00244</pub-id><?supplied-pmid 30837970?><pub-id pub-id-type="pmid">30728808</pub-id></element-citation></ref><ref id="B103-antibiotics-10-00084"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jnawali</surname><given-names>H.N.</given-names></name><name><surname>Oh</surname><given-names>T.J.</given-names></name><name><surname>Liou</surname><given-names>K.</given-names></name><name><surname>Park</surname><given-names>B.C.</given-names></name><name><surname>Sohng</surname><given-names>J.K.</given-names></name></person-group><article-title>A two-component regulatory system involved in clavulanic acid production</article-title><source>J. Antibiot.</source><year>2008</year><volume>61</volume><fpage>651</fpage><lpage>659</lpage><pub-id pub-id-type="doi">10.1038/ja.2008.92</pub-id><?supplied-pmid 19168979?><pub-id pub-id-type="pmid">19168979</pub-id></element-citation></ref><ref id="B104-antibiotics-10-00084"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kwong</surname><given-names>T.</given-names></name><name><surname>Zelyas</surname><given-names>N.J.</given-names></name><name><surname>Cai</surname><given-names>H.</given-names></name><name><surname>Tahlan</surname><given-names>K.</given-names></name><name><surname>Wong</surname><given-names>A.</given-names></name><name><surname>Jensen</surname><given-names>S.E.</given-names></name></person-group><article-title>5S clavam biosynthesis is controlled by an atypical two-component regulatory system in Streptomyces clavuligerus</article-title><source>Antimicrob. Agents Chemother.</source><year>2012</year><volume>56</volume><fpage>4845</fpage><lpage>4855</lpage><pub-id pub-id-type="doi">10.1128/AAC.01090-12</pub-id><?supplied-pmid 22751548?><pub-id pub-id-type="pmid">22751548</pub-id></element-citation></ref><ref id="B105-antibiotics-10-00084"><label>105.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Santos-Beneit</surname><given-names>F.</given-names></name></person-group><article-title>The Pho regulon: A huge regulatory network in bacteria</article-title><source>Front. Microbiol.</source><year>2015</year><volume>6</volume><fpage>402</fpage><pub-id pub-id-type="doi">10.3389/fmicb.2015.00402</pub-id><pub-id pub-id-type="pmid">25983732</pub-id></element-citation></ref><ref id="B106-antibiotics-10-00084"><label>106.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salehghamari</surname><given-names>E.</given-names></name><name><surname>Hamedi</surname><given-names>J.</given-names></name><name><surname>Elahi</surname><given-names>E.</given-names></name><name><surname>Sepehrizadeh</surname><given-names>Z.</given-names></name><name><surname>Sadeghi</surname><given-names>M.</given-names></name><name><surname>Muth</surname><given-names>G.</given-names></name></person-group><article-title>Prediction of the pho regulon in Streptomyces clavuligerus DSM 738</article-title><source>New Microbiol.</source><year>2012</year><volume>35</volume><fpage>447</fpage><lpage>457</lpage><pub-id pub-id-type="pmid">23109012</pub-id></element-citation></ref><ref id="B107-antibiotics-10-00084"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Horinouchi</surname><given-names>S.</given-names></name><name><surname>Hara</surname><given-names>O.</given-names></name><name><surname>Beppu</surname><given-names>T.</given-names></name></person-group><article-title>Cloning of a pleiotropic gene that positively controls biosynthesis of A-factor, actinorhodin, and prodigiosin in Streptomyces coelicolor A3(2) and Streptomyces lividans</article-title><source>J. Bacteriol.</source><year>1983</year><volume>155</volume><fpage>1238</fpage><lpage>1248</lpage><pub-id pub-id-type="doi">10.1128/JB.155.3.1238-1248.1983</pub-id><pub-id pub-id-type="pmid">6309746</pub-id></element-citation></ref><ref id="B108-antibiotics-10-00084"><label>108.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parajuli</surname><given-names>N.</given-names></name><name><surname>Hung</surname><given-names>T.V.</given-names></name><name><surname>Ishida</surname><given-names>K.</given-names></name><name><surname>Hang</surname><given-names>T.T.</given-names></name><name><surname>Hei</surname><given-names>C.L.</given-names></name><name><surname>Liou</surname><given-names>K.</given-names></name><name><surname>Jae</surname><given-names>K.S.</given-names></name></person-group><article-title>Identification and characterization of the afsR homologue regulatory gene from Streptomyces peucetius ATCC 27952</article-title><source>Res. Microbiol.</source><year>2005</year><volume>156</volume><fpage>707</fpage><lpage>712</lpage><pub-id pub-id-type="doi">10.1016/j.resmic.2005.03.005</pub-id><pub-id pub-id-type="pmid">15921897</pub-id></element-citation></ref><ref id="B109-antibiotics-10-00084"><label>109.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fu</surname><given-names>J.</given-names></name><name><surname>Qin</surname><given-names>R.</given-names></name><name><surname>Zong</surname><given-names>G.</given-names></name><name><surname>Zhong</surname><given-names>C.</given-names></name><name><surname>Zhang</surname><given-names>P.</given-names></name><name><surname>Kang</surname><given-names>N.</given-names></name><name><surname>Qi</surname><given-names>X.</given-names></name><name><surname>Cao</surname><given-names>G.</given-names></name></person-group><article-title>The two-component system CepRS regulates the cephamycin C biosynthesis in Streptomyces clavuligerus F613-1</article-title><source>AMB Express</source><year>2019</year><volume>9</volume><pub-id pub-id-type="doi">10.1186/s13568-019-0844-z</pub-id></element-citation></ref><ref id="B110-antibiotics-10-00084"><label>110.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>D.</given-names></name><name><surname>Liu</surname><given-names>C.</given-names></name><name><surname>Zhu</surname><given-names>J.</given-names></name><name><surname>Liu</surname><given-names>W.</given-names></name></person-group><article-title>Connecting metabolic pathways: Sigma factors in <italic>Streptomyces</italic> spp.</article-title><source>Front. Microbiol.</source><year>2017</year><volume>8</volume><fpage>2546</fpage><pub-id pub-id-type="doi">10.3389/fmicb.2017.02546</pub-id><pub-id pub-id-type="pmid">29312231</pub-id></element-citation></ref><ref id="B111-antibiotics-10-00084"><label>111.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jnawali</surname><given-names>H.N.</given-names></name><name><surname>Liou</surname><given-names>K.</given-names></name><name><surname>Sohng</surname><given-names>J.K.</given-names></name></person-group><article-title>Role of &#x003c3;-factor (orf21) in clavulanic acid production in Streptomyces clavuligerus NRRL3585</article-title><source>Microbiol. Res.</source><year>2011</year><volume>166</volume><fpage>369</fpage><lpage>379</lpage><pub-id pub-id-type="doi">10.1016/j.micres.2010.07.005</pub-id><pub-id pub-id-type="pmid">20870400</pub-id></element-citation></ref><ref id="B112-antibiotics-10-00084"><label>112.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ba&#x0015f;</surname><given-names>L.</given-names></name><name><surname>Otur</surname><given-names>&#x000c7;.</given-names></name><name><surname>Kurt-K&#x00131;z&#x00131;ldo&#x0011f;an</surname><given-names>A.</given-names></name></person-group><article-title>Enhanced Tunicamycin Biosynthesis in BldG Overexpressed Streptomyces clavuligerus</article-title><source>Appl. Biochem. Microbiol.</source><year>2020</year><volume>56</volume><fpage>412</fpage><lpage>419</lpage><pub-id pub-id-type="doi">10.1134/S000368382004002X</pub-id></element-citation></ref><ref id="B113-antibiotics-10-00084"><label>113.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chatterji</surname><given-names>D.</given-names></name><name><surname>Kumar Ojha</surname><given-names>A.</given-names></name></person-group><article-title>Revisiting the stringent response, ppGpp and starvation signaling</article-title><source>Curr. Opin. Microbiol.</source><year>2001</year><volume>4</volume><fpage>160</fpage><lpage>165</lpage><pub-id pub-id-type="doi">10.1016/S1369-5274(00)00182-X</pub-id><pub-id pub-id-type="pmid">11282471</pub-id></element-citation></ref><ref id="B114-antibiotics-10-00084"><label>114.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jin</surname><given-names>W.</given-names></name><name><surname>Ryu</surname><given-names>Y.G.</given-names></name><name><surname>Kang</surname><given-names>S.G.</given-names></name><name><surname>Kim</surname><given-names>S.K.</given-names></name><name><surname>Saito</surname><given-names>N.</given-names></name><name><surname>Ochi</surname><given-names>K.</given-names></name><name><surname>Lee</surname><given-names>S.H.</given-names></name><name><surname>Lee</surname><given-names>K.J.</given-names></name></person-group><article-title>Two relAlspoT homologous genes are involved in the morphological and physiological differentiation of Streptomyces clavuligerus</article-title><source>Microbiology</source><year>2004</year><volume>150</volume><fpage>1485</fpage><lpage>1493</lpage><pub-id pub-id-type="doi">10.1099/mic.0.26811-0</pub-id><?supplied-pmid 15133110?><pub-id pub-id-type="pmid">15133110</pub-id></element-citation></ref><ref id="B115-antibiotics-10-00084"><label>115.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gomez-Escribano</surname><given-names>J.P.</given-names></name><name><surname>Mart&#x000ed;n</surname><given-names>J.F.</given-names></name><name><surname>Hesketh</surname><given-names>A.</given-names></name><name><surname>Bibb</surname><given-names>M.J.</given-names></name><name><surname>Liras</surname><given-names>P.</given-names></name></person-group><article-title>Streptomyces clavuligerus relA-null mutants overproduce clavulanic acid and cephamycin C: Negative regulation of secondary metabolism by (p)ppGpp</article-title><source>Microbiology</source><year>2008</year><volume>154</volume><fpage>744</fpage><lpage>755</lpage><pub-id pub-id-type="doi">10.1099/mic.0.2007/011890-0</pub-id><?supplied-pmid 18310021?><pub-id pub-id-type="pmid">18310021</pub-id></element-citation></ref><ref id="B116-antibiotics-10-00084"><label>116.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>R.</given-names></name><name><surname>Townsend</surname><given-names>C.A.</given-names></name></person-group><article-title>Rational strain improvement for enhanced clavulanic acid production by genetic engineering of the glycolytic pathway in Streptomyces clavuligerus</article-title><source>Metab. Eng.</source><year>2006</year><volume>8</volume><fpage>240</fpage><lpage>252</lpage><pub-id pub-id-type="doi">10.1016/j.ymben.2006.01.003</pub-id><?supplied-pmid 16530442?><pub-id pub-id-type="pmid">16530442</pub-id></element-citation></ref><ref id="B117-antibiotics-10-00084"><label>117.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jnawali</surname><given-names>H.N.</given-names></name><name><surname>Lee</surname><given-names>H.C.</given-names></name><name><surname>Sohng</surname><given-names>J.K.</given-names></name></person-group><article-title>Enhancement of clavulanic acid production by expressing regulatory genes in gap gene deletion mutant of Streptomyces clavuligerus NRRL3585</article-title><source>J. Microbiol. Biotechnol.</source><year>2010</year><volume>20</volume><fpage>146</fpage><lpage>152</lpage><pub-id pub-id-type="doi">10.4014/jmb.0907.07020</pub-id><?supplied-pmid 20134246?><pub-id pub-id-type="pmid">20134246</pub-id></element-citation></ref><ref id="B118-antibiotics-10-00084"><label>118.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Medema</surname><given-names>M.H.</given-names></name><name><surname>Alam</surname><given-names>M.T.</given-names></name><name><surname>Heijne</surname><given-names>W.H.M.</given-names></name><name><surname>Van Den Berg</surname><given-names>M.A.</given-names></name><name><surname>M&#x000fc;ller</surname><given-names>U.</given-names></name><name><surname>Trefzer</surname><given-names>A.</given-names></name><name><surname>Bovenberg</surname><given-names>R.A.L.</given-names></name><name><surname>Breitling</surname><given-names>R.</given-names></name><name><surname>Takano</surname><given-names>E.</given-names></name></person-group><article-title>Genome-wide gene expression changes in an industrial clavulanic acid overproduction strain of Streptomyces clavuligerus</article-title><source>Microb. Biotechnol.</source><year>2011</year><volume>4</volume><fpage>300</fpage><lpage>305</lpage><pub-id pub-id-type="doi">10.1111/j.1751-7915.2010.00226.x</pub-id><?supplied-pmid 21829093?><pub-id pub-id-type="pmid">21342474</pub-id></element-citation></ref><ref id="B119-antibiotics-10-00084"><label>119.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Said</surname><given-names>I.G.</given-names></name><name><surname>Abdelwahed</surname><given-names>N.A.M.</given-names></name><name><surname>Awad</surname><given-names>H.M.</given-names></name><name><surname>Shallan</surname><given-names>M.A.</given-names></name><name><surname>El-Shahed</surname><given-names>K.Y.</given-names></name><name><surname>Abdel-Rahim</surname><given-names>E.A.</given-names></name></person-group><article-title>Enhancement of clavulanic acid production by Streptomyces sp MU-NRC77 via mutation and medium optimization</article-title><source>Trop. J. Pharm. Res.</source><year>2017</year><volume>16</volume><fpage>31</fpage><lpage>42</lpage><pub-id pub-id-type="doi">10.4314/tjpr.v16i1.5</pub-id></element-citation></ref><ref id="B120-antibiotics-10-00084"><label>120.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cruz-Hern&#x000e1;ndez</surname><given-names>I.L.</given-names></name><name><surname>Vasconcelos</surname><given-names>E.D.S.</given-names></name><name><surname>Teodoro</surname><given-names>J.C.</given-names></name><name><surname>De Baptista-Neto</surname><given-names>A.</given-names></name><name><surname>Da Costa Araujo</surname><given-names>M.L.G.</given-names></name><name><surname>Badino</surname><given-names>A.C.</given-names></name></person-group><article-title>Exploring the Optimization of UV Mutants of Streptomyces clavuligerus for Clavulanic Acid Production</article-title><source>Microbiol. Res. J. Int.</source><year>2019</year><volume>26</volume><fpage>1</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.9734/mrji/2018/v26i630080</pub-id></element-citation></ref><ref id="B121-antibiotics-10-00084"><label>121.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Song</surname><given-names>J.Y.</given-names></name><name><surname>Jeong</surname><given-names>H.</given-names></name><name><surname>Yu</surname><given-names>D.S.</given-names></name><name><surname>Fischbach</surname><given-names>M.A.</given-names></name><name><surname>Park</surname><given-names>H.-S.</given-names></name><name><surname>Kim</surname><given-names>J.J.</given-names></name><name><surname>Seo</surname><given-names>J.-S.</given-names></name><name><surname>Jensen</surname><given-names>S.E.</given-names></name><name><surname>Oh</surname><given-names>T.K.</given-names></name><name><surname>Lee</surname><given-names>K.J.</given-names></name><etal/></person-group><article-title>Draft genome sequence of Streptomyces clavuligerus NRRL 3585, a producer of diverse secondary metabolites</article-title><source>J. Bacteriol.</source><year>2010</year><volume>192</volume><fpage>6317</fpage><lpage>6318</lpage><pub-id pub-id-type="doi">10.1128/JB.00859-10</pub-id><?supplied-pmid 20889745?><pub-id pub-id-type="pmid">20889745</pub-id></element-citation></ref><ref id="B122-antibiotics-10-00084"><label>122.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Medema</surname><given-names>M.H.</given-names></name><name><surname>Trefzer</surname><given-names>A.</given-names></name><name><surname>Kovalchuk</surname><given-names>A.</given-names></name><name><surname>van den Berg</surname><given-names>M.</given-names></name><name><surname>M&#x000fc;ller</surname><given-names>U.</given-names></name><name><surname>Heijne</surname><given-names>W.</given-names></name><name><surname>Wu</surname><given-names>L.</given-names></name><name><surname>Alam</surname><given-names>M.T.</given-names></name><name><surname>Ronning</surname><given-names>C.M.</given-names></name><name><surname>Nierman</surname><given-names>W.C.</given-names></name><etal/></person-group><article-title>The sequence of a 1.8-mb bacterial linear plasmid reveals a rich evolutionary reservoir of secondary metabolic pathways</article-title><source>Genome Biol. Evol.</source><year>2010</year><volume>2</volume><fpage>212</fpage><lpage>224</lpage><pub-id pub-id-type="doi">10.1093/gbe/evq013</pub-id><?supplied-pmid 20624727?><pub-id pub-id-type="pmid">20624727</pub-id></element-citation></ref><ref id="B123-antibiotics-10-00084"><label>123.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cao</surname><given-names>G.</given-names></name><name><surname>Zhong</surname><given-names>C.</given-names></name><name><surname>Zong</surname><given-names>G.</given-names></name><name><surname>Fu</surname><given-names>J.</given-names></name><name><surname>Liu</surname><given-names>Z.</given-names></name><name><surname>Zhang</surname><given-names>G.</given-names></name><name><surname>Qin</surname><given-names>R.</given-names></name></person-group><article-title>Complete Genome Sequence of Streptomyces clavuligerus F613-1, an Industrial Producer of Clavulanic Acid</article-title><source>Genome Announc.</source><year>2016</year><volume>4</volume><fpage>4</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1128/genomeA.01020-16</pub-id><?supplied-pmid 27660792?><pub-id pub-id-type="pmid">27660792</pub-id></element-citation></ref><ref id="B124-antibiotics-10-00084"><label>124.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hwang</surname><given-names>S.</given-names></name><name><surname>Lee</surname><given-names>N.</given-names></name><name><surname>Jeong</surname><given-names>Y.</given-names></name><name><surname>Lee</surname><given-names>Y.</given-names></name><name><surname>Kim</surname><given-names>W.</given-names></name><name><surname>Cho</surname><given-names>S.</given-names></name><name><surname>Palsson</surname><given-names>B.O.</given-names></name><name><surname>Cho</surname><given-names>B.-K.</given-names></name></person-group><article-title>Primary transcriptome and translatome analysis determines transcriptional and translational regulatory elements encoded in the Streptomyces clavuligerus genome</article-title><source>Nucleic Acids Res.</source><year>2019</year><volume>47</volume><fpage>6114</fpage><lpage>6129</lpage><pub-id pub-id-type="doi">10.1093/nar/gkz471</pub-id><?supplied-pmid 31131406?><pub-id pub-id-type="pmid">31131406</pub-id></element-citation></ref><ref id="B125-antibiotics-10-00084"><label>125.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>N.</given-names></name><name><surname>Kim</surname><given-names>W.</given-names></name><name><surname>Hwang</surname><given-names>S.</given-names></name><name><surname>Lee</surname><given-names>Y.</given-names></name><name><surname>Cho</surname><given-names>S.</given-names></name><name><surname>Palsson</surname><given-names>B.</given-names></name><name><surname>Cho</surname><given-names>B.K.</given-names></name></person-group><article-title>Thirty complete Streptomyces genome sequences for mining novel secondary metabolite biosynthetic gene clusters</article-title><source>Sci. Data</source><year>2020</year><volume>7</volume><fpage>1</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1038/s41597-020-0395-9</pub-id><?supplied-pmid 32054853?><pub-id pub-id-type="pmid">31896794</pub-id></element-citation></ref><ref id="B126-antibiotics-10-00084"><label>126.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>W.</given-names></name><name><surname>Hwang</surname><given-names>S.</given-names></name><name><surname>Lee</surname><given-names>N.</given-names></name><name><surname>Lee</surname><given-names>Y.</given-names></name><name><surname>Cho</surname><given-names>S.</given-names></name><name><surname>Palsson</surname><given-names>B.</given-names></name><name><surname>Cho</surname><given-names>B.K.</given-names></name></person-group><article-title>Transcriptome and translatome profiles of Streptomyces species in different growth phases</article-title><source>Sci. Data</source><year>2020</year><volume>7</volume><fpage>1</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1038/s41597-020-0476-9</pub-id><?supplied-pmid 32385251?><pub-id pub-id-type="pmid">31896794</pub-id></element-citation></ref><ref id="B127-antibiotics-10-00084"><label>127.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>&#x000c1;lvarez-&#x000c1;lvarez</surname><given-names>R.</given-names></name><name><surname>Rodr&#x000ed;guez-Garc&#x000ed;a</surname><given-names>A.</given-names></name><name><surname>Santamarta</surname><given-names>I.</given-names></name><name><surname>P&#x000e9;rez-Redondo</surname><given-names>R.</given-names></name><name><surname>Prieto-Dom&#x000ed;nguez</surname><given-names>A.</given-names></name><name><surname>Mart&#x000ed;nez-Burgo</surname><given-names>Y.</given-names></name><name><surname>Liras</surname><given-names>P.</given-names></name></person-group><article-title>Transcriptomic analysis of S treptomyces clavuligerus &#x00394; ccaR: Tsr: Effects of the cephamycin C-clavulanic acid cluster regulator CcaR on global regulation</article-title><source>Microb. Biotechnol.</source><year>2014</year><volume>7</volume><fpage>221</fpage><lpage>231</lpage><pub-id pub-id-type="doi">10.1111/1751-7915.12109</pub-id><pub-id pub-id-type="pmid">24450885</pub-id></element-citation></ref><ref id="B128-antibiotics-10-00084"><label>128.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Santamarta</surname><given-names>I.</given-names></name><name><surname>L&#x000f3;pez-Garc&#x000ed;a</surname><given-names>M.T.</given-names></name><name><surname>Kurt</surname><given-names>A.</given-names></name><name><surname>N&#x000e1;rdiz</surname><given-names>N.</given-names></name><name><surname>&#x000c1;lvarez-&#x000c1;lvarez</surname><given-names>R.</given-names></name><name><surname>P&#x000e9;rez-Redondo</surname><given-names>R.</given-names></name><name><surname>Mart&#x000ed;n</surname><given-names>J.F.</given-names></name><name><surname>Liras</surname><given-names>P.</given-names></name></person-group><article-title>Characterization of DNA-binding sequences for CcaR in the cephamycin-clavulanic acid supercluster of Streptomyces clavuligerus</article-title><source>Mol. Microbiol.</source><year>2011</year><volume>81</volume><fpage>968</fpage><lpage>981</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2958.2011.07743.x</pub-id><pub-id pub-id-type="pmid">21696462</pub-id></element-citation></ref><ref id="B129-antibiotics-10-00084"><label>129.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Robles-Reglero</surname><given-names>V.</given-names></name><name><surname>Santamarta</surname><given-names>I.</given-names></name><name><surname>&#x000c1;lvarez-&#x000e1;lvarez</surname><given-names>R.</given-names></name><name><surname>Mart&#x000ed;n</surname><given-names>J.F.</given-names></name><name><surname>Liras</surname><given-names>P.</given-names></name></person-group><article-title>Transcriptional analysis and proteomics of the holomycin gene cluster in overproducer mutants of Streptomyces clavuligerus</article-title><source>J. Biotechnol.</source><year>2013</year><volume>163</volume><fpage>69</fpage><lpage>76</lpage><pub-id pub-id-type="doi">10.1016/j.jbiotec.2012.09.017</pub-id><pub-id pub-id-type="pmid">23147422</pub-id></element-citation></ref><ref id="B130-antibiotics-10-00084"><label>130.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mart&#x000ed;nez-Burgo</surname><given-names>Y.</given-names></name><name><surname>&#x000c1;lvarez-&#x000c1;lvarez</surname><given-names>R.</given-names></name><name><surname>Rodr&#x000ed;guez-Garc&#x000ed;a</surname><given-names>A.</given-names></name><name><surname>Liras</surname><given-names>P.</given-names></name></person-group><article-title>The pathway-specific regulator ClaR of Streptomyces clavuligerus has a global effect on the expression of genes for secondary metabolism and differentiation</article-title><source>Appl. Environ. Microbiol.</source><year>2015</year><volume>81</volume><fpage>6637</fpage><lpage>6648</lpage><pub-id pub-id-type="doi">10.1128/AEM.00916-15</pub-id><pub-id pub-id-type="pmid">26187955</pub-id></element-citation></ref><ref id="B131-antibiotics-10-00084"><label>131.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>&#x000c1;lvarez-&#x000c1;lvarez</surname><given-names>R.</given-names></name><name><surname>Rodr&#x000ed;guez-Garc&#x000ed;a</surname><given-names>A.</given-names></name><name><surname>Mart&#x000ed;nez-Burgo</surname><given-names>Y.</given-names></name><name><surname>Mart&#x000ed;n</surname><given-names>J.F.</given-names></name><name><surname>Liras</surname><given-names>P.</given-names></name></person-group><article-title>Transcriptional studies on a Streptomyces clavuligerus oppA2 deletion mutant: Nacetylglycyl- clavaminic acid is an intermediate of clavulanic acid biosynthesis</article-title><source>Appl. Environ. Microbiol.</source><year>2018</year><volume>84</volume><pub-id pub-id-type="doi">10.1128/AEM.01701-18</pub-id></element-citation></ref><ref id="B132-antibiotics-10-00084"><label>132.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>N&#x000e1;rdiz</surname><given-names>N.</given-names></name><name><surname>Santamarta</surname><given-names>I.</given-names></name><name><surname>Lorenzana</surname><given-names>L.M.</given-names></name><name><surname>Mart&#x000ed;n</surname><given-names>J.F.</given-names></name><name><surname>Liras</surname><given-names>P.</given-names></name></person-group><article-title>A rhodanese-like protein is highly overrepresented in the mutant S. clavuligerus oppA2::aph: Effect on holomycin and other secondary metabolites production</article-title><source>Microb. Biotechnol.</source><year>2011</year><volume>4</volume><fpage>216</fpage><lpage>225</lpage><pub-id pub-id-type="doi">10.1111/j.1751-7915.2010.00222.x</pub-id><?supplied-pmid 21342467?><pub-id pub-id-type="pmid">21342467</pub-id></element-citation></ref><ref id="B133-antibiotics-10-00084"><label>133.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mart&#x000ed;nez-Burgo</surname><given-names>Y.</given-names></name><name><surname>Santos-Aberturas</surname><given-names>J.</given-names></name><name><surname>Rodr&#x000ed;guez-Garc&#x000ed;a</surname><given-names>A.</given-names></name><name><surname>Barreales</surname><given-names>E.G.</given-names></name><name><surname>Tormo</surname><given-names>J.R.</given-names></name><name><surname>Truman</surname><given-names>A.W.</given-names></name><name><surname>Reyes</surname><given-names>F.</given-names></name><name><surname>Aparicio</surname><given-names>J.F.</given-names></name><name><surname>Liras</surname><given-names>P.</given-names></name></person-group><article-title>Activation of Secondary Metabolite Gene Clusters in Streptomyces clavuligerus by the PimM Regulator of Streptomyces natalensis</article-title><source>Front. Microbiol.</source><year>2019</year><volume>10</volume><fpage>1</fpage><lpage>14</lpage><pub-id pub-id-type="doi">10.3389/fmicb.2019.00580</pub-id><?supplied-pmid 30984130?><pub-id pub-id-type="pmid">30728808</pub-id></element-citation></ref><ref id="B134-antibiotics-10-00084"><label>134.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferguson</surname><given-names>N.L.</given-names></name><name><surname>Pe&#x000f1;a-Castillo</surname><given-names>L.</given-names></name><name><surname>Moore</surname><given-names>M.A.</given-names></name><name><surname>Bignell</surname><given-names>D.R.D.</given-names></name><name><surname>Tahlan</surname><given-names>K.</given-names></name></person-group><article-title>Proteomics analysis of global regulatory cascades involved in clavulanic acid production and morphological development in Streptomyces clavuligerus</article-title><source>J. Ind. Microbiol. Biotechnol.</source><year>2016</year><volume>43</volume><fpage>537</fpage><lpage>555</lpage><pub-id pub-id-type="doi">10.1007/s10295-016-1733-y</pub-id><?supplied-pmid 26790415?><pub-id pub-id-type="pmid">26790415</pub-id></element-citation></ref><ref id="B135-antibiotics-10-00084"><label>135.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>&#x000dc;nsald&#x00131;</surname><given-names>E.</given-names></name><name><surname>Kurt-K&#x00131;z&#x00131;ldo&#x0011f;an</surname><given-names>A.</given-names></name><name><surname>Voigt</surname><given-names>B.</given-names></name><name><surname>Becher</surname><given-names>D.</given-names></name><name><surname>&#x000d6;zcengiz</surname><given-names>G.</given-names></name></person-group><article-title>Proteome-wide alterations in an industrial clavulanic acid producing strain of Streptomyces clavuligerus</article-title><source>Synth. Syst. Biotechnol.</source><year>2017</year><volume>2</volume><fpage>39</fpage><lpage>48</lpage><pub-id pub-id-type="doi">10.1016/j.synbio.2016.10.003</pub-id><pub-id pub-id-type="pmid">29062960</pub-id></element-citation></ref><ref id="B136-antibiotics-10-00084"><label>136.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tahlan</surname><given-names>K.</given-names></name><name><surname>Anders</surname><given-names>C.</given-names></name><name><surname>Wong</surname><given-names>A.</given-names></name><name><surname>Mosher</surname><given-names>R.H.</given-names></name><name><surname>Beatty</surname><given-names>P.H.</given-names></name><name><surname>Brumlik</surname><given-names>M.J.</given-names></name><name><surname>Griffin</surname><given-names>A.</given-names></name><name><surname>Hughes</surname><given-names>C.</given-names></name><name><surname>Griffin</surname><given-names>J.</given-names></name><name><surname>Barton</surname><given-names>B.</given-names></name><etal/></person-group><article-title>5S clavam biosynthetic genes are located in both the clavam and paralog gene clusters in Streptomyces clavuligerus</article-title><source>Chem. Biol.</source><year>2007</year><volume>14</volume><fpage>131</fpage><lpage>142</lpage><pub-id pub-id-type="doi">10.1016/j.chembiol.2006.11.012</pub-id><?supplied-pmid 17317567?><pub-id pub-id-type="pmid">17317567</pub-id></element-citation></ref><ref id="B137-antibiotics-10-00084"><label>137.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Busche</surname><given-names>T.</given-names></name><name><surname>Tsolis</surname><given-names>K.C.</given-names></name><name><surname>Koepff</surname><given-names>J.</given-names></name><name><surname>Rebets</surname><given-names>Y.</given-names></name><name><surname>R&#x000fc;ckert</surname><given-names>C.</given-names></name><name><surname>Hamed</surname><given-names>M.B.</given-names></name><name><surname>Bleidt</surname><given-names>A.</given-names></name><name><surname>Wiechert</surname><given-names>W.</given-names></name><name><surname>Lopatniuk</surname><given-names>M.</given-names></name><name><surname>Yousra</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Multi-omics and targeted approaches to determine the role of cellular proteases in streptomyces protein secretion</article-title><source>Front. Microbiol.</source><year>2018</year><volume>9</volume><fpage>1174</fpage><pub-id pub-id-type="doi">10.3389/fmicb.2018.01174</pub-id><?supplied-pmid 29915569?><pub-id pub-id-type="pmid">29915569</pub-id></element-citation></ref><ref id="B138-antibiotics-10-00084"><label>138.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sulheim</surname><given-names>S.</given-names></name><name><surname>Kumelj</surname><given-names>T.</given-names></name><name><surname>van Dissel</surname><given-names>D.</given-names></name><name><surname>Salehzadeh-Yazdi</surname><given-names>A.</given-names></name><name><surname>Du</surname><given-names>C.</given-names></name><name><surname>Van Wezel</surname><given-names>G.P.</given-names></name><name><surname>Nieselt</surname><given-names>K.</given-names></name><name><surname>Almaas</surname><given-names>E.</given-names></name><name><surname>Wentzel</surname><given-names>A.</given-names></name><name><surname>Kerkhoven</surname><given-names>E.J.</given-names></name></person-group><article-title>Enzyme-constrained models and omics analysis of Streptomyces coelicolor reveal metabolic changes that enhance heterologous production</article-title><source>Iscience</source><year>2020</year><volume>23</volume><fpage>101525</fpage><pub-id pub-id-type="doi">10.1016/j.isci.2020.101525</pub-id><pub-id pub-id-type="pmid">32942174</pub-id></element-citation></ref><ref id="B139-antibiotics-10-00084"><label>139.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>Q.</given-names></name><name><surname>Ni</surname><given-names>M.</given-names></name><name><surname>Liu</surname><given-names>W.C.</given-names></name><name><surname>Ren</surname><given-names>J.H.</given-names></name><name><surname>Rao</surname><given-names>Y.H.</given-names></name><name><surname>Chen</surname><given-names>J.</given-names></name><name><surname>Lu</surname><given-names>C.G.</given-names></name></person-group><article-title>Omics for understanding the mechanisms of Streptomyces lydicus A01 promoting the growth of tomato seedlings</article-title><source>Plant. Soil</source><year>2018</year><volume>431</volume><fpage>129</fpage><lpage>141</lpage><pub-id pub-id-type="doi">10.1007/s11104-018-3750-2</pub-id></element-citation></ref><ref id="B140-antibiotics-10-00084"><label>140.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>Y.</given-names></name><name><surname>Lee</surname><given-names>N.</given-names></name><name><surname>Hwang</surname><given-names>S.</given-names></name><name><surname>Kim</surname><given-names>K.</given-names></name><name><surname>Kim</surname><given-names>W.</given-names></name><name><surname>Kim</surname><given-names>J.</given-names></name><name><surname>Cho</surname><given-names>S.</given-names></name><name><surname>Palsson</surname><given-names>B.O.</given-names></name><name><surname>Cho</surname><given-names>B.K.</given-names></name></person-group><article-title>System-level understanding of gene expression and regulation for engineering secondary metabolite production in Streptomyces</article-title><source>J. Ind. Microbiol. Biotechnol.</source><year>2020</year><fpage>1</fpage><lpage>14</lpage><pub-id pub-id-type="doi">10.1007/s10295-020-02298-0</pub-id><pub-id pub-id-type="pmid">31691030</pub-id></element-citation></ref><ref id="B141-antibiotics-10-00084"><label>141.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>S.H.</given-names></name><name><surname>Herazo-Maya</surname><given-names>J.D.</given-names></name><name><surname>Kang</surname><given-names>D.D.</given-names></name><name><surname>Juan-Guardela</surname><given-names>B.M.</given-names></name><name><surname>Tedrow</surname><given-names>J.</given-names></name><name><surname>Martinez</surname><given-names>F.J.</given-names></name><name><surname>Sciurba</surname><given-names>F.C.</given-names></name><name><surname>Tseng</surname><given-names>G.C.</given-names></name><name><surname>Kaminski</surname><given-names>N.</given-names></name></person-group><article-title>Integrative phenotyping framework (iPF): Integrative clustering of multiple omics data identifies novel lung disease subphenotypes</article-title><source>BMC Genom.</source><year>2015</year><volume>16</volume><elocation-id>924</elocation-id><pub-id pub-id-type="doi">10.1186/s12864-015-2170-4</pub-id></element-citation></ref><ref id="B142-antibiotics-10-00084"><label>142.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yan</surname><given-names>J.</given-names></name><name><surname>Risacher</surname><given-names>S.L.</given-names></name><name><surname>Shen</surname><given-names>L.</given-names></name><name><surname>Saykin</surname><given-names>A.J.</given-names></name></person-group><article-title>Network approaches to systems biology analysis of complex disease: Integrative methods for multi-omics data</article-title><source>Brief. Bioinform.</source><year>2017</year><volume>19</volume><fpage>1370</fpage><lpage>1381</lpage><pub-id pub-id-type="doi">10.1093/bib/bbx066</pub-id><?supplied-pmid 28679163?><pub-id pub-id-type="pmid">28679163</pub-id></element-citation></ref><ref id="B143-antibiotics-10-00084"><label>143.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krishnan</surname><given-names>K.C.</given-names></name><name><surname>Kurt</surname><given-names>Z.</given-names></name><name><surname>Barrere-Cain</surname><given-names>R.</given-names></name><name><surname>Sabir</surname><given-names>S.</given-names></name><name><surname>Das</surname><given-names>A.</given-names></name><name><surname>Floyd</surname><given-names>R.</given-names></name><name><surname>Vergnes</surname><given-names>L.</given-names></name><name><surname>Zhao</surname><given-names>Y.</given-names></name><name><surname>Che</surname><given-names>N.</given-names></name><name><surname>Charugundla</surname><given-names>S.</given-names></name></person-group><article-title>Integration of multi-omics data from mouse diversity panel highlights mitochondrial dysfunction in non-alcoholic fatty liver disease</article-title><source>Cell Syst.</source><year>2018</year><volume>6</volume><fpage>103</fpage><lpage>115</lpage><pub-id pub-id-type="doi">10.1016/j.cels.2017.12.006</pub-id><?supplied-pmid 29361464?><pub-id pub-id-type="pmid">29361464</pub-id></element-citation></ref><ref id="B144-antibiotics-10-00084"><label>144.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pinu</surname><given-names>F.R.</given-names></name><name><surname>Beale</surname><given-names>D.J.</given-names></name><name><surname>Paten</surname><given-names>A.M.</given-names></name><name><surname>Kouremenos</surname><given-names>K.</given-names></name><name><surname>Swarup</surname><given-names>S.</given-names></name><name><surname>Schirra</surname><given-names>H.J.</given-names></name><name><surname>Wishart</surname><given-names>D.</given-names></name></person-group><article-title>Systems biology and multi-omics integration: Viewpoints from the metabolomics research community</article-title><source>Metabolites</source><year>2019</year><volume>9</volume><elocation-id>76</elocation-id><pub-id pub-id-type="doi">10.3390/metabo9040076</pub-id><?supplied-pmid 31003499?><pub-id pub-id-type="pmid">31003499</pub-id></element-citation></ref><ref id="B145-antibiotics-10-00084"><label>145.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kumelj</surname><given-names>T.</given-names></name><name><surname>Sulheim</surname><given-names>S.</given-names></name><name><surname>Wentzel</surname><given-names>A.</given-names></name><name><surname>Almaas</surname><given-names>E.</given-names></name></person-group><article-title>Predicting Strain Engineering Strategies Using iKS1317: A Genome-Scale Metabolic Model of Streptomyces coelicolor</article-title><source>Biotechnol. J.</source><year>2019</year><volume>14</volume><fpage>1800180</fpage><pub-id pub-id-type="doi">10.1002/biot.201800180</pub-id></element-citation></ref><ref id="B146-antibiotics-10-00084"><label>146.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scobie</surname><given-names>D.</given-names></name><name><surname>Hjorleifsson</surname><given-names>G.</given-names></name><name><surname>Herron</surname><given-names>P.</given-names></name><name><surname>Rogers</surname><given-names>S.</given-names></name><name><surname>Duncan</surname><given-names>K.</given-names></name></person-group><article-title>The Missing Link: Developing a pipeline for accelerated antibiotic discovery from Streptomyces through linking &#x02018;omics data</article-title><source>Access Microbiol.</source><year>2020</year><volume>2</volume><fpage>753</fpage><pub-id pub-id-type="doi">10.1099/acmi.ac2020.po0646</pub-id></element-citation></ref><ref id="B147-antibiotics-10-00084"><label>147.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jamil</surname><given-names>I.N.</given-names></name><name><surname>Remali</surname><given-names>J.</given-names></name><name><surname>Azizan</surname><given-names>K.A.</given-names></name><name><surname>Nor Muhammad</surname><given-names>N.A.</given-names></name><name><surname>Arita</surname><given-names>M.</given-names></name><name><surname>Goh</surname><given-names>H.H.</given-names></name><name><surname>Aizat</surname><given-names>W.M.</given-names></name></person-group><article-title>Systematic Multi-Omics Integration (MOI) Approach in Plant Systems Biology</article-title><source>Front. Plant Sci.</source><year>2020</year><volume>11</volume><pub-id pub-id-type="doi">10.3389/fpls.2020.00944</pub-id></element-citation></ref><ref id="B148-antibiotics-10-00084"><label>148.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gutierrez</surname><given-names>J.M.</given-names></name><name><surname>Feizi</surname><given-names>A.</given-names></name><name><surname>Li</surname><given-names>S.</given-names></name><name><surname>Kallehauge</surname><given-names>T.B.</given-names></name><name><surname>Hefzi</surname><given-names>H.</given-names></name><name><surname>Grav</surname><given-names>L.M.</given-names></name><name><surname>Ley</surname><given-names>D.</given-names></name><name><surname>Baycin Hizal</surname><given-names>D.</given-names></name><name><surname>Betenbaugh</surname><given-names>M.J.</given-names></name><name><surname>Voldborg</surname><given-names>B.</given-names></name><etal/></person-group><article-title>Genome-scale reconstructions of the mammalian secretory pathway predict metabolic costs and limitations of protein secretion</article-title><source>Nat. Commun.</source><year>2020</year><volume>11</volume><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1038/s41467-019-13867-y</pub-id><pub-id pub-id-type="pmid">31911652</pub-id></element-citation></ref><ref id="B149-antibiotics-10-00084"><label>149.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>L&#x000f3;pez-Agudelo</surname><given-names>V.A.</given-names></name><name><surname>Baena</surname><given-names>A.</given-names></name><name><surname>Ramirez-Malule</surname><given-names>H.</given-names></name><name><surname>Ochoa</surname><given-names>S.</given-names></name><name><surname>Barrera</surname><given-names>L.F.</given-names></name><name><surname>R&#x000ed;os-Estepa</surname><given-names>R.</given-names></name></person-group><article-title>Metabolic adaptation of two in silico mutants of Mycobacterium tuberculosis during infection</article-title><source>BMC Syst. Biol.</source><year>2017</year><volume>11</volume><elocation-id>107</elocation-id><pub-id pub-id-type="doi">10.1186/s12918-017-0496-z</pub-id><pub-id pub-id-type="pmid">29157227</pub-id></element-citation></ref><ref id="B150-antibiotics-10-00084"><label>150.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baloni</surname><given-names>P.</given-names></name><name><surname>Funk</surname><given-names>C.C.</given-names></name><name><surname>Yan</surname><given-names>J.</given-names></name><name><surname>Yurkovich</surname><given-names>J.T.</given-names></name><name><surname>Kueider-Paisley</surname><given-names>A.</given-names></name><name><surname>Nho</surname><given-names>K.</given-names></name><name><surname>Heinken</surname><given-names>A.</given-names></name><name><surname>Jia</surname><given-names>W.</given-names></name><name><surname>Mahmoudiandehkordi</surname><given-names>S.</given-names></name><name><surname>Louie</surname><given-names>G.</given-names></name><etal/></person-group><article-title>Metabolic Network Analysis Reveals Altered Bile Acid Synthesis and Cholesterol Metabolism in Alzheimer&#x02019;s Disease</article-title><source>SSRN Electron. J.</source><year>2020</year><pub-id pub-id-type="doi">10.2139/ssrn.3596216</pub-id></element-citation></ref><ref id="B151-antibiotics-10-00084"><label>151.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Greenhalgh</surname><given-names>K.</given-names></name><name><surname>Ramiro-Garcia</surname><given-names>J.</given-names></name><name><surname>Heinken</surname><given-names>A.</given-names></name><name><surname>Ullmann</surname><given-names>P.</given-names></name><name><surname>Bintener</surname><given-names>T.</given-names></name><name><surname>Pacheco</surname><given-names>M.P.</given-names></name><name><surname>Baginska</surname><given-names>J.</given-names></name><name><surname>Shah</surname><given-names>P.</given-names></name><name><surname>Frachet</surname><given-names>A.</given-names></name><name><surname>Halder</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Integrated In Vitro and In Silico Modeling Delineates the Molecular Effects of a Synbiotic Regimen on Colorectal-Cancer-Derived Cells</article-title><source>Cell Rep.</source><year>2019</year><volume>27</volume><fpage>1621</fpage><lpage>1632.e9</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2019.04.001</pub-id><pub-id pub-id-type="pmid">31042485</pub-id></element-citation></ref><ref id="B152-antibiotics-10-00084"><label>152.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pe&#x000f1;alver Bernab&#x000e9;</surname><given-names>B.</given-names></name><name><surname>Thiele</surname><given-names>I.</given-names></name><name><surname>Galdones</surname><given-names>E.</given-names></name><name><surname>Siletz</surname><given-names>A.</given-names></name><name><surname>Chandrasekaran</surname><given-names>S.</given-names></name><name><surname>Woodruff</surname><given-names>T.K.</given-names></name><name><surname>Broadbelt</surname><given-names>L.J.</given-names></name><name><surname>Shea</surname><given-names>L.D.</given-names></name></person-group><article-title>Dynamic genome-scale cell-specific metabolic models reveal novel inter-cellular and intra-cellular metabolic communications during ovarian follicle development</article-title><source>BMC Bioinform.</source><year>2019</year><volume>20</volume><fpage>1</fpage><lpage>16</lpage><pub-id pub-id-type="doi">10.1186/s12859-019-2825-2</pub-id><?supplied-pmid 31182013?><pub-id pub-id-type="pmid">31182013</pub-id></element-citation></ref><ref id="B153-antibiotics-10-00084"><label>153.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mccloskey</surname><given-names>D.</given-names></name><name><surname>Gangoiti</surname><given-names>J.A.</given-names></name><name><surname>King</surname><given-names>Z.A.</given-names></name><name><surname>Naviaux</surname><given-names>R.K.</given-names></name><name><surname>Barshop</surname><given-names>B.A.</given-names></name><name><surname>Palsson</surname><given-names>B.O.</given-names></name><name><surname>Feist</surname><given-names>A.M.</given-names></name></person-group><article-title>A model-driven quantitative metabolomics analysis of aerobic and anaerobic metabolism in E. coli K-12 MG1655 that is biochemically and thermodynamically consistent</article-title><source>Biotechnol. Bioeng.</source><year>2014</year><volume>111</volume><fpage>803</fpage><lpage>815</lpage><pub-id pub-id-type="doi">10.1002/bit.25133</pub-id><?supplied-pmid 24249002?><pub-id pub-id-type="pmid">24249002</pub-id></element-citation></ref><ref id="B154-antibiotics-10-00084"><label>154.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kleessen</surname><given-names>S.</given-names></name><name><surname>Irgang</surname><given-names>S.</given-names></name><name><surname>Klie</surname><given-names>S.</given-names></name><name><surname>Giavalisco</surname><given-names>P.</given-names></name><name><surname>Nikoloski</surname><given-names>Z.</given-names></name></person-group><article-title>Integration of transcriptomics and metabolomics data specifies the metabolic response of Chlamydomonas to rapamycin treatment</article-title><source>Plant J.</source><year>2015</year><volume>81</volume><fpage>822</fpage><lpage>835</lpage><pub-id pub-id-type="doi">10.1111/tpj.12763</pub-id><?supplied-pmid 25600836?><pub-id pub-id-type="pmid">25600836</pub-id></element-citation></ref><ref id="B155-antibiotics-10-00084"><label>155.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pacheco</surname><given-names>M.P.</given-names></name><name><surname>Bintener</surname><given-names>T.</given-names></name><name><surname>Ternes</surname><given-names>D.</given-names></name><name><surname>Kulms</surname><given-names>D.</given-names></name><name><surname>Haan</surname><given-names>S.</given-names></name><name><surname>Letellier</surname><given-names>E.</given-names></name><name><surname>Sauter</surname><given-names>T.</given-names></name></person-group><article-title>Identifying and targeting cancer-specific metabolism with network-based drug target prediction</article-title><source>EBioMedicine</source><year>2019</year><volume>43</volume><fpage>98</fpage><lpage>106</lpage><pub-id pub-id-type="doi">10.1016/j.ebiom.2019.04.046</pub-id><?supplied-pmid 31126892?><pub-id pub-id-type="pmid">31126892</pub-id></element-citation></ref><ref id="B156-antibiotics-10-00084"><label>156.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hastings</surname><given-names>J.</given-names></name><name><surname>Mains</surname><given-names>A.</given-names></name><name><surname>Virk</surname><given-names>B.</given-names></name><name><surname>Rodriguez</surname><given-names>N.</given-names></name><name><surname>Murdoch</surname><given-names>S.</given-names></name><name><surname>Pearce</surname><given-names>J.</given-names></name><name><surname>Bergmann</surname><given-names>S.</given-names></name><name><surname>Le Nov&#x000e8;re</surname><given-names>N.</given-names></name><name><surname>Casanueva</surname><given-names>O.</given-names></name></person-group><article-title>Multi-omics and genome-scale modeling reveal a metabolic shift during C. elegans aging</article-title><source>Front. Mol. Biosci.</source><year>2019</year><volume>6</volume><fpage>2</fpage><pub-id pub-id-type="doi">10.3389/fmolb.2019.00002</pub-id><pub-id pub-id-type="pmid">30788345</pub-id></element-citation></ref><ref id="B157-antibiotics-10-00084"><label>157.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bordbar</surname><given-names>A.</given-names></name><name><surname>Monk</surname><given-names>J.M.</given-names></name><name><surname>King</surname><given-names>Z.A.</given-names></name><name><surname>Palsson</surname><given-names>B.O.</given-names></name></person-group><article-title>Constraint-based models predict metabolic and associated cellular functions</article-title><source>Nat. Rev. Genet.</source><year>2014</year><volume>15</volume><fpage>107</fpage><lpage>120</lpage><pub-id pub-id-type="doi">10.1038/nrg3643</pub-id><?supplied-pmid 24430943?><pub-id pub-id-type="pmid">24430943</pub-id></element-citation></ref><ref id="B158-antibiotics-10-00084"><label>158.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feist</surname><given-names>A.M.</given-names></name><name><surname>Palsson</surname><given-names>B.O.</given-names></name></person-group><article-title>The biomass objective function</article-title><source>Curr. Opin. Microbiol.</source><year>2010</year><volume>13</volume><fpage>344</fpage><lpage>349</lpage><pub-id pub-id-type="doi">10.1016/j.mib.2010.03.003</pub-id><?supplied-pmid 20430689?><pub-id pub-id-type="pmid">20430689</pub-id></element-citation></ref><ref id="B159-antibiotics-10-00084"><label>159.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thiele</surname><given-names>I.</given-names></name><name><surname>Palsson</surname><given-names>B.&#x000d8;.</given-names></name></person-group><article-title>A protocol for generating a high-quality genome-scale metabolic reconstruction</article-title><source>Nat. Protoc.</source><year>2010</year><volume>5</volume><fpage>93</fpage><pub-id pub-id-type="doi">10.1038/nprot.2009.203</pub-id><?supplied-pmid 20057383?><pub-id pub-id-type="pmid">20057383</pub-id></element-citation></ref><ref id="B160-antibiotics-10-00084"><label>160.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Orth</surname><given-names>J.D.</given-names></name><name><surname>Thiele</surname><given-names>I.</given-names></name><name><surname>Palsson</surname><given-names>B.O.</given-names></name></person-group><article-title>What is flux balance analysis?</article-title><source>Nat. Biotechnol.</source><year>2010</year><volume>28</volume><fpage>245</fpage><lpage>248</lpage><pub-id pub-id-type="doi">10.1038/nbt.1614</pub-id><?supplied-pmid 20212490?><pub-id pub-id-type="pmid">20212490</pub-id></element-citation></ref><ref id="B161-antibiotics-10-00084"><label>161.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gianchandani</surname><given-names>E.P.</given-names></name><name><surname>Chavali</surname><given-names>A.K.</given-names></name><name><surname>Papin</surname><given-names>J.A.</given-names></name></person-group><article-title>The application of flux balance analysis in systems biology</article-title><source>Wiley Interdiscip. Rev. Syst. Biol. Med.</source><year>2010</year><volume>2</volume><fpage>372</fpage><lpage>382</lpage><pub-id pub-id-type="doi">10.1002/wsbm.60</pub-id><?supplied-pmid 20836035?><pub-id pub-id-type="pmid">20836035</pub-id></element-citation></ref><ref id="B162-antibiotics-10-00084"><label>162.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Razmilic</surname><given-names>V.</given-names></name><name><surname>Castro</surname><given-names>J.F.</given-names></name><name><surname>Andrews</surname><given-names>B.</given-names></name><name><surname>Asenjo</surname><given-names>J.A.</given-names></name></person-group><article-title>Analysis of metabolic networks of Streptomyces leeuwenhoekii C34 by means of a genome scale model: Prediction of modifications that enhance the production of specialized metabolites</article-title><source>Biotechnol. Bioeng.</source><year>2018</year><volume>115</volume><fpage>1815</fpage><lpage>1828</lpage><pub-id pub-id-type="doi">10.1002/bit.26598</pub-id><?supplied-pmid 29578590?><pub-id pub-id-type="pmid">29578590</pub-id></element-citation></ref><ref id="B163-antibiotics-10-00084"><label>163.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amara</surname><given-names>A.</given-names></name><name><surname>Takano</surname><given-names>E.</given-names></name><name><surname>Breitling</surname><given-names>R.</given-names></name></person-group><article-title>Development and validation of an updated computational model of Streptomyces coelicolor primary and secondary metabolism</article-title><source>BMC Genom.</source><year>2018</year><volume>19</volume><elocation-id>519</elocation-id><pub-id pub-id-type="doi">10.1186/s12864-018-4905-5</pub-id><?supplied-pmid 29973148?><pub-id pub-id-type="pmid">29973148</pub-id></element-citation></ref><ref id="B164-antibiotics-10-00084"><label>164.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>C.</given-names></name><name><surname>Liu</surname><given-names>J.</given-names></name><name><surname>Liu</surname><given-names>H.</given-names></name><name><surname>Wang</surname><given-names>J.</given-names></name><name><surname>Wen</surname><given-names>J.</given-names></name></person-group><article-title>A genome-scale dynamic flux balance analysis model of Streptomyces tsukubaensis NRRL18488 to predict the targets for increasing FK506 production</article-title><source>Biochem. Eng. J.</source><year>2017</year><volume>123</volume><fpage>45</fpage><lpage>56</lpage><pub-id pub-id-type="doi">10.1016/j.bej.2017.03.017</pub-id></element-citation></ref><ref id="B165-antibiotics-10-00084"><label>165.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Toro</surname><given-names>L.</given-names></name><name><surname>Pinilla</surname><given-names>L.</given-names></name><name><surname>Avignone-Rossa</surname><given-names>C.</given-names></name><name><surname>R&#x000ed;os-Estepa</surname><given-names>R.</given-names></name></person-group><article-title>An enhanced genome-scale metabolic reconstruction of Streptomyces clavuligerus identifies novel strain improvement strategies</article-title><source>Bioprocess. Biosyst. Eng.</source><year>2018</year><volume>41</volume><fpage>657</fpage><lpage>669</lpage><pub-id pub-id-type="doi">10.1007/s00449-018-1900-9</pub-id><?supplied-pmid 29404683?><pub-id pub-id-type="pmid">29404683</pub-id></element-citation></ref><ref id="B166-antibiotics-10-00084"><label>166.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>G&#x000f3;mez-Cer&#x000f3;n</surname><given-names>S.</given-names></name><name><surname>Galindo-Betancur</surname><given-names>D.</given-names></name><name><surname>Ram&#x000ed;rez-Malule</surname><given-names>H.</given-names></name></person-group><article-title>Data set of in silico simulation for the production of clavulanic acid and cephamycin C by Streptomyces clavuligerus using a genome scale metabolic model</article-title><source>Data Br.</source><year>2019</year><volume>24</volume><fpage>103992</fpage><pub-id pub-id-type="doi">10.1016/j.dib.2019.103992</pub-id><?supplied-pmid 31193725?><pub-id pub-id-type="pmid">31193725</pub-id></element-citation></ref><ref id="B167-antibiotics-10-00084"><label>167.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kirk</surname><given-names>S.</given-names></name><name><surname>Avignone-rossa</surname><given-names>C.A.</given-names></name><name><surname>Bushell</surname><given-names>M.E.</given-names></name></person-group><article-title>Growth limiting substrate affects antibiotic production and associated metabolic fluxes in Streptomyces clavuligerus</article-title><source>Biotechnol. Lett.</source><year>2000</year><volume>22</volume><fpage>1803</fpage><lpage>1809</lpage><pub-id pub-id-type="doi">10.1023/A:1005670603596</pub-id></element-citation></ref><ref id="B168-antibiotics-10-00084"><label>168.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>G&#x000f3;mez-R&#x000ed;os</surname><given-names>D.</given-names></name><name><surname>Ram&#x000ed;rez-Malule</surname><given-names>H.</given-names></name><name><surname>Neubauer</surname><given-names>P.</given-names></name><name><surname>Junne</surname><given-names>S.</given-names></name><name><surname>R&#x000ed;os-Estepa</surname><given-names>R.</given-names></name></person-group><article-title>Data of clavulanic acid and clavulanate-imidazole stability at low temperatures</article-title><source>Data Br.</source><year>2019</year><volume>23</volume><fpage>103775</fpage><pub-id pub-id-type="doi">10.1016/j.dib.2019.103775</pub-id></element-citation></ref><ref id="B169-antibiotics-10-00084"><label>169.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bersanetti</surname><given-names>P.A.</given-names></name><name><surname>Almeida</surname><given-names>R.M.R.G.</given-names></name><name><surname>Barboza</surname><given-names>M.</given-names></name><name><surname>Ara&#x000fa;jo</surname><given-names>M.L.G.C.</given-names></name><name><surname>Hokka</surname><given-names>C.O.</given-names></name></person-group><article-title>Kinetic studies on clavulanic acid degradation</article-title><source>Biochem. Eng. J.</source><year>2005</year><volume>23</volume><fpage>31</fpage><lpage>36</lpage><pub-id pub-id-type="doi">10.1016/j.bej.2004.10.007</pub-id></element-citation></ref><ref id="B170-antibiotics-10-00084"><label>170.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roubos</surname><given-names>J.A.</given-names></name><name><surname>Krabben</surname><given-names>P.</given-names></name><name><surname>De Laat</surname><given-names>W.</given-names></name><name><surname>Heijnen</surname><given-names>J.J.</given-names></name></person-group><article-title>Clavulanic Acid Degradation in Streptomyces clavuligerus Fed-Batch Cultivations</article-title><source>Biotechnol. Prog.</source><year>2002</year><volume>18</volume><fpage>451</fpage><lpage>457</lpage><pub-id pub-id-type="doi">10.1021/bp020294n</pub-id><pub-id pub-id-type="pmid">12052058</pub-id></element-citation></ref><ref id="B171-antibiotics-10-00084"><label>171.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ramirez-Malule</surname><given-names>H.</given-names></name><name><surname>Junne</surname><given-names>S.</given-names></name><name><surname>L&#x000f3;pez</surname><given-names>C.</given-names></name><name><surname>Zapata</surname><given-names>J.</given-names></name><name><surname>S&#x000e1;ez</surname><given-names>A.</given-names></name><name><surname>Neubauer</surname><given-names>P.</given-names></name><name><surname>Rios-Estepa</surname><given-names>R.</given-names></name></person-group><article-title>An improved HPLC-DAD method for clavulanic acid quantification in fermentation broths of Streptomyces clavuligerus</article-title><source>J. Pharm. Biomed. Anal.</source><year>2016</year><volume>120</volume><fpage>241</fpage><lpage>247</lpage><pub-id pub-id-type="doi">10.1016/j.jpba.2015.12.035</pub-id><pub-id pub-id-type="pmid">26760242</pub-id></element-citation></ref><ref id="B172-antibiotics-10-00084"><label>172.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vahdat</surname><given-names>L.</given-names></name><name><surname>Sunderland</surname><given-names>V.B.</given-names></name></person-group><article-title>Kinetics of amoxicillin and clavulanate degradation alone and in combination in aqueous solution under frozen conditions</article-title><source>Int. J. Pharm.</source><year>2007</year><volume>342</volume><fpage>95</fpage><lpage>104</lpage><pub-id pub-id-type="doi">10.1016/j.ijpharm.2007.05.029</pub-id><?supplied-pmid 17592747?><pub-id pub-id-type="pmid">17592747</pub-id></element-citation></ref><ref id="B173-antibiotics-10-00084"><label>173.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peace</surname><given-names>N.</given-names></name><name><surname>Olubukola</surname><given-names>O.</given-names></name><name><surname>Moshood</surname><given-names>A.</given-names></name></person-group><article-title>Stability of reconstituted amoxicillin clavulanate potassium under simulated in-home storage conditions</article-title><source>J. Appl. Pharm. Sci.</source><year>2012</year><volume>2</volume><fpage>28</fpage><lpage>31</lpage></element-citation></ref><ref id="B174-antibiotics-10-00084"><label>174.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nur</surname><given-names>A.O.</given-names></name><name><surname>Hassan</surname><given-names>A.A.</given-names></name><name><surname>Gadkariem</surname><given-names>E.A.</given-names></name><name><surname>Osman</surname><given-names>Z.</given-names></name></person-group><article-title>Stability of Co-Amoxiclav Reconstituted Injectable Solution</article-title><source>Eur. J. Pharm. Med. Res.</source><year>2015</year><volume>2</volume><fpage>109</fpage><lpage>123</lpage></element-citation></ref><ref id="B175-antibiotics-10-00084"><label>175.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jerzsele</surname><given-names>&#x000c1;.</given-names></name><name><surname>Nagy</surname><given-names>G.</given-names></name></person-group><article-title>The stability of amoxicillin trihydrate and potassium clavulanate combination in aqueous solutions</article-title><source>Acta Vet. Hung.</source><year>2009</year><volume>57</volume><fpage>485</fpage><lpage>493</lpage><pub-id pub-id-type="doi">10.1556/avet.57.2009.4.3</pub-id><?supplied-pmid 19897453?><pub-id pub-id-type="pmid">19897453</pub-id></element-citation></ref><ref id="B176-antibiotics-10-00084"><label>176.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>G&#x000f3;mez-R&#x000ed;os</surname><given-names>D.</given-names></name><name><surname>Ram&#x000ed;rez-Malule</surname><given-names>H.</given-names></name><name><surname>Neubauer</surname><given-names>P.</given-names></name><name><surname>Junne</surname><given-names>S.</given-names></name><name><surname>R&#x000ed;os-Estepa</surname><given-names>R.</given-names></name></person-group><article-title>Degradation Kinetics of Clavulanic Acid in Fermentation Broths at Low Temperatures</article-title><source>Antibiotics</source><year>2019</year><volume>8</volume><elocation-id>6</elocation-id><pub-id pub-id-type="doi">10.3390/antibiotics8010006</pub-id><?supplied-pmid 30658482?><pub-id pub-id-type="pmid">30658482</pub-id></element-citation></ref><ref id="B177-antibiotics-10-00084"><label>177.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jin</surname><given-names>X.</given-names></name><name><surname>Cao</surname><given-names>G.</given-names></name><name><surname>Zhang</surname><given-names>X.</given-names></name><name><surname>Chen</surname><given-names>Y.</given-names></name><name><surname>Wang</surname><given-names>L.</given-names></name><name><surname>Zhong</surname><given-names>C.</given-names></name></person-group><article-title>Studies on the formation and synthetic mechanism of related substance G in potassium clavulanate production</article-title><source>Braz. J. Pharm. Sci.</source><year>2015</year><volume>51</volume><fpage>77</fpage><lpage>83</lpage><pub-id pub-id-type="doi">10.1590/S1984-82502015000100008</pub-id></element-citation></ref><ref id="B178-antibiotics-10-00084"><label>178.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Forte</surname><given-names>M.B.S.</given-names></name><name><surname>Rodrigues</surname><given-names>M.I.</given-names></name><name><surname>Filho</surname><given-names>F.M.</given-names></name></person-group><article-title>Clavulanic Acid Adsorption Studies in Zeolites</article-title><source>Adsorpt. Sci. Technol.</source><year>2011</year><volume>29</volume><fpage>391</fpage><lpage>403</lpage><pub-id pub-id-type="doi">10.1260/0263-6174.29.4.391</pub-id></element-citation></ref><ref id="B179-antibiotics-10-00084"><label>179.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Forte</surname><given-names>M.B.S.</given-names></name><name><surname>Mazutti</surname><given-names>M.A.</given-names></name><name><surname>Filho</surname><given-names>F.M.</given-names></name><name><surname>Rodrigues</surname><given-names>M.I.</given-names></name></person-group><article-title>Evaluation of kinetic and mass transfer parameters for adsorption of clavulanic acid into natural and synthetic zeolites</article-title><source>Biotechnol. Bioprocess. Eng.</source><year>2011</year><volume>16</volume><fpage>1223</fpage><lpage>1230</lpage><pub-id pub-id-type="doi">10.1007/s12257-011-0210-8</pub-id></element-citation></ref><ref id="B180-antibiotics-10-00084"><label>180.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barboza</surname><given-names>M.</given-names></name><name><surname>Almeida</surname><given-names>R.M.R.G.</given-names></name><name><surname>Hokka</surname><given-names>C.O.</given-names></name></person-group><article-title>Kinetic studies of clavulanic acid recovery by ion exchange chromatography</article-title><source>Bioseparation</source><year>2001</year><volume>10</volume><fpage>221</fpage><lpage>227</lpage><pub-id pub-id-type="doi">10.1023/A:1016365827265</pub-id><pub-id pub-id-type="pmid">12233745</pub-id></element-citation></ref><ref id="B181-antibiotics-10-00084"><label>181.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barboza</surname><given-names>M.</given-names></name><name><surname>Almeida</surname><given-names>R.M.R.G.</given-names></name><name><surname>Hokka</surname><given-names>C.O.</given-names></name></person-group><article-title>Influence of temperature on the kinetics of adsorption and desorption of clavulanic acid by ionic exchange</article-title><source>Biochem. Eng. J.</source><year>2003</year><volume>14</volume><fpage>19</fpage><lpage>26</lpage><pub-id pub-id-type="doi">10.1016/S1369-703X(02)00103-1</pub-id></element-citation></ref><ref id="B182-antibiotics-10-00084"><label>182.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Almeida</surname><given-names>R.M.R.G.</given-names></name><name><surname>Barboza</surname><given-names>M.</given-names></name><name><surname>Hokka</surname><given-names>C.O.</given-names></name></person-group><article-title>Continuous Clavulanic Acid Adsorption Process</article-title><source>Biotechnology for Fuels and Chemicals</source><person-group person-group-type="editor"><name><surname>Davison</surname><given-names>B.H.</given-names></name><name><surname>Lee</surname><given-names>J.W.</given-names></name><name><surname>Finkelstein</surname><given-names>M.</given-names></name><name><surname>McMillan</surname><given-names>J.D.</given-names></name></person-group><publisher-name>Humana Press</publisher-name><publisher-loc>Totowa, NJ, USA</publisher-loc><year>2003</year><fpage>867</fpage><lpage>879</lpage><isbn>978-1-4612-0057-4</isbn></element-citation></ref><ref id="B183-antibiotics-10-00084"><label>183.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cuel</surname><given-names>M.</given-names></name><name><surname>Barboza</surname><given-names>M.</given-names></name><name><surname>Hokka</surname><given-names>C.</given-names></name><name><surname>Kwong</surname><given-names>W.</given-names></name></person-group><article-title>Heterogeneous Model of the Process of Clavulanic Acid Purification by Ionic Exchange in a Fixed-Bed Column</article-title><source>Chem. Prod. Process. Model.</source><year>2011</year><volume>6</volume><pub-id pub-id-type="doi">10.2202/1934-2659.1454</pub-id></element-citation></ref><ref id="B184-antibiotics-10-00084"><label>184.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Forte</surname><given-names>M.B.S.</given-names></name><name><surname>Elias</surname><given-names>&#x000c9;.C.L.</given-names></name><name><surname>Pastore</surname><given-names>H.O.</given-names></name><name><surname>Filho</surname><given-names>F.M.</given-names></name><name><surname>Rodrigues</surname><given-names>M.I.</given-names></name></person-group><article-title>Evaluation of Clavulanic Acid Adsorption in MgAl-Layered Double Hydroxides: Kinetic, Equilibrium and Thermodynamic Studies</article-title><source>Adsorpt. Sci. Technol.</source><year>2012</year><volume>30</volume><fpage>65</fpage><lpage>80</lpage><pub-id pub-id-type="doi">10.1260/0263-6174.30.1.65</pub-id></element-citation></ref><ref id="B185-antibiotics-10-00084"><label>185.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Forte</surname><given-names>M.B.S.</given-names></name><name><surname>Taviot-Gu&#x000e9;ho</surname><given-names>C.</given-names></name><name><surname>Leroux</surname><given-names>F.</given-names></name><name><surname>Rodrigues</surname><given-names>M.I.</given-names></name><name><surname>Maugeri Filho</surname><given-names>F.</given-names></name></person-group><article-title>Development and characterization of a new adsorbent for biomolecule separation: Intercalation and adsorption of clavulanic acid in layered double hydroxides</article-title><source>J. Chem. Technol. Biotechnol.</source><year>2016</year><volume>91</volume><fpage>1709</fpage><lpage>1719</lpage><pub-id pub-id-type="doi">10.1002/jctb.4759</pub-id></element-citation></ref><ref id="B186-antibiotics-10-00084"><label>186.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Forte</surname><given-names>M.B.S.</given-names></name><name><surname>Taviot-Gu&#x000e9;ho</surname><given-names>C.</given-names></name><name><surname>Leroux</surname><given-names>F.</given-names></name><name><surname>Rodrigues</surname><given-names>M.I.</given-names></name><name><surname>Maugeri Filho</surname><given-names>F.</given-names></name></person-group><article-title>Clavulanic acid separation on fixed bed columns of layered double hydroxides: Optimization of operating parameters using breakthrough curves</article-title><source>Process. Biochem.</source><year>2016</year><volume>51</volume><fpage>509</fpage><lpage>516</lpage><pub-id pub-id-type="doi">10.1016/j.procbio.2016.01.011</pub-id></element-citation></ref><ref id="B187-antibiotics-10-00084"><label>187.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carneiro-da-Cunha</surname><given-names>M.N.</given-names></name><name><surname>Souza</surname><given-names>K.P.S.</given-names></name><name><surname>Mota</surname><given-names>A.M.O.</given-names></name><name><surname>Teixeira</surname><given-names>J.A.</given-names></name><name><surname>Porto</surname><given-names>C.S.</given-names></name><name><surname>Porto</surname><given-names>T.S.</given-names></name><name><surname>Porto</surname><given-names>A.L.F.</given-names></name></person-group><article-title>Stability of clavulanic acid in PEG/citrate and liquid-liquid extraction in aqueous two-phase system</article-title><source>Fluid Phase Equilib.</source><year>2014</year><volume>375</volume><fpage>104</fpage><lpage>109</lpage><pub-id pub-id-type="doi">10.1016/j.fluid.2014.04.036</pub-id></element-citation></ref><ref id="B188-antibiotics-10-00084"><label>188.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Videira</surname><given-names>M.</given-names></name><name><surname>Aires-Barros</surname><given-names>M.R.</given-names></name></person-group><article-title>Liquid-liquid extraction of clavulanic acid using an aqueous two-phase system of polyethylene glycol and potassium phosphate</article-title><source>J. Chromatogr. A</source><year>1994</year><volume>668</volume><fpage>237</fpage><lpage>240</lpage><pub-id pub-id-type="doi">10.1016/0021-9673(94)80113-4</pub-id></element-citation></ref><ref id="B189-antibiotics-10-00084"><label>189.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Silva</surname><given-names>C.S.</given-names></name><name><surname>Bovarotti</surname><given-names>E.</given-names></name><name><surname>Rodrigues</surname><given-names>M.I.</given-names></name><name><surname>Hokka</surname><given-names>C.O.</given-names></name><name><surname>Barboza</surname><given-names>M.</given-names></name></person-group><article-title>Evaluation of the effects of the parameters involved in the purification of clavulanic acid from fermentation broth by aqueous two-phase systems</article-title><source>Bioprocess. Biosyst. Eng.</source><year>2009</year><volume>32</volume><fpage>625</fpage><lpage>632</lpage><pub-id pub-id-type="doi">10.1007/s00449-008-0285-6</pub-id><pub-id pub-id-type="pmid">19093135</pub-id></element-citation></ref><ref id="B190-antibiotics-10-00084"><label>190.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pereira</surname><given-names>J.F.B.</given-names></name><name><surname>Santos</surname><given-names>V.C.</given-names></name><name><surname>Johansson</surname><given-names>H.O.</given-names></name><name><surname>Teixeira</surname><given-names>J.A.C.</given-names></name><name><surname>Pessoa</surname><given-names>A.</given-names></name></person-group><article-title>A stable liquid-liquid extraction system for clavulanic acid using polymer-based aqueous two-phase systems</article-title><source>Sep. Purif. Technol.</source><year>2012</year><volume>98</volume><fpage>441</fpage><lpage>450</lpage><pub-id pub-id-type="doi">10.1016/j.seppur.2012.08.008</pub-id></element-citation></ref><ref id="B191-antibiotics-10-00084"><label>191.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Panas</surname><given-names>P.</given-names></name><name><surname>Lopes</surname><given-names>C.</given-names></name><name><surname>Cerri</surname><given-names>M.O.</given-names></name><name><surname>Ventura</surname><given-names>S.P.M.</given-names></name><name><surname>Santos-Ebinuma</surname><given-names>V.C.</given-names></name><name><surname>Pereira</surname><given-names>J.F.B.</given-names></name></person-group><article-title>Purification of clavulanic acid produced by Streptomyces clavuligerus via submerged fermentation using polyethylene glycol/cholinium chloride aqueous two-phase systems</article-title><source>Fluid Phase Equilib.</source><year>2017</year><volume>450</volume><fpage>42</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.1016/j.fluid.2017.07.005</pub-id></element-citation></ref><ref id="B192-antibiotics-10-00084"><label>192.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>da Silva</surname><given-names>C.S.</given-names></name><name><surname>Cuel</surname><given-names>M.F.</given-names></name><name><surname>Barreto</surname><given-names>V.O.</given-names></name><name><surname>Kwong</surname><given-names>W.H.</given-names></name><name><surname>Hokka</surname><given-names>C.O.</given-names></name><name><surname>Barboza</surname><given-names>M.</given-names></name></person-group><article-title>Separation of clavulanic acid from fermented broth of amino acids by an aqueous two-phase system and ion-exchange adsorption</article-title><source>New Biotechnol.</source><year>2012</year><volume>29</volume><fpage>428</fpage><lpage>431</lpage><pub-id pub-id-type="doi">10.1016/j.nbt.2011.05.012</pub-id></element-citation></ref><ref id="B193-antibiotics-10-00084"><label>193.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Viana Marques</surname><given-names>D.A.</given-names></name><name><surname>Pessoa-J&#x000fa;nior</surname><given-names>A.</given-names></name><name><surname>Lima-Filho</surname><given-names>J.L.</given-names></name><name><surname>Converti</surname><given-names>A.</given-names></name><name><surname>Perego</surname><given-names>P.</given-names></name><name><surname>Porto</surname><given-names>A.L.F.</given-names></name></person-group><article-title>Extractive fermentation of clavulanic acid by Streptomyces DAUFPE 3060 using aqueous two-phase system</article-title><source>Biotechnol. Prog.</source><year>2011</year><volume>27</volume><fpage>95</fpage><lpage>103</lpage><pub-id pub-id-type="doi">10.1002/btpr.526</pub-id><?supplied-pmid 21312359?><pub-id pub-id-type="pmid">21312359</pub-id></element-citation></ref><ref id="B194-antibiotics-10-00084"><label>194.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marques</surname><given-names>D.A.V.</given-names></name><name><surname>Santos-Ebinuma</surname><given-names>V.C.</given-names></name><name><surname>Pessoa-Junior</surname><given-names>A.</given-names></name><name><surname>Porto</surname><given-names>A.L.F.</given-names></name><name><surname>Rivas Torres</surname><given-names>B.</given-names></name><name><surname>Concerti</surname><given-names>A.</given-names></name></person-group><article-title>Effect of Aeration and Agitation on Extractive Fermentation of Clavulanic Acid by Using Aqueous Two-phase System</article-title><source>Biotechnol. Prog.</source><year>2016</year><volume>32</volume><fpage>1444</fpage><lpage>1452</lpage><pub-id pub-id-type="doi">10.1002/btpr.2333</pub-id><?supplied-pmid 27451982?><pub-id pub-id-type="pmid">27451982</pub-id></element-citation></ref><ref id="B195-antibiotics-10-00084"><label>195.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Costa</surname><given-names>C.L.L.</given-names></name><name><surname>Badino</surname><given-names>A.C.</given-names></name></person-group><article-title>Overproduction of clavulanic acid by extractive fermentation</article-title><source>Electron. J. Biotechnol.</source><year>2015</year><volume>18</volume><fpage>154</fpage><lpage>160</lpage><pub-id pub-id-type="doi">10.1016/j.ejbt.2015.03.001</pub-id></element-citation></ref><ref id="B196-antibiotics-10-00084"><label>196.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guedes De Andrade</surname><given-names>E.</given-names></name><name><surname>De Siqueira Cardoso Silva</surname><given-names>M.</given-names></name><name><surname>Brand&#x000e3;o Haga</surname><given-names>R.</given-names></name><name><surname>Carvalho Santos</surname><given-names>V.</given-names></name><name><surname>Pessoa</surname><given-names>A.</given-names><suffix>Jr.</suffix></name><name><surname>Rangel-Yagui</surname><given-names>C.D.O.</given-names></name></person-group><article-title>Extraction of clavulanic acid using aqueous two-phase micellar system</article-title><source>Biotechnol. Appl. Biochem.</source><year>2011</year><volume>58</volume><fpage>103</fpage><lpage>108</lpage><pub-id pub-id-type="doi">10.1002/bab.20</pub-id></element-citation></ref><ref id="B197-antibiotics-10-00084"><label>197.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Santos</surname><given-names>V.C.</given-names></name><name><surname>Hasmann</surname><given-names>F.A.</given-names></name><name><surname>Converti</surname><given-names>A.</given-names></name><name><surname>Pessoa</surname><given-names>A.</given-names></name></person-group><article-title>Liquid-liquid extraction by mixed micellar systems: A new approach for clavulanic acid recovery from fermented broth</article-title><source>Biochem. Eng. J.</source><year>2011</year><volume>56</volume><fpage>75</fpage><lpage>83</lpage><pub-id pub-id-type="doi">10.1016/j.bej.2011.05.011</pub-id></element-citation></ref><ref id="B198-antibiotics-10-00084"><label>198.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Siqueira Cardoso Silva</surname><given-names>M.</given-names></name><name><surname>de Carvalho Santos-Ebinuma</surname><given-names>V.</given-names></name><name><surname>Lopes</surname><given-names>A.M.</given-names></name><name><surname>de Oliveira Rangel-Yagui</surname><given-names>C.</given-names></name></person-group><article-title>Dextran sulfate/Triton X two-phase micellar systems as an alternative first purification step for clavulanic acid</article-title><source>Fluid Phase Equilib.</source><year>2015</year><volume>399</volume><fpage>80</fpage><lpage>86</lpage><pub-id pub-id-type="doi">10.1016/j.fluid.2015.04.026</pub-id></element-citation></ref><ref id="B199-antibiotics-10-00084"><label>199.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brites</surname><given-names>L.M.</given-names></name><name><surname>Oliveira</surname><given-names>J.H.</given-names></name><name><surname>Barboza</surname><given-names>M.</given-names></name><name><surname>Hokka</surname><given-names>C.O.</given-names></name></person-group><article-title>Effect of physicochemical properties of solvents on clavulanic acid extraction from fermentation broth</article-title><source>Lat. Am. Appl. Res.</source><year>2012</year><volume>42</volume><fpage>65</fpage><lpage>70</lpage></element-citation></ref><ref id="B200-antibiotics-10-00084"><label>200.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Mancilha</surname><given-names>M.A.</given-names></name><name><surname>Guimar&#x000e3;es</surname><given-names>G.C.</given-names></name><name><surname>de Nardi</surname><given-names>J.C.S.C.</given-names></name><name><surname>de Oliveira</surname><given-names>J.H.H.L.</given-names></name><name><surname>Hirata</surname><given-names>D.B.</given-names></name></person-group><article-title>Optimization of Liquid-Liquid Extraction Step for Clavulanic Acid From Fermentation Broth Using Solvent Mixtures</article-title><source>Quim. Nova</source><year>2014</year><volume>37</volume><fpage>1335</fpage><lpage>1341</lpage><pub-id pub-id-type="doi">10.5935/0100-4042.20140213</pub-id></element-citation></ref><ref id="B201-antibiotics-10-00084"><label>201.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hirata</surname><given-names>D.B.</given-names></name><name><surname>Oliveira</surname><given-names>J.H.H.L.</given-names></name><name><surname>Leao</surname><given-names>K.V.</given-names></name><name><surname>Rodrigues</surname><given-names>M.I.</given-names></name><name><surname>Ferreira</surname><given-names>A.G.</given-names></name><name><surname>Giulietti</surname><given-names>M.</given-names></name><name><surname>Barboza</surname><given-names>M.</given-names></name><name><surname>Hokka</surname><given-names>C.O.</given-names></name></person-group><article-title>Optimization of the precipitation of clavulanic acid from fermented broth using T-octylamine as intermediate</article-title><source>Braz. J. Chem. Eng.</source><year>2013</year><volume>30</volume><fpage>231</fpage><lpage>244</lpage><pub-id pub-id-type="doi">10.1590/S0104-66322013000200002</pub-id></element-citation></ref><ref id="B202-antibiotics-10-00084"><label>202.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hirata</surname><given-names>D.B.</given-names></name><name><surname>Oliveira</surname><given-names>J.H.H.L.</given-names></name><name><surname>Le&#x000e3;o</surname><given-names>K.V.</given-names></name><name><surname>Rodrigues</surname><given-names>M.I.</given-names></name><name><surname>Ferreira</surname><given-names>A.G.</given-names></name><name><surname>Giulietti</surname><given-names>M.</given-names></name><name><surname>Barboza</surname><given-names>M.</given-names></name><name><surname>Hokka</surname><given-names>C.O.</given-names></name></person-group><article-title>Precipitation of clavulanic acid from fermentation broth with potassium 2-ethyl hexanoate salt</article-title><source>Sep. Purif. Technol.</source><year>2009</year><volume>66</volume><fpage>598</fpage><lpage>605</lpage><pub-id pub-id-type="doi">10.1016/j.seppur.2009.01.010</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="antibiotics-10-00084-f001" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Clavulanic acid (CA) structure. Red and blue C atoms correspond to those coming from C-3 and C-5 precursors, respectively. * Stereochemical centers on CA structure.</p></caption><graphic xlink:href="antibiotics-10-00084-g001"/></fig><fig id="antibiotics-10-00084-f002" orientation="portrait" position="float"><label>Figure 2</label><caption><p>Holistic overview of the CA production process.</p></caption><graphic xlink:href="antibiotics-10-00084-g002"/></fig><fig id="antibiotics-10-00084-f003" orientation="portrait" position="float"><label>Figure 3</label><caption><p>Summary of the CA biosynthetic pathway in <italic>S. clavuligerus</italic>. The green, blue, and red Cs represent the carbon atoms coming from metabolic intermediates such as glycine, glyceraldehyde 3-phosphate, and L-arginine, respectively. Adapted from the work in [<xref rid="B43-antibiotics-10-00084" ref-type="bibr">43</xref>].</p></caption><graphic xlink:href="antibiotics-10-00084-g003"/></fig><fig id="antibiotics-10-00084-f004" orientation="portrait" position="float"><label>Figure 4</label><caption><p>The evolution of <italic>S. clavuligerus</italic> metabolic models. Species abbreviations are Sclav: <italic>Streptomyces clavuligerus</italic>, Sco: <italic>Streptomyces coelicolor</italic>, Sce: <italic>Saccharomyces cerevisiae</italic>, Eco: <italic>Escherichia coli</italic>. Similarly, number of genes, metabolites, and reactions were included after a/symbol, respectively.</p></caption><graphic xlink:href="antibiotics-10-00084-g004"/></fig><table-wrap id="antibiotics-10-00084-t001" orientation="portrait" position="float"><object-id pub-id-type="pii">antibiotics-10-00084-t001_Table 1</object-id><label>Table 1</label><caption><p>Studies reporting the highest CA production with engineered <italic>S. clavuligerus</italic> strains.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Strain</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Operation Mode</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Strain Intervention</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Supplement</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Titers (g&#x02219;L<sup>&#x02212;1</sup>)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Ref.</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1"><italic>S. clavuligerus</italic> IDG3</td><td align="center" valign="middle" rowspan="1" colspan="1">Fed-batch</td><td align="center" valign="middle" rowspan="1" colspan="1">Overexpression: <italic>cas2</italic>, <italic>ccaR</italic>, <italic>claR</italic></td><td align="center" valign="middle" rowspan="1" colspan="1">Glycerol trioleate</td><td align="center" valign="middle" rowspan="1" colspan="1">6.690</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B95-antibiotics-10-00084" ref-type="bibr">95</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><italic>S. clavuligerus</italic> M3-19</td><td align="center" valign="middle" rowspan="1" colspan="1">Batch</td><td align="center" valign="middle" rowspan="1" colspan="1">Reporter gene neo fused downstream of <italic>claR</italic></td><td align="center" valign="middle" rowspan="1" colspan="1">-</td><td align="center" valign="middle" rowspan="1" colspan="1">4.330</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B96-antibiotics-10-00084" ref-type="bibr">96</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><italic>S. clavuligerus</italic> NEO</td><td align="center" valign="middle" rowspan="1" colspan="1">Batch</td><td align="center" valign="middle" rowspan="1" colspan="1">Reporter gene neo fused downstream of <italic>claR</italic></td><td align="center" valign="middle" rowspan="1" colspan="1">-</td><td align="center" valign="middle" rowspan="1" colspan="1">3.260</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B96-antibiotics-10-00084" ref-type="bibr">96</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic>Streptomyces sp. MU-NRC77</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">Fed-batch/Batch</td><td align="center" valign="middle" rowspan="1" colspan="1">UV mutagenesis</td><td align="center" valign="middle" rowspan="1" colspan="1">H<sub>2</sub>O<sub>2</sub>/Activated animal charcoal</td><td align="center" valign="middle" rowspan="1" colspan="1">0.649/0.683</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B119-antibiotics-10-00084" ref-type="bibr">119</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><italic>S. clavuligerus</italic> 70</td><td align="center" valign="middle" rowspan="1" colspan="1">Batch</td><td align="center" valign="middle" rowspan="1" colspan="1">UV mutagenesis</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td><td align="center" valign="middle" rowspan="1" colspan="1">0.500</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B120-antibiotics-10-00084" ref-type="bibr">120</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic>S. clavuligerus</italic> OR</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Batch</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Random mutagenesis and <italic>cas1</italic>, <italic>ccaR</italic> and <italic>claR</italic> overexpression</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5.520 (OR/pCAS1)<break/>6.010 (OR/pCCAR-CLAR)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B97-antibiotics-10-00084" ref-type="bibr">97</xref>]</td></tr></tbody></table></table-wrap></floats-group></article>